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B. fragilis is considered an opportunistic pathogen, often isolated from abdominal abscesses, 
bloodstream infections and peritonitis. B. fragilis can produce multiple capsular polysaccharides 
including an immunomodulatory, zwitterionic, polysaccharide A (PSA) capable of stimulating 
anti-inflammatory interleukin-10 (IL-10) production. Conversely, some strains can produce a 
putative carcinogenic toxin, the metalloprotease Bacteroides fragilis toxin (BFT). BFT has been 
demonstrated to promote colonic cell proliferation and DNA damage in mammalian cell culture 
and animal models. An additional putative B. fragilis virulence factor present in select strains is 
a eukaryotic-like ubiquitin protein (BfUbb). BfUbb is capable of interfering with the host 
ubiquitination cascade this protein but the consequence of this on host health in unknown.  
 
This study describes the robust design and validation of PCR-based assay to target specific 
bacterial taxa and putative virulence genes. The PCR assay was subsequently used to 
determine prevalence in a collection of gastrointestinal tissue samples from individuals with and 
without disease. The bft gene was found to have a significantly higher prevalence in individuals 
newly diagnosed with polyps/cancer compared with a healthy patient group. This finding further 
points towards the importance of BFT in colonic tumorigenesis. Contrary to previous CRC 
literature the prevalence of Fusobacterium and fadA were not significant in the cohorts 
investigated in this study. Colonic location and histological type of Fusobacterium-positive 
tumours did not result in any significant associations, but the trends observed support previous 
suggestions of an association between Fusobacterium species and right-sided colon cancer. 
 
Presented here is the first reported determination of B. fragilis capsular PSA promoter 
orientation in vivo. Furthermore, individuals with IBD had a significantly lower percentage of the 
B. fragilis population PSA orientated on in comparison with a healthy cohort. Similarly, bft-
positivity was significantly associated with a lower proportion of the PSA promoter orientated on. 
 
In conclusion, overall the results presented indicate that the common gastrointestinal species, 
B. fragilis, can have wide ranging effects on gastrointestinal health. Between-strain differences 
and within-strain antigenic variation were shown to have significant associations with patient 
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populations and argue for a gene-centric, and not taxonomic-centric, approach to microbiome 
research.  
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Chapter 1 : INTRODUCTION 
1.1 The Colon 
The main functions of the colon are considered to be water and electrolyte absorption and 
microbiome metabolism. The majority of nutrient absorption occurs within the small intestine 
however this is often accompanied by the release of water into the lumen. An important role of 
the colon is therefore to conserve this water and to concentrate waste faecal matter.  
Approximately 90% of water that is released through the ileocaecal valve into the colon is 
recovered (Debongnie and Phillips, 1978). 
 
1.1.1 Macroscopic Anatomy 
The distal region of the alimentary canal is the large intestine, which ranges from the ileocaecal 
valve to the anus; including the colon and rectum. The colon originates at the caecum and is 
divided from the small intestine by the ileocaecal valve. The caecum contains a worm-shaped 
outpouching known as the vermiform appendix, notorious for being a potential life-threatening 
site of inflammation. Proceeding distally along the colon is the ascending colon (on the right side 
of the abdomen) which bends at the hepatic flexure to become the transverse colon. The 
transverse colon bends at the splenic flexure into the descending colon (left side of the 
abdomen). Distal to the descending colon is the S-shaped curvature of the sigmoid colon before 
the colon terminates at the rectum and anus (Figure 1-1A). 
  





Figure 1-1 Colon Anatomy 
(A) Macroscopic anatomy of the colon adapted from (Ellis, 2010). 
(B) A cross-sectional representation of the layered colon wall 
 
1.1.2 Histology 
From the outside of the colonic wall to the inside luminal space the colonic wall has four distinct 
layers (Figure 1-1B): 
I. Serosa 
II. Muscularis externa  
III. Submucsoa  
IV. Mucosa 
 
I. The serosa is the outer lining of the colon and rectum and is composed of 
connective tissue. This layer is lined by mesothelial cells and their associated 
basement which secrete fluid to allow for movement of the organ within the body 
cavity. Pouches of fat or appendices epiploicae are located intermittently attached 
to the serosa. 
 
II. The muscularis externa is made up of two layers of muscle cells, an outer 
longitudinal muscle layer and an inner (closer to the lumen) sheet of circular 
muscle. Parasympathetic nervous tissue (myenteric plexus) is situated between the 
two layers innervating the muscle for peristalsis. 



















III. The submucosa is an area of loose connective tissue also containing neurones, 
blood vessels and, scavenging immune cells. 
 
IV. The mucosa comprises the epithelial cell layer, lamina propria (connective tissue) 
and the muscularis mucosae (a thin layer of smooth muscle cells). The mucosal 
epithelium surface of the colon is smooth without villi, only regularly arranged 
colonic glands. These glandular structures are known as the crypts of Lieberkϋhn 
and extend down towards the muscularis mucosae (Figure 1-1B). Cell types that 
make up this epithelial layer are predominantly columnar absorptive enterocytes but 
there are also many goblet cells. The goblet cells secrete mucus which serves to 
protect the colonic epithelium and aid the passage of faecal matter.  Proliferating 
stem cells are located at the base of the crypt which migrate upwards as they 
differentiate. Supporting the epithelium and surrounding the crypts is the lamina 
propria. This layer is predominantly loose connective tissue containing many 
fibroblasts but also holds a large population of immune cells (lymphocytes) and 
neurovascular elements (Kerr, 2010). 
 
1.1.3 The Gut microbiome 
In more recent years the significance of the influence of the colonic microbiome on human 
health has been appreciated and consequently is now considered a valuable function of the 
colon and the body as a whole. The metagenomic sequencing projects, Human Microbiome 
Project (HMP) (Group et al., 2009) and MetaHIT (Li et al., 2014)  revealed a vast genomic 
catalogue within this ‘second genome’ and a surprising amount of diversity in species 
composition between individuals, although gene function is relatively conserved (Group et al., 
2009). 
 
A significant function of the microbiome is bacterial fermentation of dietary fibre into short chain 
fatty acids (SCFAs), typically acetate, propionate and butyrate. Humans lack the enzymes to 
break down complex carbohydrates which instead are metabolised by anaerobic bacteria in the 
caecum and colon. SCFAs can then be used as an energy source by the host, particularly in the 
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maintenance of colonocytes. Microbes within the gut are also able to synthesise vitamins and 
essential amino acids of benefit for host nutrition (den Besten et al., 2013). 
The density of microbes increases distally along the GI tract. In the small intestine the 
concentration of microbes is limited through host mechanisms such as the secretion of 
immunoglobulin A (IgA) (Macpherson and McCoy, 2015) and antimicrobial peptides (Vaishnava 
et al., 2011). This limited microbial component enables nutrient absorption while in the colon 
density is increased as oxygen concentration decreases and SCFA production is encouraged. 
The colonic epithelium is covered in a layer of mucus which can be subdivided into an inner 
dense layer and a luminal-exposed less dense layer. It was originally thought based on 
fluorescent in situ hybridization (FISH) techniques that this mucus layer was effectively sterile 
(van der Waaij et al., 2005). In recent years there has been mounting evidence for the presence 
of a crypt-associated microbiota. Techniques such electron microscopy, laser microdissection 
and methodological improvements to conserve the mucus layer during histological fixation and 
washing have revealed a community of primarily aerobic Acinetobacter sp. but also the common 
GI commensal Bacteroides fragilis (Donaldson et al., 2016, Lee et al., 2013).  
 
1.2 Inflammatory Bowel Disease (IBD) 
IBD is of unknown aetiology but is likely to be multifactorial through a combination of genetics, 
the host immune system and environmental factors. An over reactive immune reaction to the 
commensal gut microbiota and disruption to the intestinal mucosal barrier are thought to be key 
in IBD pathogenesis (Scaldaferri and Fiocchi, 2007). 
 
1.2.1 What is inflammation? 
The process of inflammation describes the immunovascular response to tissue injury. A change 
in normal tissue homeostasis may be a consequence of harmful biological, chemical or physical 
stimuli. The host protects the tissue against these stimuli and resolves tissue damage via the 
induction of inflammatory mechanisms (Ahmed, 2011). At a macroscopic level inflammation is 
classically characterised by redness, heat, pain and swelling. Histologically inflammation is 
accompanied by an increased blood supply, increased permeability of blood vessels and 
infiltration of leukocytes into the tissue.  Altogether this allows for the recruitment of relevant 
immune cells to clear any infection and initiate wound repair mechanisms.  The stages of the 
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acute inflammatory response are initiation of inflammation to rapidly recruit leukocytes to the 
injured tissue, amplification of the response depending on the extent of the injured tissue, 
destruction and elimination of the harmful stimuli and finally termination of the response 
including healing of damaged tissue (Ward and Lentsch, 1999). In some cases this acute 
inflammation is not resolved resulting in chronic inflammation which may include persistence of 
a pathogen, tissue damage, fibrosis, autoimmune conditions and even cancer (Kumar et al., 
1997). 
 
1.2.2 Clinical aspects of Inflammatory Bowel Disease (IBD) 
IBD is characterised by chronic inflammation in the gastrointestinal tract and is comprised of two 
main types, Crohn’s disease (CD) and Ulcerative colitis (UC) (Fakhoury et al., 2014). The two 
subtypes differ primarily on the GI tract location and extent of inflammation. Main differentiating 
features between UC and CD are that in CD inflammation is transmural (across the entire wall 
of the bowel) and can be present anywhere along the length of the G.I tract. In contrast, UC 
inflammation is limited to the mucosal layer and often starts in the rectum spreading proximally, 
also known as pancolitis when the inflammation extends along the length of the colon. 
Diagnosis is made by a combination of clinical, laboratory, endoscopic and radiographic 
observations. Due to the similarities between CD and UC, diagnosis of the disease subtype is 
not always straightforward and sometimes is classed as indeterminate colitis. Approximately 10-
15% of individuals diagnosed with IBD (Guindi and Riddell, 2004) are categorised as having 
indeterminate colitis. Determination of the disease subtype influences patient management and 
therefore correct diagnosis may determine the responsiveness to treatment. Differentiating 
factors between CD and UC are summarised in Table 1-1 and discussed below. 
 
1.2.2.1 Histopathology 
Characteristic histological features of UC disease are mucin depletion, neutrophil infiltrate in the 
lamina propria and altered crypt architecture (Geboes, 2003). Crypt histopathology includes 
transepithelial migration of neutrophils, and sometimes eosinophils, into the mucosal epithelium 
known as cryptitis and is considered a measure of active disease. Crypt abscesses may also 
form in which this infiltrate migration extends to the lumen. Fibrotic regions of the mucosa and 
submucosa become more common with repeated tissue injury and healing which may result in a 
narrowed and shortened colon. Over time UC affected colonic crypts may become shortened, 
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branched or bifid (with double lumina). Other long-term artefacts of UC are repeated healing of 
mucosal ulcers may lead to elevated sessile nodules known as pseudopolyps (Kelly and Gabos, 
1987).  
 
In early CD ulcers are often small, multiple superficial lesions, known as aphthoid ulcers which 
tend to be found in areas of the mucosa overlying lymphoid follicles (Magro et al., 2013). 
Multiple ulcerated regions surrounded by unaffected areas are known as ‘skip lesions’ and over 
time may converge to form deep, discrete ulcers. This combination of longitudinal and 
transverse ulceration gives rise to the classic histological ‘cobblestone appearance’. Extensive 
transmural ulcers may pass through the muscularis and create a connecting pathway, or fistula, 
to another organ or outside of the body.  
 
Microscopic appearance of CD is characterised by epitheliod granulomas which are activated 
macrophages resembling epithelial cells. Granulomas may be associated with blood vessels, or 
may be limited to inflammatory cell infiltrate. Submucosal features of CD are lymphoid 
aggregates, nerve hyperplasia and over time large amounts of collagen. Collagenous material 
also present in the muscularis mucosae alongside increased smooth muscle cells, collagen, 
laminin, tenascin and abundant mast cells can result in narrowing, or stricturing, of the bowel 
wall. Strictures are a common complication of longstanding CD.  
 
An additional type of intestinal inflammation is microscopic colitis which is characterised by the 
presence of watery diarrhoea, a normal appearance of the colon at endoscopy but with a 
distinct histological pattern. 
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Table 1-1 Differentiating factors between Crohn's Disease and Ulcerative Colitis 
 Crohn’s Disease Ulcerative Colitis 
Location 
Anywhere - terminal ileum is the most 
usual location of inflammation 
Colon - usually starts in the rectum 
and extends proximally 
Symptoms 
Peri-anal problems more common. 
Strictures and fistulae 
Rectal bleeding more common 
Inflammation 





Epithelioid granulomas, fat wrapping, 
increased thickness of bowel wall 
Mucin depletion, distorted crypt 
architecture; lamina propria cell 
infiltrate 
Pseudopolyps 
Less common but tend to be 
depressed 
More common 
Tobacco Aggravating Preventative 
 
1.2.3 Importance of the intestinal barrier in IBD 
The intestinal mucosal barrier is a physical ‘wall’ comprised of specialised components whose 
role is to provide a shield from the potentially harmful luminal contents, predominantly microbial 
pathogens and environmental toxins. Barrier integrity is maintained by a number of components 
including specialised epithelial cell types, cell-cell junctions and the mucus constituents (Figure 
1-2A). A variety of techniques including the lactulose/mannitol test (Fries et al., 2005), confocal 
laser endomicroscopy (Buda et al., 2014) and 51Cr-ETDA absorption (Jenkins et al., 1988) have 
shown an increased intestinal permeability in IBD. Increased paracellular permeability may 
allow for translocation of luminal contents to the basement membrane and induction of an 
inflammatory response (Chang et al., 2017). The importance of these barrier-maintaining 
components, the consequence of intestinal barrier dysfunction, and the link with IBD is 








The colonic epithelium is coated in mucus including a thick, viscous inner layer of the mucus 
and an outer thinner mucus layer (Figure 1-2A). Features of the intestinal mucus are its 
lubricant properties to reduce friction with passing luminal contents and its ‘sticky’ nature to trap 
ingested particles requiring removal (Cone, 2009, Kamphuis et al., 2017). The bulk of mucus 
contents is formed from heavy glycosylated mucin oligomers with surface acting hydrophobic 
phospholipids (Lichtenberger, 1995). 
 
 
Figure 1-2 Intestinal mucosal barrier 
(A) Colonic intestinal barrier functions to separate luminal contents from the mucosal immune 
system. Taken from (Peterson and Artis, 2014) 
(B) Adjacent epithelial cells with adjoining cell-cell junctions. Schematic depicts tight junctions, 
adherens junctions and desmosomes. Figure adapted from (Odenwald and Turner, 2017). 
TAMPs = Tight-junction associated marvel domain-containing proteins 
 
Evidence of the importance of mucus layer in maintenance of the intestinal barrier can be 
observed in Muc2(-/-) mice that lack the gene required for synthesis of the most common 
intestinal mucin, mucin 2 (Van der Sluis et al., 2006). Phenotypically these mice have altered 
crypt architecture and over time spontaneously develop intestinal colitis. Using the 
aforementioned Muc2(-/-) mouse model combined with treatment of a chemical inducer of colitis 
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pronounced colitis, compared with DSS treatment only, resulted in bacterial translocation. 
Altogether the research suggests an outcome of a reduced mucus layer is that the barrier 
function is overridden with subsequent inflammation. 
 
Cell-cell junctions 
Another important component maintaining the intestinal barrier are cell-cell junctions between 
adjacent epithelial cells (Figure 1-2B). Multiple types of junction exist between cells that allow 
for intercellular communication and a selectively permeable barrier. Cell-cell junctions also help 
to maintain the intestinal barrier when epithelial cells are shed from the surface of the epithelium 
(Watson and Hughes, 2012). 
 
Tight junctions are comprised of occludins, claudins, tricellulin and junctional adhesion molecule 
protein and have a role in selective ion permeability. The tight junction proteins interact with the 
cytoskeleton scaffold zonula occludins which itself is linked to F-actin (Figure 1-2B). Claudins 
are considered the backbone proteins of tight junctions and studies suggest this protein is key in 
tight junction regulated intestinal permeability. Studies have shown that claudin-7-/- mice 
develop colonic inflammation and increased paracellular permeability of small organic solutes 
(Tanaka et al., 2015). Occludin protein expression is decreased at the site of inflamed mucosa 
in CD and UC while claudin-1 and zonula occludins (ZO) only have decreased expression at the 
edge of the inflamed site (Kucharzik et al., 2001). 
 
E-cadherin is a transmembrane protein that is important in cell-cell adhesion via the formation of 
Ca2+-dependent intra- and intercellular homophilic interactions between its’ extracellular 
domains (Hatta et al., 1988). These cadherin connections between neighbouring cells are the 
backbone of adherens junctions. The intracellular domain of E-cadherin interacts with β-catenin 
which is associated with α-catenin and the actin cytoskeleton (Yamada et al., 2005). In a DSS-
induced mouse model of colitis intestinal deficiency of E-cadherin aggravates disease (Grill et 
al., 2015). Genetic variants of the E-cadherin gene (CDH1) result in mis-localisation of the 
protein and are associated with CD (Muise et al., 2009, van Heel et al., 2003) . In actively 
inflamed UC gene transcription but no protein expression of E-cadherin can be detected 
(Gassler et al., 2001).  
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Desmosomes are strongly adhering junctional complexes linked to intermediate filaments and 
capable of resisting mechanical stress (Garrod and Chidgey, 2008). Little is known about their 
importance in intestinal homeostasis but loss of E-cadherin in intestinal epithelial cells results in 
loss of desmosomes (Schneider et al., 2010). 
 
1.2.4 Interleukin-10 (IL-10) 
IL-10 is considered a potent anti-inflammatory cytokine capable of resolving inflammation. While 
leukocytes are the predominant cellular source of IL-10 it can also be produced by intestinal 
epithelial cells (Hyun et al., 2015). Homodimeric IL-10 binds to heterotetrameric IL-10 receptor 
complex to activate IL-10 signalling. Ligand binding induces the associated Jak1 and Tyk2 
tyrosine kinases to phosphorylate an intracellular portion of the IL-10 receptor. Phosphorylation 
of the receptor results in recruitment of signal transducer and activator of transcription 3 
(STAT3) protein (Weber-Nordt et al., 1996). Jak1 and Tyk2 also phosphorylate the newly 
associated STAT3, which leads to its homodimerisation, translocation to the nucleus and altered 
expression of IL-10 regulated genes (Donnelly et al., 1999, Shouval et al., 2014). Anti-
inflammatory actions of IL-10 include inhibition of NF-κB signalling, with a subsequent 
decreased pro-inflammatory gene expression. Figure 1-3 summarises the key aspects of the IL-
10 signalling pathway. 
 
IL-10 is important for maintaining intestinal mucosal homeostasis and resolving inflammatory 
responses to commensal microorganisms. Evidence for this can be seen in IL-10-/- mice, which 
develop enterocolitis along the entire intestinal tract. Similarly, IL-10 receptor 1 knockout mice 
also develop spontaneous colitis (Spencer et al., 1998). The importance of the microbiota in 
colitis is highlighted by studies undertaken in IL-10-/- mice which showed that under specific 
pathogen free (SPF) conditions IL10-/- develop local, attenuated disease (Kuhn et al., 1993). 
Commensal Bacteroides species (Bloom et al., 2011), Helicobacter hepaticus (Kullberg et al., 
1998) and other bacterial species have all been shown to initiate colitis in IL-10/receptor 
deficient mice but not in wild-type mice.  
 




Figure 1-3 IL-10 signalling pathway (Berti et al., 2017) 
Binding of the IL-10 homodimer to the IL-10 receptor initiates phosphorylation of Tyk2 and 
JAK1. Stat3 is phosphorylated by the Tyk2 and JAK1 kinases resulting in its homodimerization. 
The activated Stat3 dimer translocates to the nucleus where it can act as a transcription factor 
inducing IL-10 responsive gene transcription. The SOCS3 protein negatively feedbacks onto the 
signalling pathway and inhibits MAPK activated pro-inflammatory gene transcription. 
 
In addition to the findings from mouse models a connection between IL-10 signalling and human 
IBD has been identified through genome wide linkage and association studies (GWAS) (Pigneur 
et al., 2013), for example early-onset IBD with a severe phenotype which has been linked to 
mutations in the IL-10 receptor resulting in decreased STAT3 activation following IL-10 
stimulation (Glocker et al., 2009). 
 
Currently the literature suggests interleukin-10 signalling is an important component in 
maintaining the intestinal barrier and aiding tolerance to the commensal microbiota and 
therefore is likely to be involved in the aetiology of IBD. 
 
1.2.5 Gut microbiome involvement 
A dysbiotic microbiome with decreased alpha-diversity, or species richness, has been observed 
in many studies of the IBD microbiota (Kostic et al., 2014). Characteristics of the observed 
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changes are an increase in Proteobacteria (Gevers et al., 2014) and a decrease in anaerobes 
and anti-inflammatory commensals e.g. Faecalibacterium prausnitzii (Sokol et al., 2008). These 
studies are informative for knowledge of the IBD microbiome but do not distinguish between 
IBD-associated and/or causative microbes. Microbial metabolites and impaired microbiome 
sensing by the host immune system are mechanisms showing the significance of the 
microbiome in promoting intestinal inflammation.  
 
The first gene to be linked to Crohn’s Disease was Nucleotide-binding Oligomerization Domain-
containing protein 2 (NOD2) (Hugot et al., 2001). The NOD2 ligand is a muramyldipeptide, a 
motif of bacterial peptidoglycan, and so this innate immune receptor is considered an 
intracellular bacterial sensor. GWAS have also linked the autophagy genes ATG16L1 (Hampe 
et al., 2007) and IRGM (Parkes et al., 2007) genes to CD susceptibility. Autophagy is a cellular 
recycling process but is also involved in clearance of pathogens so could indicate the 
involvement of an intracellular pathogen (Pareja and Colombo, 2013). NOD2 has subsequently 
been shown to recruit the ATG16L1 protein to the plasma membrane with mutant NOD2 failing 
to form effective bacterial clearing autophagosomes (Travassos et al., 2010). CD-associated 
NOD2 and ATG16L1 are also associated with poor autophagy induction, bacterial trafficking, 
and antigen presentation in dendritic cells (Cooney et al., 2010). 
 
Caspase recruitment domain family member 9 (CARD9) is another IBD associated protein with 
links to the microbiota. IBD risk alleles exist in the caspase recruitment domain family member 9 
(CARD9) gene (Beaudoin et al., 2013) and CARD9-/- mice are more susceptible to colitis 
(Lamas et al., 2016). CARD9 is linked with the intracellular sensing of pathogens via its 
association with the aforementioned NOD2 (Hsu et al., 2007), induction of IL-22 (Bergmann et 
al., 2017), fungal innate immunity (Gross et al., 2006) and microbial anti-inflammatory aryl 
hydrocarbon receptor signalling (Lamas et al., 2016). 
 
Some microbial metabolites are able to positively influence the integrity of the intestinal barrier. 
The SCFA butyrate can enhance tight junction formation (Peng et al., 2009) and SCFAs can 
signal through the regulatory T cell GPCR43 receptor to protect against intestinal inflammation 
(Smith et al., 2013). More recently Peptostreptococcus russellii has been shown to increase 
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Muc2 producing goblet cells via the production of the small metabolite indoleacrylic acid 
(Wlodarska et al., 2017) thereby increasing mucus production. 
 
1.3 Cancer 
1.3.1 What is cancer? 
Cancer is a broad term used to describe many diseases originating from different cell types and 
anatomical sites. For this reason, to define cancer is a somewhat philosophical question but a 
key characteristic is uncontrolled cellular growth by cells that have acquired a cancerous, or 
malignant, phenotype. Cancer is a multistage process of monoclonal origin whereby a single 
cell acquires a malignant phenotype in a process known as cell transformation. Transformed 
cells proliferate indefinitely to form a mass of cells known as a tumour. Tumours are described 
as cancerous once they have evolved to invade surrounding, healthy tissue and sometimes 
have the ability to metastasise to other tissues. Indeed, in Colorectal Cancer (CRC) tumours are 
defined as cancerous if they invade into the bowel wall (Ruddon, 2007, Knowles and Selby, 
2005).  
Table 1-2 Definitions of types of cellular adaptation (Weinberg, 2014) 
Type of Cellular Adaption Definition 
Anaplasia 
Cells lack differentiation and specialised characteristics, often a 
feature of malignant tumours 
Dysplasia 
Disordered cell proliferation as result of changes in cellular 
arrangement, size and shape. 
Neoplasia 
A region of cellular growth that has escaped normal regulatory 
controls usually through the acquisition of DNA mutations. Solid 
neoplasms are commonly referred to as tumours 
Hyperplasia  An area of increased and abnormal cell proliferation 
Metaplasia Cells that have transformed into another differentiated cell type 
 
A more relevant question than what is cancer is perhaps to ask what are the characteristics of 
transformed cells? Table 1-2 Summarises features of cellular adaption that are seen in tissues 
with transformed cells. In 2000 Hanahan and Weinberg (Hanahan and Weinberg, 2000) 
described a process by which cells transform to become malignant by the acquisition of certain 
traits. This landmark paper identified central neoplastic traits that were named as the six 
hallmarks of cancer and have since been updated to add additional hallmarks (Table 1-3) 
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(Hanahan and Weinberg, 2011). Criticisms of these hallmarks are that some features described 
are required for tumourigenesis and not specific for carcinogenesis (Lazebnik, 2010). However, 
it is important to note is that ‘hallmarks’ are defined in the paper as ‘distinctive and 
complementary capabilities that enable tumour growth and metastatic dissemination’ (Hanahan 
and Weinberg, 2000). An additional criticism is that the paper follows the somatic mutation 
theory (SMT) (Boveri, 2008) where cancer arises clonally from a single cell rather than cancer 
as a disease of disordered tissue organisation as proposed by the tissue organisation field 
theory (TOFT) (Sonnenschein and Soto, 2013). TOFT considers the altered biophysical and 
biomechanical properties of cancer tissue, something often overlooked in cancer biology. This 
landmark paper has been pivotal for summarising key features and properties of malignant cells 
but contains no reference to cancer causation. 
Table 1-3 Hanahan and Weinberg Hallmarks of Cancer 
Hanahan and Weinberg Hallmark Description 
Sustained proliferative signalling Do not require external growth factor signals to divide 
Evading growth suppressors 
Obtain activating mutations capable of sustained 
downstream signalling 
Avoiding immune destruction* 
Evasion and inhibitor strategies to avoid tumour killing 
immune cells 
Enabling replicative immortality 
Cells can enter a non-proliferative senescent state. 
Rarely cancer cells escape from senescence with the 
ability to divide indefinitely (immortalisation).  
Tumour-promoting inflammation* 
Most tumours are infiltrated by immune cells. 
Inflammation can supply tumorigenic molecules to the 
tumour microenvironment. Chronic inflammation has 
been associated with carcinogenesis. 
Activating invasion & metastasis 
Acquire traits to invade surrounding healthy tissue and 
ability to metastasise or transit via the circulatory system 
to distant tissues 
Inducing angiogenesis 
Required to sustain nutrient availability and exclude 
metabolic waste in the area of increased cell mass 
Genome instability & mutation* 
DNA damage can result in mutations that may confer a 
selective advantage. 
Resisting cell death 
Evolve strategies to become resistant to programmed cell 
death (apoptosis). 
Deregulating cellular energetics* 
Altered cell metabolism is required for sustained cell 
growth and proliferation (Warburg, 1956). 
* = Added or updated in Hanahan & Weinberg 2011 
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1.3.2 Cell Cycle and DNA damage 
The eukaryotic cell cycle describes a methodical series of events including regulatory checks 
that are required in order for a cell to divide with high fidelity. There are four major phases of the 
cell cycle; G1, S, G2 and M phase. During G1 cells grow in size and synthesise the required 
components for cell division (Lodish et al., 2013). In S phase DNA synthesis and replication 
happens, followed by another growth phase (G2). The final phase is M phase, or mitosis, 
whereby the cell divides to produce two identical daughter cells. Cells can also exit the cell cycle 
during G1 to enter a quiescent, resting state known as G0. 
 
Control of the cell cycle is governed by regulatory proteins, mainly cyclins and cyclin-dependent 
kinases (CDKs), at specific checkpoints throughout the cell cycle (Satyanarayana and Kaldis, 
2009). Cyclins are specific to a cell cycle phase and can form complexes with CDKs to activate 
or inhibit regulatory proteins and control progression through the cell cycle.  
 
Cells contain machinery to sense DNA lesions, amplify the damage signal, and initiate a cellular 
response, such as cell cycle arrest or beginning DNA repair, in a process known as the DNA 
damage response (DDR) (Jackson and Bartek, 2010). Different types of DNA damage can 
occur such as double stranded breaks (DSB) and DNA mismatches that induce specific DNA 
repair mechanisms. Identification of DNA damage and efficient repair are required by the cell to 
prevent the accumulation of mutations. A feature of cancer is that these cell cycle protective 
mechanisms, including the DDR, are dysregulated allowing for a cell to accrue mutations, avoid 
apoptosis and continue to proliferate (Ishikawa et al., 2006). Incomplete DNA repair can have 
the consequence of increased mutagenesis and genomic instability, a hallmark of cancer 
(section 1.4.3). 
 
The identification of DNA damage or cellular abnormalities at cell cycle checkpoints can result in 
various cellular outcomes. Initially cell-cycle arrest prevents proliferation of an abnormal cell, 
followed by induction of autophagy (a form of cellular degradation and recycling) and, if 
required, DNA repair. If the cell is severely damaged it will undergo programmed cell death 
otherwise known as apoptosis or enter a state of irreversible senescence where the cell is 
unable to proliferate. 
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1.4 Colorectal Cancer (CRC) 
1.4.1 Adenomatous polyps and colorectal cancer  
The aetiological factors of CRC include genetics, diet and environmental factors however it is 
also a heterogeneous disease (Linnekamp et al., 2015). Colorectal cancer is known to develop 
over many years and undergo a multi-step process. Initially hyperproliferation of the intestinal 
epithelium is seen leading to the development of an adenomatous polyp which may become 
cancerous defined by invasion of the tumour into the bowel wall (Vogelstein et al., 2013). Not all 
polyps will become malignant and there currently exists a lack of predictive biomarkers (Lech et 
al., 2016). Despite advances in the molecular analysis of CRC, methods of staging currently 
remain using clinicopathological criteria. The current clinical CRC prognosis criteria is the TNM 
staging system which takes into account Tumour size, inclusion of lymph Nodes and the 
presence of Metastatic cells (Amin et al., 2017). An accumulation of evidence has led to the 
consensus that polyps may evolve into cancer over time via a locus of malignancy that develops 
within the tumour. One example of such evidence is that the removal of adenomas 
(polypectomy) during screening colonoscopies has been shown to reduce the incidence of CRC 
development (Winawer et al., 1993).  
 
Polyps can differ in their endoscopic and histological appearance, size and location within the 
colon (Hazewinkel and Dekker, 2011). Figure 1-4 shows images of colonic pathology taken 
during colonoscopy and the endoscopic appearance of various tumour types. Mucosal biopsies 
of newly diagnosed polyps are sent for histological analysis for sub-typing and information on 
malignant potential. Table 1-4 summarises key phenotypic and epidemiological features of 
different adenoma types based on the WHO Classification of Tumours of the Digestive System 
(Bosman et al., 2010).  
 




Figure 1-4 Colonic tumourigenesis (adapted from Hazewinkel and Dekker 2011) 
Endoscopic images of a healthy colon, small sessile adenoma highlighted by indigo carmine 
dye spray, a large pedunculated adenoma and a carcinoma. The endoscopic appearance box 
highlights the different shapes of tumours seen in the colon and their terminology. 
 
Table 1-4 Summary of adenomatous polyp subtypes (Bosman et al., 2010) 
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and Bettington, 2014). Saw 
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Healthy colon Small sessile adenoma
Large pedunculated (stalk) 
adenoma
Endoscopic appearance
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1.4.2 Genetic pathways of CRC 
There is a low rate of mutation in healthy human cells while large doses of carcinogens are 
likely to lead to cell death. For these reasons and from the study of specific cancer types it is 
thought that key events must occur on their own and in a sequential order for a cancer to form, 
often referred to as a genetic pathway (Knowles and Selby, 2005). The classic multi stage 
description of CRC carcinogenesis, sometimes referred to as the adenoma-carcinoma 
sequence or the ‘Vogelgram’, was described by Fearon and Vogelstein in 1988 (Vogelstein et 
al., 1988). This model refers to the sequential progression of CRC which is accompanied by the 
temporal accumulation of somatic mutations in key genes/pathways, including the common 
mutations at specific steps of cancer progression. Since Fearon and Vogelstein the genomic 
heterogeneity of colorectal adenomas and carcinomas has been realised with additional 
pathways of CRC progression also described.  
 
1.4.3 Genomic instability 
Genomic instability refers to chromosome aberrations and is a common feature of CRC. Two 
main types have been described, chromosomal instability (CIN) and microsatellite instability 
(MSI) (Figure 1-5). MSI occurs due to faulty DNA replication during S phase whereas CIN 
occurs due to a chromosome segregation error during mitosis. It is also possible for cells to 
acquire more than one type of genomic instability (Pikor et al., 2013). 
 
Chromosomal instability (CIN) refers to defective chromosome segregation with the outcome 
being an altered number of chromosomes (aneuploidy) or chromosome instability. The cause of 
CIN is linked to mutations in genes associated with mitosis, for example mutations resulting in 
centrosome mis-segregation (Rao and Yamada, 2013). A mutation in the adenomatous 
polyposis coli (APC) gene (section 1.4.4) is common in the early stages of adenoma 
development and is linked to CIN, whether mutated APC causes CIN or vice versa is of some 
debate (Rusan and Peifer, 2008). This type of genomic instability is also associated with poor 
prognosis in CRC (Hveem et al., 2014). 
 
 




Figure 1-5 Types of Genomic Instability in Colorectal Cancer 
(A) Chromosomal instability refers to alterations in chromosome number or structure often 
resulting from mutations associated with mitosis. 
(B) Microsatellite repeat sequences can result in replication errors such as an insertion, deletion 
or point mutation. Mutations in DNA mismatch repair in CRC do enable repair of these errors. 
(C) Hypermethylated CpG promoters in colorectal cancer can result in tumour suppressor genes 
being switched off. CpG sites are represented by blue ‘lollipops’. ‘M’ denotes a methylated CpG 
site. 
 
Microsatellites are tandem repeats of short DNA sequences (1-5 bp) that can be prone to errors 
during replication from slippage of the DNA polymerase. In a healthy cell these microsatellite 
alterations are compensated for by the existence of mismatch repair (MMR) mechanisms. The 
primary contributor in CRC to microsatellite expansions and contractions, in other words MSI, 
(Boland and Goel, 2010) (Figure 1-5B) are mutations in important MMR genes such as MLH1. 
Germline mutations in MMR genes result in a syndrome known as hereditary nonpolyposis 
colorectal cancer (HNPCC) or Lynch syndrome whereby these individuals have an increased 
risk of developing CRC (Lynch and Krush, 1971, Douglas et al., 2005). 
 
An alternative molecular phenotype of CRC development an epigenetic instability pathway 
known as the CpG island methylator phenotype (CIMP) was first described by Toyota et al., 
1999 (Figure 1-5C). Some gene promoters are rich in CG dinucleotides known as CpG islands. 
A common form of epigenetic regulation is via methylation of CpG islands and consequential 
A. Chromosomal instability 
(CIN)
B. Microsatellite instability (MSI) C. CpG island methylator phenotype 
(CIMP)
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transcriptional silencing. CIMP describes a subset of CRC with hypermethylated promoters that 
result in switched off tumour suppressor genes (Nazemalhosseini Mojarad et al., 2013). 
 
1.4.4 Importance of APC and β-catenin signalling in CRC  
Wnt signalling is a significant pathway for embryonic development, maintenance of cellular 
homeostasis and wound healing (Clevers, 2006). These important cellular functions are 
mediated through fine regulation of the abundance and localisation of the transcriptional co-
activator, β-catenin. When located within the nucleus β-catenin interacts with the TCF/LEF 
transcription factor to induce gene expression including the protooncogenes c-Myc and cyclin 
D1. Regulation of total β-catenin is mediated by the β-catenin destruction complex, which 
comprises of the proteins, APC, Axin, glycogen synthase kinase 3 (GSK-3) and casein kinase 1 
(CK1) (MacDonald et al., 2009). In the canonical Wnt signalling pathway the destruction 
complex can be activated by Wnt ligand binding to an upstream membrane-bound receptor. In 
the absence of Wnt activation β-catenin is phosphorylated and targeted for degradation to the 
proteasome. Wnt ligand activation promotes β-catenin separation from the cytoplasmic protein 
complex and subsequent translocation to the nucleus thereby inducing gene expression.  
 
Cross-talk with other pathways such as Hippo signalling (Konsavage Jr et al., 2012, Kim and 
Jho, 2014) enables fine regulation of β-catenin quantity and location. The main pool of β-catenin 
is associated with cadherin-mediated cell adhesion. β-catenin can be sequestered at the 
intercellular adherens junctions via its binding to E-cadherin. Cleavage of E-cadherin results in 
β-catenin dissociation and accumulation in the nucleus. 
 
Evidence for the importance of β-catenin signalling in CRC is observed based on the fact that 
80% of CRC tumours have acquired mutations within this pathway (Rowan et al., 2000). APC is 
a potent CRC tumour suppressor with somatic mutations resulting in loss of function or 
production of a truncated protein (Rowan et al., 2000). Germline mutations in APC are linked to 
the hereditary condition familial adenomatous polyposis (FAP) whereby individuals develop 
multiple (over a hundred) colonic adenomatous polyps (Half et al., 2009). A common mouse 
model of intestinal tumourigenesis is the minimal intestinal neoplasia mouse model (Apc(Min/+)). 
These mice are heterozygous for a point mutation in the APC gene resulting in the development 
of multiple intestinal adenomas (Su et al., 1992). 




APC mutations in CRC often occur within a portion of the gene referred to as the mutation 
cluster region (MCR), a region required for β-catenin binding (Nagase and Nakamura, 1993). 
Aside from its role as a scaffold protein within the β-catenin destruction complex APC also has 
other functions that may be of relevance to its association with CRC. APC can bind to and 
stabilise microtubules (Mimori-Kiyosue et al., 2000, Zumbrunn et al., 2001) thereby associating 
APC with cell division and CIN. Not all adenomas with mutant APC are aneuploidy suggesting 
that mutations in APC predate and therefore could cause CIN (Sieber et al., 2002). APC can 
also bind to components of the DNA repair mechanism base-excision repair linking it with cell 
fate of DNA damaged cells and MSI (Jaiswal and Narayan, 2008). 
 
1.4.5 Colonoscopy 
Colonoscopy is an endoscopic procedure considered the ‘gold standard’ for the detection of 
gastrointestinal pathology such as colonic polyps or inflammation. Clinical indications for referral 
include anaemia, unexplained changes in bowel habit, unexplained weight loss and rectal 
bleeding. Following bowel preparation medication, a colonoscope is passed through the length 
of the colon through the ileocaecal valve and ending at the terminal ileum. The colonoscope is 
then removed gradually with patient position changes to look carefully for any tumours. 
Suspected regions of abnormal mucosa can be stained using a dye such as indigo carmine dye 
(Figure 1-4). Despite this there is still an estimated 2% polyp miss rate (Hazewinkel and Dekker, 
2011). On finding a polyp/neoplasm some biopsies are taken for histological assessment and 
the polyp itself removed by a procedure known as a polypectomy. 
 
1.5 Bacterial pathogenesis and virulence factors 
The red queen hypothesis of evolution describes an evolutionary arms race between competing 
species for finite resources  i.e. ‘it takes all the running you can do to stay in the same place’ 
(Van Valen, 1973). An updated version of this evolutionary hypothesis details how species 
expand in population size to a peak, with a failure to expand resulting in a decline towards 
extinction (Zliobaite et al., 2017).  Competing organisms therefore require genome plasticity and 
the acquisition of mutations to adapt and evolve against competitors. Within a single bacterial 
species there can exist a large genomic diversity between individual isolates or strains and this 
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has been highlighted with the advancement of DNA sequencing technology and subsequent 
surge in comparative genomics. The pan-genome of a species comprises a core genome 
present in all isolates and an accessory genome present in only some strains. As more 
genomes of a species are sequenced the number of unique genes identified decreases 
however extrapolating the curve suggests that a non-zero asymptotic value is reached (Tettelin 
et al., 2005).  
 
Bacterial pathogens carry virulence factors that play a role in disease pathogenesis (Brogden et 
al., 2000). Loss of virulence factors generally does not affect viability of the organism but does 
affect virulence. Commonly these virulence factors are associated with colonisation (e.g. 
adherence factors), evasion of the host immune response (e.g. capsule formation), host tissue 
invasion or translocation of effector molecules into host cells via secretion systems or damage 
to the host via toxin production. Virulence factors are often part of the aforementioned 
accessory genome coded for on DNA elements such as prophages, transposons, plasmids and 
pathogenicity islands (Brown et al., 2012). This suggests these genes have either been 
acquired recently in evolutionary terms or are easy transmissible between organisms. 
 
An interesting evolutionary question regarding pathogenicity is what benefit does the pathogen 
gain by damaging or even killing its host? The answer to this is likely to be subtly different on a 
case-by-case basis but an interesting example is Clostridium botulinum, which has a very potent 
virulence factor in botulinum toxin. This toxin is easily able to kill the human host but the 
bacterium itself is soil-based and cannot grow/thrive in humans therefore humans are an 
ecological sink for the bacterium (Sokurenko et al., 2006). A comprehensive review on the topic 
of virulence factors and their evolution is described by (Brown et al., 2012). 
 
1.5.1 Bacterial toxins 
Toxins are common bacterial virulence factor and effectors of bacterial pathogenesis (Rudkin et 
al., 2017). Traditionally bacterial toxins were defined as causing cellular damage and death but 
it has become apparent that they can also attack and hijack host cell function. Various subtypes 
of bacterial toxins exist. Pore-forming toxins can induce pore formation in cellular membranes, 
intracellular toxins act within the cell and the third category mimic host signalling molecules. 
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1.5.2 B. fragilis – an example of a pathobiont 
Opportunistic pathogens or pathobionts usually live in symbiosis with the host (commensals) but 
under certain conditions can become pathogenic.  Often opportunistic pathogens are 
compartmentalised into environments where they cause disease and locations where they are 
commensal (Brown et al., 2012). For example, B. fragilis can be commensal within the healthy 
GI tract but following disruption of the intestinal wall may trigger intra-abdominal abscess 
formation and sepsis (Wexler, 2007). 
 
1.5.2.1 BfUbb 
Whole genome sequencing of the B. fragilis type strain NCTC9343 revealed a low GC% region, 
suggesting the presence of a pathogenicity island which was found to include a protein with 
homology to human ubiquitin (Patrick et al., 2011). Expression of BfUbb has been confirmed 
and the protein is likely to be delivered to cells in outer membrane vesicles (OMVs). BfUbb 
differs from human ubiquitin due to a C-terminal cysteine instead of a glycine residue. This 
cysteine residue can form a disulphide bridge with human E1 activating enzyme. BfUbb 
inactivates E1 and is likely to have profound effects on the ubiquitination cascade and 
subsequently the host cell, and therefore is a putative virulence factor (Patrick and Blakely, 
2012). 
 
Although BfUbb is the first bacterial protein identified with direct homology to ubiquitin other 
bacterial pathogens have been shown to modulate the host ubiquitination system using a 
variety of mechanisms (Zhou and Zhu, 2015).  
 
1.6 Microbial-induced cancer 
A range of epidemiological studies have reported associations between bacterial pathogens 
and/or microbiome dysbiosis and an increased incidence of a specific cancer. Table 1-5 lists 
examples of bacteria and bacteria-associated diseases that have been epidemiologically linked 
to cancer. 
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Table 1-5 Bacterial pathogens and bacterial dysbiosis epidemiologically linked to a 
specific cancer type 
Authors 
Bacterium or bacterial 
dysbiosis 
Cancer type Risk 




Elevated P. gingivalis 
antibody titre associated 
with a two-fold increased 
risk 
(Abnet et al., 2001) 
Poor oral health as 
indicated by tooth loss 
Oesophageal 
and gastric 
Oesphageal RR: 1.3 
Gastric non-cardia RR: 1.8 
(Zeng et al., 2016) 
Meta-analysis 
Periodontal disease Lung 
HR = 1.24 adjusted for 
smoking status 
(Randi et al., 2006) S. typhi and S. paratyphi Gallbladder Pooled RR: 4.8 
RR = Relative risk; HR = Hazard ratio 
 
The aforementioned examples are associations and therefore not necessarily causative. 
Potential oncogenic mechanisms of specific bacteria and their virulence factors have been 
identified and are detailed in section 1.6.2.  
 
1.6.1 HPV - a viral example 
Arguably the best evidence for causality of cancer by a microorganism is available for Human 
Papilloma Virus (HPV). In the UK vaccinations to prevent colonisation of HPV are now routinely 
given to teenage girls to reduce the incidence of cervical cancer (Drolet et al., 2015). The 
primary mechanism of tumorigenesis is executed by the HPV oncoproteins (E6 and E7) which 
can inactivate p53 and retinoblastoma (pRB) tumour suppressor proteins thereby driving 
aberrant cell proliferation (DeFilippis et al., 2003). The well-characterised oncogenic 
mechanisms of HPV provide insight into microbe-induced tumourigenesis. Microbe-driven 
nuclear localisation of β-catenin has also been observed as an oncogenic characteristic of HPV 
(Rampias et al., 2010). 
 
1.6.2 Bacterial mechanisms of cell cycle modulation 
Putative carcinogenic bacteria have a range of mechanisms by which they can induce cellular 
transformation. Impairment of cell cycle regulation and DNA damage response (Figure 1-6), 
modulation of host cell signalling (Figure 1-7) and direct immune system perturbation are the 
main categories by which bacteria can push cells towards a malignant phenotype. 
Comprehensive reviews on this subject can be found in (Lax, 2005) and (Gagnaire et al., 2017). 





Figure 1-6 Bacterial impairment of cell cycle regulation and DNA damage response 
Examples of mechanisms used by bacterial pathogens to disrupt cell cycle regulation and the 
DNA damage response subsequently leading to cellular transformation. ROS = Reactive 
Oxygen Species 
 
Bacteria can directly damage DNA by a number of mechanisms. These include the production 
of the genotoxin colibactin in E. coli (section 1.7.2) that induces double strand breaks 
(Nougayrede et al., 2006). Host cell cycle checkpoints exist to identify and initiate repair of DNA 
damage although repair may be incomplete while chronic DNA damage can result in genomic 
instability or cellular senescence. Another bacterial genotoxin, cytolethal distending toxin (CDT), 
when chronically applied to cells at a sublethal dose, blocks initiation of DDR and cells 
transform towards a malignant phenotype (Guidi et al., 2013). Bacteria can also damage DNA 
indirectly; for example Enterococcus faecalis can produce extracellular superoxide, a precursor 
of many types of reactive oxygen species (ROS) (Wang et al., 2012). DNA damage and 
genomic instability as a result of E. faecalis superoxide production has been shown in vitro and 
in vivo (Huycke and Moore, 2002). 
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Cycle-inhibiting factor (Cif) was first discovered in E. coli in 1997 (De Rycke et al., 1997) when it 
was observed that it induced actin stress fibres and enlarged cells. Cif can also be found in 
other bacteria: Yersina pseudotuberculosis, Photohabdus luminescens, Photohabdus 
asymbiotica and Burkholderia pseudomallei (Jubelin et al., 2009). Cif does not trigger DNA 
damage but instead interacts with host protein NEDD8 resulting in inhibited ubiquitin ligase 
activity (Cui et al., 2010, Jubelin et al., 2010, Morikawa et al., 2010), accumulation of p21Waf1/cip1 
and p27kip2 (Samba-Louaka et al., 2008) and inhibitory phosphorylation of cyclin dependent 
kinase-1 (CDK-1). The consequence is cell cycle arrest in the host cell. 
 
Other bacterial mechanisms do not damage DNA but impair the DNA damage response. For 
example, Listeria monocytogenes toxin listeriolysin O (LLO) induces DNA damage and triggers 
degradation of the DDR protein Mre11, a mechanism required for sustained L. monocytogenes 
infection (Samba-Louaka et al., 2014). 
 
E. coli Cytotoxin necrotizing factor CNF1 promotes cell survival via the Akt/IκB pathway, 
ultimately leading to Bcl-2 overexpression and prevention of apoptosis (Miraglia et al., 2007). 
The Salmonella flexneri effector VirA can also inhibit apoptosis via the degradation of p53 
(Bergounioux et al., 2012). VirA achieves this by activating the host protease calpain to degrade 
p53. Other bacteria have been found to manipulate the p53 pathway (Zaika et al., 2015), 
including Helicobacter pylori cytotoxin-associated gene-A (CagA) (Buti et al., 2011)  and 
Chlamydia trachomatis (Siegl et al., 2014). 
 
1.6.3 Oncogenic modulation of host cell signalling by bacteria 
Cellular transformation can be promoted by bacterial modulation of host cell signalling pathways 
(Figure 1-7). Many of the mechanisms result in sustained cell proliferation which may increase 
the rate of cell transformation (Lax and Thomas, 2002). One mechanism used by bacteria to 
initiate cell proliferation is to activate β-catenin signalling (section 1.6.5). This can be achieved 
either through disruption of adherens junctions either through direct E-cadherin cleavage, for 
example by the Fusobacterium nucleatum adhesin FadA (Rubinstein et al., 2013) or indirectly 
via γ-secretase as occurs in B. fragilis toxin (BFT) (Wu et al., 2007). The other consequence of 
targeting adherens junctions in epithelial cells in that this impairs the barrier property of the 
epithelium allowing for paracellular migration of the microbiota and consequent inflammation. 





Figure 1-7 Bacterial modulation of host cell signalling 
Mechanisms used by bacterial pathogens to modulate host cell signalling, driving the cell 
towards cellular transformation. 
 
S. enterica SPI effectors can induce sustained activation of the AKT and MAPK pathways 
initiating a range of cell signalling that can lead to cell proliferation, growth and differentiation 
and ultimately cellular transformation (Scanu et al., 2015). Another example of an oncogenic 
pathway targeted by bacterial pathogens is Signal transducers and activators of transcription 3 
(STAT3). H. pylori infection results in phosphorylation and therefore activation of (STAT3) in a 
CagA mediated process (Bronte-Tinkew et al., 2009). When activated, dimeric STAT3 can 
translocate to the nucleus to act as a transcription factor and in epithelial cells will initiate cell 
proliferation, migration, and transformation. In immune cells STAT3 activation results in a pro-
inflammatory phenotype (Cheng et al., 2003). 
 
1.6.4 Helicobacter pylori - a bacterial example 
The most established link between bacteria and cancer causation is between H. pylori and 
gastric adenocarcinoma. Originally the connection between H. pylori and cancer was unclear 
but a convincing factor was the evidence that eradication of the bacterium was associated with 
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al., 2005). H. pylori can cause inflammation of the lining of the stomach (gastritis) (Marshall et 
al., 1985) and if left untreated this long-term inflammation has been associated with malignancy 
(Uemura et al., 2001). Extensive literature exists on mechanisms of H. pylori-induced 
tumourigenesis and therefore provides an excellent model when investigating other links 
between bacteria and cancer. Numerous H. pylori virulence factors have been attributed to the 
carcinogenic process but primarily the toxins, CagA and Vacuolating cytotoxin A (VacA), are 
considered instrumental. 
 
The cagA gene is located on the cag pathogenicity island (PAI) that codes for a type IV 
secretion system and is not present in all H. pylori strains. CagA+ strains have been shown to 
increase the risk of H. pylori-induced gastric cancer (Parsonnet et al., 1991). The cag type IV 
secretion system (T4SS) is a molecular syringe that allows for the injection of the CagA effector 
protein into a host cell (Odenbreit et al., 2000). Inside the cell CagA becomes phosphorylated at 
the amino acid motif EPIYA by host Src kinases (Stein et al., 2002). CagA then binds and 
degregulates SRC homology 2 domain (SH2)-containing tyrosine phosphatase SHP-2 (Higashi 
et al., 2002b) to initiate a range of cell signalling events that push the cell towards malignancy. 
H. pylori strains can differ in their number of EPIYA motifs altering binding affinity for the host 
SHP-2 phosphatase and therefore have been associated with the carcinogenic potential of a 
strain (Higashi et al., 2002a). T4SS expression and CagA delivery into the cell occurs 
basolaterally (Tegtmeyer et al., 2017). To permit paracellular transmigration disruption of the 
tight and adherens junctions is carried out by another H. pylori virulence factor, the serine 
protease high-temperature requirement A (HtrA) (Hoy et al., 2010). 
 
The VacA toxin is multifunctional but named after its ability to bind cells, become internalised 
and induce cytoplasmic vacuolation of host cells (Leunk et al., 1988). Following internalization 
into endosomal-like vesicles (Papini et al., 1994) VacA forms anion-selective channels (Iwamoto 
et al., 1999) in the vesicle membrane, triggering osmotic swelling (Tombola et al., 1999) and 
vacuolation. VacA can indirectly activate multiple cellular signalling pathways including, p38 and 
ERK1/2 (Nakayama et al., 2004) and has also been shown to cause damage to the 
mitochondria (Kimura et al., 1999) triggering apoptosis (Galmiche et al., 2000). All strains 
contain the vacA gene but there are variations in sequence with some genotypes linked with an 
increased risk of developing gastric cancer (Miehlke et al., 2000). The ability of VacA to target 
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immune cells provides an effective method of immune evasion which facilitates the persistence 
of H. pylori (Djekic and Muller, 2016). 
 
Tumour necrosis factor-α (TNF-α) inducing protein (Tipα) is an additional putative carcinogenic 
toxin produced by H. pylori (Suganuma et al., 2008). Tipα induces NFκB activation resulting in 
increased chemokine and TNF-α secretion. 
 
Other H. pylori virulence factors that have been proposed to be associated with gastric 
tumourigenesis are Outer inflammatory protein A (OipA) (Yamaoka et al., 2000) and Duodenal 
ulcer promoting gene a (dupA) (Lu et al., 2005a). The OipA gene can be present in strains in 
functional (on) or non-functional (off) forms with a meta-analysis concluding that the on form is 
significantly associated with gastric cancer (Liu et al., 2013). Putative oncogenic mechanisms of 
OipA include aiding translocation of CagA (Horridge et al., 2017), activating p38 and NFkB 
pathways to induce interleukin-6 (IL-6) secretion (Lu et al., 2005b) and suppressing apoptosis in 
gastric cells (Al-Maleki et al., 2017). 
 
The dupA gene is strongly associated with duodenal ulcer formation but preventative against 
gastric cancer (OR = 0.41, (Lu et al., 2005a). dupA and the surrounding gene cluster is 
proposed to form a T4SS with DupA being an effector protein (Jung et al., 2012). DupA exhibits 
ATPase activity, is associated with increased IL-8 production and aids H. pylori tolerance to the 
low stomach pH via increased urease secretion (Wang et al., 2015). A possible anti-cancer 
property of DupA is its ability to trigger apoptosis (Wang et al., 2015). Conflicting results exist in 
the literature as to the relationship between dupA and gastric cancer. A meta-analysis found a 
positive association between dupA and duodenal ulcer but no significant association with gastric 
cancer (Shiota et al., 2010). 
 
1.6.5 Modulation of β-catenin signalling 
The finely regulated Wnt/β-catenin signalling pathway (previously introduced in section 1.4.4) is 
targeted by many bacterial pathogens in diverse ways. As many genes transcriptionally 
activated by β-catenin are involved in cell proliferation and differentiation this pathway is often 
exploited in microbial-induced cancer.   
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H. pylori targets many components of β-catenin signalling using both species and strain-specific 
virulence factors. A common mechanism of bacterial modulation of β-catenin is to target the E-
cadherin associated pool of β-catenin either through binding to or cleaving E-cadherin. H. pylori 
can influence E-cadherin directly and indirectly to stimulate nuclear accumulation of β-catenin. 
H. pylori Toll-like Receptor 2 (TLR2) signalling can induce E-cadherin cleavage via the host 
protease, calpain (O'Connor et al., 2011) while the gastric cancer associated protein CagA has 
been shown to directly bind to E-cadherin with resultant upregulated gene expression (Murata-
Kamiya et al., 2007). H. pylori vacuolating cytotoxin A (VacA) targets a different aspect of β-
catenin signalling by activating the epidermal growth factor receptor (EGFR) with downstream 
inactivation of the destruction complex protein GSK3β (Nakayama et al., 2009). 
 
 The F. nucleatum FadA adhesin and BFT also use mechanisms of E-cadherin/β-catenin 
mediated oncogenesis (Wu et al., 2003, Rubinstein et al., 2013). These organisms and 
virulence factors are described in more detail in sections 1.7.4 and 1.7.5 respectively. 
 
Previously considered non-pathogenic the Salmonella typhimurium strain PhoPc decreases 
levels of ubiquitinated β-catenin and promotes its nuclear accumulation. This strain was shown 
to increase c-Myc expression and cell proliferation via the effector protein AvrA (Sun et al., 
2004). These findings were replicated in the AOM/DSS mouse model of intestinal neoplasia with 
the consequence of altered β-catenin signalling being that AvrA+ Salmonella strains significantly 
increased tumour incidence compared with AvrA- strains and no bacteria (Lu et al., 2014). 
 
An example of an oral pathogen with a link to β-catenin and carcinogenesis is Porphyromonas 
gingivalis. The P. gingivalis proteases gingipains can proteolytically cleave β-catenin and 
members of the destruction complex (Zhou et al., 2015). These β-catenin cleavage products 
can translocate to the nucleus where it is functionally active. P. gingivalis treatment has been 
shown to accelerate the cell cycle and invasive abilities of human immortalized oral epithelial 
cells (HIEOECs) (Katz et al., 2000). Taken together these results suggest P. gingivalis infection 
may transform oral epithelial cells and promote carcinogenesis. 
 
The pattern recognition receptor toll-like receptor 4 (TLR4) is overexpressed in colitis-
associated and sporadic CRC (Santaolalla et al., 2013). TLR4 is an innate immune receptor that 
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recognises bacterial lipopolysaccharide (LPS). TLR4 can activate the β-catenin pathway 
therefore TLR4 overexpression can lead to increased crypt cell proliferation. Whilst not an 
example of a specific bacterial pathogen modulating β-catenin signalling it highlights the 
importance between bacteria, β-catenin and CRC (Santaolalla et al., 2013). 
 
Viral pathogens, for example Rift Valley fever virus (RVFV), can also modulate β-catenin 
signalling, possibly to manipulate cell cycle conditions for viral replication (Harmon et al., 2016). 
 
1.7 CRC microbiome 
1.7.1 Hypotheses of microbiota-induced CRC 
A variety of hypotheses have been proposed by which the microbiome may induce/drive 
colorectal carcinogenesis. The alpha bug hypothesis (Sears and Pardoll, 2011) describes the 
role of the microbiome in the tripartite relationship between colonic epithelial cells, inflammation 
and microbiome in the development of CRC. The theory describes how ‘alpha bugs’ crowd out 
protective species and have pro-oncogenic characteristics that can trigger a cascade that 
results in colonic tumour growth as per the ‘Volgelgram’ model (section 1.4.2). The driver-
passenger model for CRC builds on the concept of alpha-bugs instead referring to these as 
‘driver’ organisms. A focus of this hypothesis is that the local microenvironment of the tumour 
site will change temporally as the healthy epithelium progresses into an adenoma and finally a 
carcinoma. A consequence of this environmental change is altered selection pressures on the 
associated microbiome. It is proposed that initial driver microbes have properties that can 
initiate tumourigenesis whereas ‘passenger’ species have a competitive advantage in this 
altered tumour milieu allowing for their colonisation. Passenger species may have either tumour 
promoting or suppressive characteristics (Tjalsma et al., 2012). 
 
A significant aspect of unpicking mechanisms of microbial driven CRC will be to make clear 
distinctions between the CRC-associated microbiome and CRC-causing (and CRC-preventing) 
microbes.  
 
Chapter 1.7.2 Escherichia coli toxins and CRC 
48 
 
1.7.2 Escherichia coli toxins and CRC 
Bacterial toxins linked to CRC (briefly introduced in section 1.6.3) can be divided into two 
groups; genotoxins due to their DNA-damaging properties and toxins that manipulate host cell 
signalling. Phylogenetic analysis divides E. coli strains into four main phylotypes (A, B1, B2 and 
D) (Selander et al., 1986). Phylotypes B2 and D tend to contain strains with more virulence 
factors (Picard et al., 1999), including a range of putative tumorigenic toxins. 
 
Cytolethal distending toxin (CDT) is a holotoxin made up of three proteins, CdtA, CdtB and 
CdtC. CDT is not only found in E. coli but also in multiple other species of Gram-negative 
bacteria including S. typhi and Campylobacter jejuni. CdtB has homology to human DNase and 
indeed cells treated with CDT exhibit markers of DNA damage (Lara-Tejero and Galan, 2000). 
CDT can denature or relax supercoiled plasmid DNA in vitro while nuclear translocation of CdtB 
has also been observed (McSweeney and Dreyfus, 2004). Various DNA damage responses 
have been shown to be induced by cell exposure to CDT treatment (Fedor et al., 2013, Fahrer 
et al., 2014). Following the DDR in cells treated with CDT they enter irreversible G2/M cell cycle 
arrest (Poon et al., 1997, Bielaszewska et al., 2005). 
 
The pks+ genotoxicity island (Nougayrede et al., 2006) encodes machinery for the synthesis of 
peptide-polyketide hybrid compounds, including synthesis of the genotoxin colibactin. Colibactin 
is another E. coli genotoxin able to induce double-stranded DNA breaks (Viljoen et al., 2015, 
Vizcaino and Crawford, 2015). E. coli induced genotoxicity triggers cell cycle arrest and cell 
death (Nougayrede et al., 2006). Cells treated with colibactin are enlarged (megalocytosis) 
which is a sign of incomplete DNA repair and genomic instability (Cuevas-Ramos et al., 2010). 
A common CRC mouse model when treated with colibactin-producing E. coli develop an 
increased number of colonic tumours in a mechanism dependent on the senescence-associated 
secretory phenotype (SASP) (Cougnoux et al., 2014). 
 
An E. coli toxin that is not genotoxic is cytotoxic necrotizing factor (CNF). CNF deamidates a 
specific glutamine residue of the small GTPases RhoA, Rac and Cdc42 (Schmidt et al., 1998) 
leading to cytoskeletal alterations (Fiorentini et al., 1988) and senescence. CNF can prevent 
apoptosis by a mechanism previously mentioned in section 1.6.3. Cif also does not induce 
genotoxicity but similarly to CNF is a cyclomodulin thereby initiating cell cycle arrest. 




The literature shows a lack of consensus regarding the association between E. coli and CRC in 
humans (Table 1-6). Geographical location and tumour site within the colon may be important 
factors to explain variation seen amongst the studies. 
Table 1-6 E. coli findings in human colorectal cancer (CRC) samples 
Author Sample origin Findings 
(Buc et al., 
2013) 
France 
Increased prevalence of cdt, cif, cnf and pks in tumour 
samples compared with diverticulosis 
(Bonnet et al., 
2014) 
France 
Tumours contained an increased level of mucosa-
associated and internalised E. coli 
(Raisch et al., 
2014) 
France 
Pks and cnf genes were significantly more prevalent in 
CRC than diverticulosis. CRC E. coli strains had low levels 
of adhesion and invasion but increased capacity to form 
biofilms 
(Viljoen et al., 
2015) 
South Africa 
High level colonisation of pks-positive E. coli was 
significantly associated with tumour samples 
(Gagniere et al., 
2017) 
France Pks status was associated with MSI CRC phenotype 
(Shimpoh et al., 
2017) 
Japan 
No significant difference in pks status amongst control, 
adenoma and CRC patients. 
 
1.7.3 Streptococcus gallolyticus subsp. gallolyticus 
Historically the bacterium with the longest association to CRC is Streptococcus gallolyticus. 
Originally named Streptococcus bovis this and related taxa have subsequently been subdivided 
with biotype I (now classified as Streptococcus gallotlyticus subsp. gallolyticus, (Schlegel et al., 
2003) having the strongest linked with CRC bacteremia. The original association with CRC was 
due to the observation that 65-70% individuals with S. bovis endocarditis had previously 
undiagnosed gastrointestinal tumours (Bayliss et al., 1984, Beeching et al., 1985). A meta-
analysis of all studies linking S.bovis/S.gallolyticus to CRC confirmed an increased prevalence 
in adenoma/carcinoma cases than healthy individuals. Interestingly, a higher prevalence (43%) 
was associated with adenomas compared with 18% for carcinomas indicative perhaps of an 
initiating/driver role in tumourigenesis (Boleij et al., 2011b). Seropositivity to peptidoglycan 
anchored pilin proteins has also been shown to be significantly higher in CRC cases compared 
to controls (Butt et al., 2016) (Butt et al., 2016). Boleij et al., 2011 discovered invasive strains 
that could translocate across polarised Caco-2 cells via a paracellular mechanism. 
Translocation of the bacteria may also explain seropositivity and link with bacteremia. S. 
gallolyticus may have a colonisation advantage, and therefore be a candidate passenger 
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bacterium, due to its ability to bind intestinal mucins, fibrinogen (Martins et al., 2015, Martins et 
al., 2016), and collagen rich tumour tissue (Boleij et al., 2011a). A recent report, however, 
provides evidence of a S. gallolyticus tumour driver mechanism in that the bacterium can 
increase cell proliferation via β–catenin signalling in cultured cell lines (Kumar et al., 2017). 
Evidence that this translates to an in vivo environment was shown in a mouse model of CRC as 
mice orally gavaged with S. gallolyticus developed a significantly higher tumour burden than 
mice challenged with control bacteria (Kumar et al., 2017). 
 
1.7.4 Fusobacterium nucleatum 
Fusobacterium nucleatum is a heterogeneous species currently classified into 5 subspecies; 
animalis, fusiforme, vincentii, polymorphum and nucleatum (Allen-Vercoe et al., 2011). Recent 
publications suggest fusiforme and vincentii do not differ sufficiently to be classed as separate 
subspecies and indeed the remaining subspecies should be classified as individual species in 
their own right (Manson McGuire et al., 2014, Kook et al., 2017). These bacteria are commonly 
found in the oral cavity and are linked with odontogenic and periodontal disease. F. nucleatum 
is a highly adhesive species able to invade host cells (Manson McGuire et al., 2014) and is also 
recognized as a ‘bridging organism’ in the development of dental plaque, a multi-species biofilm 
(Kaplan et al., 2009). The mechanism of adhesion and invasion is by the formation of a complex 
between secreted and anchored forms of the FadA adhesin (Xu et al., 2007).  The complex 
binds to a host receptor, including the adherens junction protein E-cadherin (Rubinstein et al., 
2013), and is then able to facilitate invasion of the bacterium into the host cell following 
internalisation of FadA. Strains of F. nucleatum can vary in their invasive capacity as strains 
isolated from IBD patients were found to be more invasive than strains isolated from healthy 
individuals (Strauss et al., 2011). 
 
16S rRNA and metagenomic sequencing of the CRC microbiome has led to the discovery of 
specific bacterial taxa associated with the tumour microenvironment (Tahara et al., 2014). 
Arguably the most consistent of these findings is that Fusobacterium species or more 
specifically F. nucleatum is enriched at the site of tumour tissue. A potential reason for this 
tumour tissue colonisation is via F. nucleatum Fap2 binding to Gal-GalNAc which is 
overexpressed in CRC. Fusobacterium isolates have also been cultured from liver metastases 
and share a high level of genome identity with Fusobacterium from the primary cancer 
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suggesting the bacterium can migrate with cancer cells to the metastatic site (Bullman et al., 
2017). 
 
As with many microbes linked to cancer F. nucleatum can activate β-catenin signalling (Section 
1.6.5). Two mechanisms behind this activation have been identified. The aforementioned FadA 
adhesin can bind to E-cadherin and induce nuclear translocation of β–catenin (Rubinstein et al., 
2013) while F. nucleatum lipopolysaccharide (LPS) can trigger TLR4 mediated β–catenin 
signalling (Chen et al., 2017). In Apc Min/+ mice F. nucleatum accelerated tumour onset and 
significantly increased the number of tumours compared with controls but did not stimulate 
colitis. F. nucleatum did not induce tumourigenesis or colitis in IL10 -/- mice or T-bet -/- Rag2- /- 
mice (Kostic et al., 2013). 
 
Other oncogenic mechanisms linked to F. nucleatum include immune cell evasion and 
chemoresistance. The ability of its Fap2 protein to inhibit host immune cell killing of tumour cells 
(Gur et al., 2015) and the activation of autophagy via Toll-like receptor 4 (TLR4) resulting in 
reduced apoptosis and therefore chemoresistance (Yu et al., 2017). 
 
1.7.5 Bacteroides fragilis toxin (BFT) 
A subset of B. fragilis strains, termed Enterotoxigenic B. fragilis (ETBF), secrete a zinc 
metalloprotease known as BFT or fragilysin. A pivotal finding into the virulence potential of this 
toxin was made by injection of the purified protein into ligated animal intestinal loops. The result 
was a dose-dependent secretory response, tissue damage, crypt hyperplasia and neutrophil 
infiltration (Obiso et al., 1995). The bft gene is contained on a 6kb pathogenicity island (BfPAI) 
(Franco, 2004) alongside another zinc metalloprotease (MPII) with 56% sequence similarity 
(Shiryaev et al., 2014) within a conjugative transposon (Buckwold et al., 2007). BFT can exist as 
one of three isotypes (bft-1, bft-2, bft-3) with whole genome sequencing revealing that non-
toxigenic strains have likely acquired the BfPAI multiple times during evolution (Pierce and 
Bernstein, 2016). The majority of B. fragilis strains can be classed as either pattern I (contains 
BfPAI and transposon), pattern II (no BfPAI or transposon), or pattern III (transposon 
only)(Buckwold et al., 2007). 
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BFT is a 397-residue protein with a signal peptide (18 residues), pro-domain (193 residue) and 
catalytic domain (181 residues). The catalytic domains of both BFT and MPII contain a zinc-
binding consensus motif (HEXXHXXGXXH) and Met-turn characteristic of metzincin 
metalloproteinases. The 3D structure of both proteins have been determined and shows 
structural homology to human matrix metalloproteases (MMPs) and a disintegrin and 
metalloproteases (ADAMs) (Goulas et al., 2011, Shiryaev et al., 2014). The prodomain of both 
proteins is structurally similar and has a unique protein fold. 
 
1.7.5.1 BFT mechanism of action 
The bft gene codes for a 44kDa preproprotein which when processed produces a 20kDa active 
toxin (Chung et al., 1999). BFT Is released into B. fragilis Outer Membrane Vesicles (OMVs) 
due to the formation of interactions with membrane components (Zakharzhevskaya et al., 2017). 
It has been suggested that BFT binds to a currently unidentified membrane receptor (Wu et al., 
2006) or the OMVs are taken up by host eukaryotic cells (Zakharzhevskaya et al., 2017) and 
subsequently trigger extensive signal transduction. BFT has been shown to induce cleavage 
and loss of the cell adhesion molecule, E-cadherin in HT-29 cells in vitro (Wu et al., 1998) and 
in animal models (Rhee et al., 2009) with rearrangement of the F-actin cytoskeleton (Saidi et al., 
1997). The adherens junction, located at cell-cell junctions, is a protein complex comprising of 
E-cadherin bound to and retaining β-catenin in the cytoplasm. Ectodomain shedding of E-
cadherin by BFT is followed by γ-secretase dependent processing of the intracellular fragment 
(Wu et al., 2007). The consequence of BFT-induced E-cadherin cleavage is IL-8 secretion 
(Hwang et al., 2013) and nuclear localization of β-catenin (Figure 1-8).  Once in the nucleus β-
catenin can bind to transcription factors and induce pro-carcinogenic gene expression including 
c-Myc and cyclin D1 (Wu et al., 2003). 




Figure 1-8 Pathogenic mechanisms of B. fragilis toxin (BFT) 
Oncogenic mechanisms of B. fragilis toxin and how they relate to the hallmarks of cancer. 
Figure adapted from (Hanahan and Weinberg, 2011). 
 
1.7.5.2 ETBF animal models 
Animal models have been used to gain a greater understanding of the pathology of both acute 
and chronic ETBF infection. ApcMin/+ mice ordinarily develop small intestine adenomas but when 
orally challenged with ETBF an earlier onset of mainly distally located tumours and inflammatory 
colitis is triggered (Housseau and Sears, 2010, Lu et al., 2005b). The transcription factor signal 
transducer and activator of transcription-3 (STAT3) is rapidly activated which subsequently 
results in differentiation of TH17 cells and IL-17 secretion (Wu et al., 2009, Wick et al., 2014). 
 
Wild type C57BL/6 mice infected with ETBF develop mucosal thickening, crypt abscesses, crypt 
hyperplasia and extensive neutrophilic infiltration whilst chronic ETBF infection results in 
persistent subclinical inflammation, enhanced epithelial hyperplasia and DNA damage 
(measured by activation of γ-H2A.x) via upregulation of spermine oxidase (SMO) and 
production of reactive oxygen species (Rhee et al., 2009, Goodwin et al., 2011, Brouwer et al., 
2013). ETBF colonization in either germ free mice or Mongolian gerbils gives rise to severe and 
consequently lethal colitis (Rhee et al., 2009, Yim et al., 2013) 
  
Oncogenic mechanisms of BFT
Discovered in vitro and validated in mouse models
Spermine oxidase-
dependent DNA 
damage via increased 
ROS production 
(Goodwin et al., 2011)
Induction of the anti-
apoptotic protein c-
IAP-2
(Kim et al., 2008)
Nuclear β-catenin signalling -> 
increased expression of c-Myc
and cyclin-D1
(Wu et al., 2003; Rhee et al., 2009)
• Increased G.I barrier 
permeability via E-cadherin 
cleavage (Wu et al., 1998)
• Pro-inflammatory cytokine 
release: IL-8, TNF-α. (Kim et al., 
2002)
• Activation of the STAT3-IL-17 
pathway (Wu et al., 2009)
Induction of E-cadherin  
degradation, which is a 
marker of EMT
(Wu et al., 1998)




The primary aim of this project is to investigate the contribution of the gastrointestinal 
commensal, Bacteroides fragilis, to gastrointestinal health and disease, with a specific focus on 
the multi-step process of colonic tumorigenesis.  
 
1.8.1 Why B. fragilis? 
The primary reason for studying B. fragilis is that some strains are potentially carcinogenic due 
to the ability to synthesise a tumourigenic toxin (BFT) (Wu et al., 2003, Wu et al., 2009, 
Housseau and Sears, 2010). B. fragilis as a species is a pathobiont and is ubiquitous in the G.I. 
tract. B. fragilis has recently been proposed as a probiotic species (Wang et al., 2017) due to 
beneficial properties such as its ability to synthesise immunomodulatory capsular 
polysaccharides (Mazmanian et al., 2005). The most studied of these polysaccharides is 
polysaccharide A (PSA), capable of inducing immune cell activation and preventing 
experimental colitis in mice (Mazmanian et al., 2005). Bacterial capsules can also be considered 
a virulence factor as it is an immune system evasion strategy employed by the bacterium. B. 
fragilis is also a suitable organism for the study of host-microbe interactions as previous 
research suggests a predominately mucosal-associated organism. This property is shown by its 
ability to bind intestinal mucin in vitro (Huang et al., 2011) and localisation within colonic crypts 
(Lee et al., 2013). 
 
The contribution of B. fragilis to gastrointestinal health is expected to involve both within-strain 




i. Sample collection 
• Establish a comprehensive sample collection comprising intestinal 
biopses, caecal fluid and blood samples from different patient cohorts with 
a focus on colon tumourigenesis 
• Establish robust methods for detection of relevant species and genes of 
interest 
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ii. Between-strain differences 
• Determine the prevalence of B. fragilis as a species within samples 
collected from different patient cohorts and identify whether putative 
virulence genes are present in selected B. fragilis strains from these 
patient groups 
• Given that multiple sequencing studies have identified Fusobacterium 
species as being enriched in the colorectal cancer microbiome, 
determination of the prevalence of Fusobacterium within these cohorts was 
undertaken to allow comparison with colorectal cancer microbiome 
sequencing studies 
iii. Within-strain differences 
• Determine PSA promoter orientation (% on) within the different patient 
cohorts 
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Chapter 2 : MATERIALS AND METHODS 
2.1 Sample Collection 
2.1.1 Subject Recruitment and Ethics Statement 
Participants undergoing routine diagnostic colonoscopy were recruited and samples collected at 
the Endoscopy Units at Guy’s and St. Thomas NHS Hospital Foundation Trust. Ethical approval 
was sought from WALES REC 7 committee (REC number: 14/WA/1221) and Guy’s & St 
Thomas’ NHS Foundation Trust Research and Development (number: RJ115/N211). Informed 
written consent was obtained from all participants. Patient information sheet part 1 and 2 and 
the consent form are found in appendix 1 & 2. Exclusion criteria for recruitment included: under 
the age of 18, macroscopically active inflammatory bowel disease, antibiotics within the last 4 
weeks, positive stool culture for the known enteropathogen Clostridium difficile. Individuals were 
divided into cohorts depending on the reason for attendance for, or result of colonoscopy. 
Subjects were recruited into newly diagnosed polyps/cancer (n = 32), previous polyps/cancer (n 
= 14), inflammatory bowel disease (n = 14) and healthy controls (n = 22) and are listed in tables 
2.1 – 2.5. Some individuals were assigned multiple cohorts and consequently are listed 
separately in table 2.5. Healthy controls were defined as individuals with anaemia or rectal 
bleeding as an indication for colonoscopy with no signs of GI disease upon colonoscopy. 
 
2.1.2 Sample Collection and Processing 
2.1.2.1 Mucosal Biopsies 
During colonoscopy mucosal biopsies were collected using 5 mm endoscopic biopsy forceps 
following completion to the caecum. Two mucosal biopsies from the ascending colon and two 
from the descending colon were collected and immediately frozen on dry ice. Similarly, two 
mucosal biopsies from the ascending colon and two from the descending colon were collected 
and immediately placed into RNAlater® (Sigma-Aldrich, Gillingham, UK) at room temperature. 
Biopsy samples collected from individuals with newly diagnosed tumours larger than 1 cm were 
collected on the tumour (x4 biopsies), 2 cm distal (x4 biopsies) and 10 cm distal (x4 biopsies). 
Samples stored in RNAlater® were kept at room temperature overnight then stored at -80 °C 
until used for analysis. 
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2.1.2.2 Caecal effluent  
Luminal fluid (20-30 mL) was collected from the caecum into a 40 mL Bard® mucus specimen 
trap (Bard Medical, Georgia, USA). Immediately following collection, the fluid was aliquoted into 
3-4 x 15 mL Corning tubes with 50% filter sterilised glycerol. Samples were then frozen on dry 
ice and stored long term at -80 °C. 
 
2.1.2.3 Blood  
A maximum of 26 mL blood was collected from each patient into relevant blood collection tubes 
and stored on ice packs in a cool bag until laboratory processing. All blood aliquots were stored 
long term at -80 °C. 
i. Whole blood: Approximately 8 mL blood was collected into 2 x 4 mL vacutainer EDTA 
blood collection tubes (BDTM, Berkshire, UK). In the laboratory 1 mL aliquots of whole 
blood were made on ice inside a class II microbiological safety cabinet, type A2 
(Nuaire).  
ii. Plasma: Approximately 8 mL blood was collected into 2 x 4 mL vacutainer EDTA blood 
collection tubes (BDTM). Blood was centrifuged at 2000g for 10 min in a Microlite 
refrigerated centrifuge (Thermo-Fisher Scientific, Nottingham, UK) at 4°C. Aliquots (500 
μL) were made on ice inside a class II microbiological safety cabinet (Nuaire, Caerphily, 
Wales). 
Serum: Approximately 10 mL blood was collected into a vacutainer SS II Advance Tube with 
gold hemogard closure (BDTM). The clot was removed by centrifugation at 2000g for 10 min in a 
Microlite refrigerated centrifuge (Thermo-Fisher Scientific) at 4°C. Aliquots (500 μL) were made 
on ice inside a class II microbiological safety cabinet (Nuaire).  
 
The relevant clinical data was also obtained (see Tables 2.1 – 2.5 on pages 60-69).




Table 2-1 Healthy patient cohort 









Other medical history 
BF012 AC, DC N/A N/A 77 M Anaemia N/A 
BF018 AC, DC 3 x aliquots N/A 49 M Rectal bleeding N/A 
BF022 AC, DC 3 x aliquots 
8 x Whole blood, 8 x 
Plasma, 8 x Serum 
aliquots 
41 M Anaemia Type 1 diabetes, OGD also clear 
BF031 AC, DC 4 x aliquots 
8 x Whole blood, 8 x 
Plasma, 8 x Serum 
aliquots 
21 F 




BF036 AC, DC 4 x aliquots 
8 x Whole blood, 8 x 
Plasma, 8 x Serum 
aliquots 
79 F Anaemia 
Ischemic heart disease, triple bypass, 
hypertension, type II diabetes 
BF046 AC, DC 4 x aliquots 
8 x Whole blood, 8 x 
Plasma, 12 x Serum 
aliquots 
57 M 
Rectal bleeding, altered 
bowel habit, loss of weight 
Bladder cancer transurethral resection 
BF051 AC, DC 4 x aliquots 
8 x Whole blood, 9 x 
Plasma, 8 x Serum 
aliquots 
65 F 
Rectal bleeding, family 
history of CRC 
Colonoscopy found small rectal leimyoma 
On statins and thyroxine 
BF052 AC, DC 3 x aliquots 
8 x Whole blood, 8 x 
Plasma, 7 x Serum 
aliquots 
53 M Rectal bleeding N/A 
BF057 AC, DC 4 x aliquots N/A 51 F 
Rectal bleeding, altered 
bowel habit 
Found an ulcer in the ileocaecal valve and 
DC. No inflammation at the site of the 
biopsies 
BF063 AC, DC 3 x aliquots 
8 x Whole blood, 7 x 
Plasma, 7 x Serum 
aliquots 
79 M Rectal bleeding Pacemaker 
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BF064 AC, DC 4 x aliquots 
9 x Whole blood, 8 x 
Plasma, 8 x Serum 
aliquots 
57 F Anaemia N/A 
BF065 AC, DC 1 x aliquot 
8 x Whole blood, 7 x 
Plasma, 9 x Serum 
aliquots 
49 F 
Rectal bleeding, family 
history of CRC 
N/A 
BF074 AC, DC 4 x aliquots 
7 x Whole blood, 3 x 
Plasma, 5 x Serum 
aliquots 
55 M Anaemia Diverticular, OGD H. pylori positive 
BF077 AC, DC N/A 
11 x Whole blood, 8 x 
Plasma, 6 x Serum 
aliquots 
25 M Rectal bleeding N/A 
BF086 AC, DC 3 x aliquots 
8 x Whole blood, 7 x 
Plasma, 7 x Serum 
aliquots 
49 M Anaemia Diverticular disease 
BF088 AC, DC 3 x aliquots 
7x Whole blood, 7 x 
Plasma, 5 x Serum 
aliquots 
47 F Rectal bleeding Diverticular disease and haemorrhoids 
BF095 AC, DC 4 x aliquots N/A 62 M Rectal bleeding N/A 
BF106 AC, DC 3 x aliquots 
6 x Whole blood, 6 x 






BF111 AC, DC 3 x aliquots 
6 x Whole blood, 5 x 
Plasma, 7 x Serum 
aliquots 
61 F Anaemia Diverticular disease 
BF121 AC, DC 3 x aliquots 
6 x Whole blood, 6 x 
Plasma, 5 x Serum 
aliquots 
59 M Rectal bleeding 
CVA, type 2 diabetes, hypercholesterol 
 
BF123 AC, DC 3 x aliquots 
7 x Whole blood, 5 x 
Plasma, 5 x Serum 
aliquots 
35 F Rectal bleeding N/A 
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BF124 AC, DC 3 x aliquots N/A 49 F Rectal bleeding N/A 
AC = Ascending colon; DC = Descending colon; OGD = oesophago-gastroduodenoscopy; CVA = Cerebrovascular accident 
  




Table 2-2 Inflammatory Bowel Disease Patient Cohort 






Sex Histopathology Results Other medical history 
BF001 AC, DC N/A 
8 x Whole blood, 7 x 
Plasma, 8 x Serum 
aliquots 
54 F 
Biopsies showed no 
inflammation 
Ulcerative colitis (UC) 
BF003 AC, DC N/A N/A 42 F 
Mild patchy inflammation 
with focal active inflammation 
Colonic Crohn’s, angina, hypertension 
BF015 AC, DC 3 x aliquots 
8 x Whole blood, 6 x 






moderate active, chronic 
colitis 
Colonic Crohns, pancolitis and primary 
sclerosing cholangitis (PSC) 
BF020 AC,DC 3 x aliquots 
8 x Whole blood, 7 x 
Plasma, 6 x Serum 
aliquots 
36 F Currently inactive colitis Previous surgery for colitis 
BF033 AC,DC 4 x aliquots 
8 x Whole blood, 7 x 
Plasma, 7 x Serum 
aliquots 
34 M No inflammation Unclassified UC 
BF070 AC,DC 3 x aliquots 
8 x Whole blood, 6 x 
Plasma, 4 x Serum 
aliquots 
37 M Inactive 
Severe flare March 2015, multiple post-
inflammatory pseudopolyps 
BF084 AC,DC 4 x aliquots 
8 x Whole blood, 8 x 
Plasma, 7 x Serum 
aliquots 
54 M 
AC biopsy taken near 
anastomosis, biopsies 
showed some inflammation 
Pan-enteric Crohn’s, previous right 
hemicolectomy 
BF099 AC,DC 3 x aliquots 
7 x Whole blood, 6 x 
Plasma, 6 x Serum 
aliquots 
75 F N/A Diverticular disease, Colonic Crohn’s 
BF117 AC,DC 3 x aliquots 
7 x Whole blood, 6 x 
Plasma, 4 x Serum 
aliquots 
41 M N/A Pan - UC 
AC = Ascending colon; DC = Descending colon 
 
 




Table 2-3 Previous polyps/cancer patient cohort 






Sex Indication for colonoscopy Other medical history 
BF016 AC,DC 3 x aliquots 
7 x Whole blood, 8 x 
Plasma, 8 x Serum 
aliquots 
64 M Polyp surveillance Previous right sided hemicolectomy 
BF017 AC,DC N/A N/A 59 M Polyp surveillance Prostrate cancer 
BF024 AC,DC 4 x aliquots 
8 x Whole blood, 8 x 





Changes in bowel habits and 
weight loss 
N/A 
BF042 AC,DC 4 x aliquots 
8 x Whole blood, 8 x 
Plasma, 5 x Serum 
aliquots 
76 F 
Polyp surveillance, change in 
bowel habits 
Previous rectal polyp 3 years ago 
(tubular adenoma), rheumatoid arthritis, 
diverticular disease 
BF045 AC,DC 4 x aliquots 
8 x Whole blood, 8 x 
Plasma, 5 x Serum 
aliquots 
57 M CRC surveillance 
Previous adenocarcinoma, anterior 
resection 
BF059 AC,DC 4 x aliquots 
8 x Whole blood, 9 x 
Plasma, 3 x Serum 
aliquots 
51 F Polyp surveillance 
Previous pedunculated distal, sigmoid 
polyp 
BF060 AC,DC N/A 
8 x Whole blood, 8 x 
Plasma, 6 x Serum 
aliquots 
73 F CRC surveillance 
Previous adenocarcinoma, right sided 
hemicolectomy 
BF071 AC,DC 4 x aliquots N/A 59 M Recent rectal bleeding Previous anal cancer, HIV positive 
BF076 AC,DC 4 x aliquots 
7 x Whole blood, 8 x 
Plasma, 7 x Serum 
aliquots 
65 M Polyp surveillance 
Previous polyp (2011 tubulovillous 
adenoma) 
BF080 AC,DC N/A N/A 75 M 
Family history CRC, change 
in bowel habit 
Previous polyp, diverticular disease, 
COPD, gout, hypertension 
BF091 AC,DC 3 x aliquots 6 x Whole blood, 6 x 72 M CRC surveillance Previous moderately differentiated 
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Plasma, 5 x Serum 
aliquots 
adenocarcinoma pT3a N0, anterior 
resection 
BF097 AC,DC 3 x aliquots 
7 x Whole blood, 6 x 
Plasma, 6 x Serum 
aliquots 
43 M Family history CRC 
Previous polyp with low grade 
dysplasia (transverse colon, tubular 
adenoma) 
BF098 AC,DC 4 x aliquots 
8 x Whole blood, 8 x 
Plasma, 7 x Serum 
aliquots 
81 F CRC surveillance Previous CRC, transverse colon 2014 
AC = Ascending colon; DC = Descending colon; COPD = Chronic obstructive pulmonary disease 
 
  













Sex Colonoscopy/Histopathology Results Other medical history 
BF002 OT, NT, AT N/A N/A 73 M Tubular adenoma 
Right hemicolectomy due to 
previous adenocarcinoma, type 2 
diabetes, haemorrhoids 
BF005 OT, NT, AT 2 x aliquots 
8 x Whole blood, 7 
x Plasma, 8 x 
Serum aliquots 
54 M N/A N/A 
BF006 OT, NT, AT N/A N/A 91 M N/A N/A 
BF007 OT, NT, AT N/A N/A 72 F N/A N/A 
BF008 OT, NT, AT N/A N/A 71 F 
Transverse serrated sessile polyp and 2cm 
sessile lesion (biopsies taken from) is 
adenocarcinoma T3(b) No nodes Dukes B, 
proximal AC 
Previous polyp, breast cancer, 
previous skin cancer 
BF009 AC, DC N/A N/A 73 F 
Found 3 new polyps in caecum, 2x sigmoid 
and 1 descending colon 
N/A 
BF011 AC, DC N/A N/A 69 M 
Multiple new small polyps, 1 large in rectum 
and flat hyperplastic polyp in caecum 
Previous adenomas and serrated 
lesions, raised cholesterol 
BF013 OT, AC N/A N/A N/A M Unknown 
Previous polyps in AC and 
caecum, hypertension 
BF023 AC, DC 4 x aliquots 
8 x Whole blood, 7 
x Plasma, 8 x 
Serum aliquots 
68 M Small caecal polyp 
Iron deficient anaemia, 
Metastatic, prostrate cancer 
BF027 OT, NT, AT 4 x aliquots 
8 x Whole blood, 4 
x Plasma, 2 x 
Serum aliquots 
36 M 
Pedunculated polyp in DC- inflammatory 
pseudopolyp 
Change in bowel habit, weight 
loss, Diabetic renal transplant 
BF028 OT, NT, AT 3 x aliquots N/A 70 F Sessile, flat hyperplastic polyps. Biopsies 
taken from sigmoid colon. Previous 
Squamous cell carcinoma on leg, 
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tubuloadenoma and hyperplastic polyps 
BF029 OT, NT, AT 4 x aliquots 
8 x Whole blood, 8 
x Plasma, 5 x 
Serum aliquots 
76 F 
3 small sessile polyps in descending colon, 
biopsies taken from large pedunculated 
tubulovillous adenoma with low grade 
dysplasia in sigmoid colon. 
N/A 
BF030 AC, DC 4 x aliquots 
8 x Whole blood, 6 
x Plasma, 6 x 
Serum aliquots 
51 M 
Presented with rectal bleeding. Hyperplastic 
polyp in the distal transverse colon. 2 tubular 
adenomas with low grade dysplasia in 
sigmoid colon 
N/A 
BF032 AC, DC 4 x aliquots 
1 x Whole blood, 7 
x Plasma, 6 x 
Serum aliquots 
74 F Caecal polyp N/A 
BF034 OT, NT, AT N/A 
8 x Whole blood, 8 
x Plasma, 8 x 
Serum aliquots 
54 F 
Pedunculated polyp - tubular adenoma low 
grade dysplasia 
HIV positive, varices, portal vein 
thrombosis 
BF043 AC, DC 3 x aliquots 
8 x Whole blood, 8 
x Plasma, 8 x 
Serum aliquots 
74 M 
Presented with persistent anaemia and 
change in bowel habit. Inflammatory polyp in 
sigmoid colon 
N/A 
BF044 AC 4 x aliquots 
8 x Whole blood, 9 
x Plasma, 8 x 
Serum aliquots 
61 M 
Presented with rectal bleeding and previous 
polyps. Tubulovillous adenoma in AC. 
Unknown previous polyps histology 
Type 2 diabetes, failed renal 
transplant 
BF047 AC, DC 3 x aliquots 
8 x Whole blood, 9 
x Plasma, 8 x 
Serum aliquots 
37 M 
Small hyperplastic rectal polyp. Previous 
rectal polyps, Family history of CRC 
N/A 
BF048 OT, NT, AT N/A 
8 x Whole blood, 8 
x Plasma, 7 x 
Serum aliquots 
45 M 
Large sigmoid polyp, 2 small polyps distal to 
larger polyp 
N/A 
BF054 AC, DC N/A 
8 x Whole blood, 8 
x Plasma, 8 x 
Serum aliquots 
59 M 
Small tubular adenoma descending colon; 




BF058 AC, OT 4 x aliquots 8 x Whole blood, 8 42 M Previous polyp removed from ascending N/A 
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x Plasma, 4 x 
Serum aliquots 
colon. New polyp. 
BF061 OT, NT, AT 4 x aliquots 
8 x Whole blood, 8 
x Plasma, 6 x 
Serum aliquots 
76 M 
Presented with rectal bleeding and 
constipation. Rectosigmoid cancer 
Thyroid disease and osteoarthritis 
BF068 OT, DC N/A 
8 x Whole blood, 5 
x Plasma, 6 x 
Serum aliquots 
82 M 
Presented with diarrhoea and anaemia. 
Severe splenic stricture, probable cancer 
Previous hemicolectomy due to 
adenomatous polyp 
BF071 AC, DC 3 x aliquots N/A 59 M Presented with rectal bleeding 
Previous anal cancer, HIV 
positive 
BF072 OT, NT, AT N/A 
8 x Whole blood, 6 
x Plasma, 5 x 
Serum aliquots 
48 M 
Presented with diarrhoea and weight loss. 
Small sigmoid polyp 
Diabetes 
BF079 NT, AT N/A 
10 x Whole blood, 
8 x Plasma, 6 x 
Serum aliquots 
76 M 
Presented with anaemia and previous polyps. 
New polyps which were sessile serrated, 
hyperplastic and tubular adenomas 
Diabetes, renal disease, COPD, 
hypertension 
BF090 AC, DC 4 x aliquots 
8 x Whole blood, 7 
x Plasma, 4 x 
Serum aliquots 
73 F 1cm rectal tubular adenoma Diverticular disease, hypertension 
BF100 AC, DC 4 x aliquots 2 x Whole blood, 59 F 
Presented with rectal bleeding. Small polyp in 
ascending colon. Tubular adenoma in rectum 
Recent lung cancer and previous 
breast cancer 
BF115 OT, NT, AT 3 x aliquots N/A 73 M Tubulovillous adenoma sigmoid colon. 
Deceased March 2017. Metastatic 
right renal cell carcinoma, 
ischaemic heart disease 
AC = Ascending colon; DC = Descending colon; OT = On tumour; NT = Next to tumour; AT = Away from tumour 
 
  














Colonoscopy/Histopathology Results and 
other medical history 
Patient groups assigned 
BF014 AC, DC N/A N/A 77 M No new polyps or inflammation IBD and previous polyps/cancer 
BF019 OT, NT, AT N/A 
8 x Whole blood, 6 
x Plasma, 7 x 
Serum aliquots 
61 M 
2 x tubulovillous polyps with low grade 
dyplasia. 1 in hepatic flexure, 1 in sigmoid 
colon (~2 cm). Biopsies taken from sigmoid 
polyp. 
IBD and newly diagnosed 
polyp/cancer 
BF035 AC, DC 4 x aliquots 
8 x Whole blood, 8 
x Plasma, 8 x 
Serum aliquots 
63 M 
Long-term IBD (UC), pseudopolyps, abnormal 
areas in ileocaecal valve, transverse and 
sigmoid colon. High grade dysplasia 
adenocarcinoma found in sigmoid colon. 
Primary sclerosing cholangitis, varices 
IBD and newly diagnosed 
polyp/cancer 
BF041 AC, DC 4 x aliquots 
8 x Whole blood, 7 
x Plasma, 7 x 
Serum aliquots 
25 M 
Inflammatory polyps in caecum. Crohn’s in 
remission 
IBD and newly diagnosed 
polyp/cancer 
BF049 OT, NT, AT N/A N/A 49 M 
Tubulovillous adenoma in rectum. Ileocolonic 
Crohn’s –no inflammation 
IBD and newly diagnosed 
polyp/cancer 
BF056 AC, DC 4 x aliquots N/A 70 F 
Distal UC. Small rectal polyp, no 
inflammation. Previous tubulovillous adenoma 
with low grade dysplasia in sigmoid colon. 
IBD and newly diagnosed 
polyp/cancer 
AC = Ascending colon; DC = Descending colon; OT = On tumour; NT = Next to tumour; AT = Away from tumour




2.2 DNA Processing 
2.2.1 DNA Extraction from Intestinal Biopsies 
DNA was extracted from intestinal biopsy samples using the FastDNA SPIN kit for soil (MP 
Biologicals, California, USA) following the manufacturer’s instructions. DNA extraction included 
a bead-beating step using a FastPrep24 (MP Biologicals) homogenizer. Other DNA extraction 
steps were carried out in a Class II microbiological safety cabinet (Nuaire). DNA aliquots were 
placed into 0.5 mL DNase free DNA LoBind® microcentrifuge tubes (Sigma-Aldrich). Extracted 
DNA aliquots were stored at -20°C until further processing, while extracted DNA was 
refrigerated short-term at 4°C. Extracted DNA was initially subjected to PCR using universal 
primers to determine suitability of the DNA for further PCR analysis. 
 
2.2.2 DNA Quantification 
DNA was quantified by a fluorescence-based method using the Qubit™ double-stranded DNA 
high sensitivity assay kit (Life Technologies, California, USA) and Qubit™ 3.0 Fluorometer 3.0 
(Life Technologies). Quantification was carried out according to the manufacturer’s instructions. 
 
2.3 End-point Polymerase Chain Reaction (PCR) 
2.3.1 Primers 
PCR primers were ordered from Eurofins Genomics (Ebersburg, Germany) and obtained in a 
lyophilised form. Primers were rehydrated in sterile molecular grade water (Sigma-Aldrich) to a 
concentration of 100 pmol/μL. Primer aliquots at a concentration of 10 pmol/μL were made up 
ready for use in PCR and stored long term at -20°C and short term at 4°C.  
 
2.3.2 Polymerase Chain Reaction (PCR) 
PCR reactions were performed in a final volume of 25 μL with each reaction mixture containing: 
12.5 μL 2X DreamTaq™ polymerase mastermix (Fermentas, Waltham, USA), 10.5 μL sterile 
molecular grade H2O (Sigma-Aldrich), 0.5 μL forward primer 10 pmol/μL (Eurofins genomics), 
0.5 μL reverse primer (10 pmol/μL) (Eurofins genomics) and 1 μL of template DNA. All PCR 
reactions were normalised to use 40 ng of extracted biopsy DNA. PCR reactions were carried 
out in a TC 412 thermal cycler using cycling conditions of an initial denaturation step of 5 min at 
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95°C; 30 cycles of amplification consisting of denaturation (45 s at 95°C), annealing (45 s at 
X°C) and extension (X at 72°C); and a final extension of 15 min at 72°C where X is variable for 
each PCR target. A no DNA template, negative control was included in every PCR. 
 
2.3.3 Colony PCR 
Colony PCR in this thesis refers to PCR performed on bacterial DNA without a specific DNA 
extraction step. A single bacterial colony was collected into 50 μL sterile molecular grade H2O 
(Sigma-Aldrich) and 1 μL of this used as a DNA template per PCR reaction. An initial 
denaturation step of the PCR programme (5 min at 95°C) was used to lyse bacterial cells and 
release the DNA. PCR reactions were carried out using thermal cycling conditions as described 
in section 2.3.2. 
 
2.3.4 DNA Agarose Gel Electrophoresis 
PCR amplicons and extracted DNA were visualized on a 1-2% (w/v) agarose gels. Agarose gels 
were made using molecular grade agarose (Sigma-Aldrich) dissolved in 0.5X Tris-Borate EDTA 
(TBE) buffer (VWR) containing 0.01% (v/v) GelRed™ nucleic acid gel stain (VWR). Individual 
samples were mixing with 6X loading dye (Thermo-Scientific, Nottingham, UK) and visualised 
on the AlphaImager HP Gel Imaging System (Alpha Innotech, California, USA). The molecular 
size of the DNA fragments were estimated using either GeneRuler Express DNA ladder 
(Thermo-Fisher Scientific), GeneRuler 100 bp Plus DNA ladder (Thermo-Fisher Scientific) or 
Lambda DNA-Hind III Digest (New England Biolabs) molecular markers. 
 
2.3.5 PCR Amplicon Purification and Sequencing 
The method of PCR amplicon purification depended on whether one or multiple DNA fragments 
were present. If multiple bands were present the fragment of interest was excised from the gel 
and purified using the QIAquick PCR purification kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s instructions. If a single band was present the PCR product was purified using 
the CleanSweep™ PCR purification kit (Thermo-Fisher Scientific). CleanSweep™ reagent (2 μL) 
was added to 5 μL PCR product and incubated at 37°C for 15 min followed by 15 min 
incubation at 80°C using the PCR thermocycler. Purified PCR amplicons were sent for DNA 
sequencing using Eurofins Genomics TubeSeq service.
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2.4 Protein techniques 
2.4.1 Protein Extraction from Intestinal Biopsy Samples 
Single intestinal biopsies stored in RNAlater® were used for simultaneous RNA (data not 
shown) and protein extraction. Excess RNAlater® was removed and the biopsy divided in half. 
Ice-cold RIPA lysis and extraction buffer (250 μL) (Thermo Fisher) was added to the half of the 
biopsy allocated for protein extraction. The sample was then incubated on ice for 20-30 min. 
The sample was centrifuged at 10,000 g for 15 min at 4°C before being aliquoted and stored at -
80°C until analysis. 
 
2.4.2 Total protein quantification 
Protein was quantified by a fluorescence-based method in duplicate using the Qubit™ protein 
assay kit (Life Technologies) and Qubit™ 3.0 Fluorometer 3.0 (Life Technologies) according to 
the manufacturer’s instructions.  
 
2.4.3 Enzyme-Linked Immunosorbant Assay (ELISA) 
The human IL-10 ELISA kit (Invitrogen) was used to quantify IL-10 concentrations in serum and 
intestinal biopsy tissue lysates. 15 μL of biopsy lysate diluted in 35 μL standard diluent buffer or 
50 μL of serum were added in duplicate. Following a 2 hour incubation at room temperature the 
96 well plate was washed four times using 1X wash buffer. 100 μL Hu IL-10 biotin conjugate 
was added to all wells except chromogen blanks and incubated for 2 hours at room 
temperature. The plate was washed four times with 1 x wash buffer and 100 μL streptavidin-
HRP solution was added to all wells except chromogen blanks. The plate was incubated for 30 
minutes and washed four times with 1 x wash buffer. 100 μL stabilized chromogen was added 
to the plate and incubated for 30 minutes at room temperature in the dark. The reaction was 
stopped using 100 μL stop solution and the plate read at an absorbance of 450 nm. 
 
Tissue IL-10 concentration in pg/mL was normalized against total protein, as determined by 
Qubit protein assay, i.e. ELISA IL-10 concentration (pg/mL) / total protein concentration (mg/mL) 
to obtain a final result in terms of pg IL-10 per mg protein. Serum and tissue IL-10 
concentrations were not normally distributed so non-parametric statistical tests were used. 
Comparison of medians amongst all patient groups was carried out using the Kruskal-Wallis 
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test. Dunn’s multiple comparisons test was used to compare means between pairs of patient 
groups. Analysis of correlation between IL-10 and B. fragilis PSA orientation was tested using 




Bacterial reference strains were purchased either from Thermo Scientific Oxoid or the Japan 
Collection of Microorganisms (JCM), RIKEN BioResource Center, Ibaraki, Japan. Bacterial 
reference species and strains are detailed in Tables 1-2–1-4. 
Table 2-6 Table of Bacterial Reference Strains 















(Eggerth and Gagnon, 
1933) 












Japan Collection of 
Microorganisms 
Bacteroides sartorii 





(Hayashi et al., 2007) 
JCM 13818* Human faeces 
Prevotella 
melaninogenica 




ATCC® 9817™ Unknown 
Fusobacterium 
periodonticum 
ATCC® 33693™ Periodontitis 
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Table 2-7 Table of Bacteroides fragilis Reference Strains 
* = Type strain 
Bacteroides fragilis 
Strain 
B. fragilis toxin 
(BFT) 
Original Source of 
Isolate 
Supplier 








(Odamaki et al., 2008) 
BFT Subtype 1 Human faeces 
Japan Collection of 
Microorganisms 
JCM 17586 
(Odamaki et al., 2008) 
BFT Subtype 2 Human faeces 
JCM 17587 
(Odamaki et al., 2008) 
BFT Subtype 3 Human faeces 
 
Table 2-8 Table of Fusobacterium nucleatum Reference Strains 
* = Type strain 
Fusobacterium 
nucleatum 










polymorphum ATCC® 10953™* Inflamed gingiva 
animalis 





Japan Collection of 
Microorganisms 
vincentii 
(Dzink et al., 1990) 
ATCC® 49256 ™ 
(JCM 11023) 
Human oral cavity 
fusiforme 





Kind gift from Professor 
William Wade 
 
2.5.2 Culturing Conditions 
Reference Culti-Loop™ strains were streaked onto reduced Fastidious Anaerobe Agar (Lab M 
Limited, Bury, UK) with 5% (v/v) defibrinated horse blood (Thermo-Fisher Scientific). Strains 
obtained from JCM were supplied as lyophilized bacterial cultures and rehydrated using nutrient 
broth. Nutrient broth was prepared using 0.5% w/v Bacto Peptone (Becton Dickinson, New 
Jersey, USA), 0.3% w/v beef extract (Sigma-Aldrich), pH 7.0. Bacteria were cultured in a 
MACS-MG-1000 anaerobic workstation (Don Whitley, Shipley, UK) with an atmosphere of 80% 
N2, 10% H2 and 10% CO2 at 37°C.  
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For long-term storage strains were cultured in either pre-reduced Brain-Heart Infusion (BHI) 
Broth (VWR International, Pennsylvania, USA) or Tryptone Soya Broth (VWR International) and 
frozen with 10% (v/v) glycerol (VWR) at -80°C. 
 
2.5.3 Plate wash method to detect bacterial isolates 
Caecal effluent (500 mL) sample was used to make 3-4 10-fold serial dilutions. Dilutions were 
made using 50 μL caecal effluent diluted in 450 μL pre-reduced tryptone soya broth. 100 μL 
each dilution were spread in duplicate onto Bacteroides Selective Agar and Fusobacterium 
Selective Agar.  The Bacteroides Selective Agar used was Schaedler Agar (Sigma-Aldrich) 
supplemented with 100 mg/L kanamycin (Santa Cruz Biotechnology, Texas, USA), 7.5 mg/L 
vancomycin (Sigma-Aldrich) and 5% defibrinated sheep blood (Thermo-Fisher Scientific). The 
agar selective for Fusobacterium was Schaedler Agar supplemented with 5 mg/L crystal violet, 
4 mg/L erythromycin and 5% defibrinated sheep blood. The agar plates were cultured for 72 h in 
an anaerobic environment. One plate of each dilution was washed using 200 μL sterile water 
and ‘colony’ PCR (section 2.3.3) using relevant primers carried out. Plates with positive results 
were used to pick 10-20 colonies, which were restreaked onto Fastidious Anaerobic Agar 
supplemented with 5% (v/v) defibrinated horse blood. ‘Colony’ PCR was used to detect the 
presence of any B. fragilis or Fusobacterium isolates and positive strains were cultured in TSB 
to make glycerol stocks as described previously. 
 
2.6 Polysaccharide A (PSA) Promoter Orientation 
PSA promoter orientation was determined using a method adapted from (Krinos et al., 2001; 
Troy et al., 2010). PCR of a fragment of DNA including the PSA promoter was carried out using 
the PSAF1 and PSAF2 primers (Table 2-11). PCRs were set up as described in section 2.3.2 
using an annealing temperature of 57 °C and an extension time of 70 s. A restriction digest of 
the PCR amplicons was set up in a 1.5 mL microcentrifuge tube using 19 μL sterile, DEPC 
treated water (Sigma-Aldrich), 8 μL PCR product DNA, 2 μL FastDigest green buffer (Thermo-
Fisher Scientific) and 1 μL FastDigest SspI enzyme (Thermo-Fisher Scientific). Restriction 
digests were incubated for 20 min at 37°C. 8 μL restriction digest was loaded and visualised 
using DNA agarose gel electrophoresis as described in section 2.3.4. Agarose gels were 
visualised using the ChemiDoc™ MP UV transilluminator (Bio-Rad Laboratories) and DNA band 
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intensity determined using the Image Lab (version 5.2.1) software (Bio-Rad Laboratories). The 
expected sizes of the undigested and digested fragments are detailed in Table 2-10. 
Table 2-9 PCR digestion fragment sizes 
Product size (bp) Fragment sizes (bp) ON Fragment sizes (bp) OFF 
1076 257 819 148 928 
 
The percentage of the B. fragilis population with the PSA promoter oriented on was calculated 
as follows: 
= (Total band intensity of ‘ON’ fragments / Total band intensity of all fragments) x 100 
 
Non-parametric statistical comparison of medians amongst all patient groups was carried out 
using the Kruskal-Wallis test. Dunn’s multiple comparisons test was used to compare means 
between pairs of patient groups. 
Table 2-10 Polysaccharide A Promoter Region Primers 
Primer name Primer Sequence (5’-3’) GC content % Tm (°C) Size (bp) 
PSAF1 TGTGTAAATGATAGGAGGCTAGGG 61.0 45.8 24 
PSAR1 GTTGACGGAAATGATCGGTATAG 58.9 43.5 23 
 
2.7 Statistical Analysis 
Statistical analysis was performed using Prism v. 7.0 for Mac OS (GraphPad Software, San 
Diego, California). Determination of significant differences amongst patient groups in terms of 
prevalence of bacterial taxa and strains/genes of interest was determined using the Fisher’s 
exact test. 
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Chapter 3 : END-POINT POLYMERASE CHAIN REACTION 
DEVELOPMENT 
3.1 Introduction and Aims 
Advances in next generation sequencing technology and a subsequent reduction in cost have 
resulted in a large expansion of microbiome research. This technology has provided a wealth of 
in-depth data and progressed knowledge of bacterial diversity within the G.I. tract, including 
previously undescribed and as yet unculturable species. In regards to the CRC microbiome 
many studies have been carried out and their key findings are summarised in detail in section 
1.7. Unfortunately, the data sets from microbiome studies often contain insufficient information 
to look at strain level detail to test the hypothesis that BFT is associated with human CRC. 
There are therefore limitations to this large data approach and a more specific methodology was 
sought and optimised. Previous studies specifically investigating BFT epidemiology (Toprak et 
al., 2006, Boleij et al., 2015) have limitations, particularly in respect to a lack of a suitable 
healthy cohort or sample type. This chapter describes the development of a PCR assay to 
robustly investigate the prevalence of Fusobacterium and its associated virulence gene fadA 
(section 1.7.4), and the species B. fragilis, and its putative virulence genes bft (section 1.7.5) 
and ubb (section 1.5.2.1). A comprehensive collection of colonic tissue samples from various 
patient cohorts was collected to probe the association of the aforementioned bacterial taxa and 
genes with gastrointestinal disease, and in particular with colon tumorigenesis. 
 
3.1.1 Methods of bacterial identification and characterisation 
There is no gold standard method for bacterial detection and/ or identification, but all methods 
can be classed as culture-dependent or culture-independent. Results using both methods are 
described in this thesis but primarily a culture-independent method was used and its 
development is described within this chapter.  
 
Culture-dependent methods grow viable bacteria from a sample with subsequent identification 
based on morphology, phenotypic characterisation or sequencing. Shortcomings of this 
technique are that some species have no known method of culture and bacteria have 
mechanisms by which they can outcompete each other or exchange genetic material.  
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Culture-independent methods include the sequencing of DNA or cDNA which allows the 
identification of both non-viable and viable bacteria respectively. This technique can be affected 
by contamination, results may vary depending on the method of DNA extraction used (Kennedy 
et al., 2014) and DNA sequencing does not discriminate between viable and non-viable 
organisms. 
 
3.1.1.1 Bacterial identification using the 16S rRNA gene  
A common sequencing method of bacterial identification uses taxonomy dependent differences 
in the 16S rRNA gene. This gene codes for 16S ribosomal RNA in bacteria and archaea and is 
a component of the 30S small subunit of prokaryotic ribosomes. An early finding of DNA 
sequencing of 16S rRNA and eukaryotic 18S rRNA genes led to the realisation that rRNA 
sequences of various organisms could be used to determine phylogenetic relationships.  Indeed 
Carl Woese used this insight to identify three domains of life: Archaea, Bacteria, and Eukarya 
whereas previously only prokaryota and eukaryota were described (Woese et al., 1990). 
 
This housekeeping gene is commonly used for bacterial identification in part because it is an 
ancient gene with an unchanged function and therefore sequence changes are likely to be the 
result of gradual evolution over time. The primary reason for the use of this gene for bacterial 
identification is that regions of the sequence are universally conserved across species while 
other regions are taxa-specific including some species-specific regions. Another motivation for 
the use of this housekeeping gene is that comprehensive quality-controlled databases of full-
length 16S rRNA sequences exist (Maidak et al., 1999, Quast et al., 2013). 
 
3.1.2 Polymerase Chain Reaction  
Polymerase Chain Reaction (PCR) is a technique employed to enzymatically replicate nucleic 
acid and consequently amplify deoxyribonucleic acid (DNA). Significant early research into DNA 
replication was carried out by Kleppe including a key theoretical description of DNA 
amplification using primers (Kleppe et al., 1971). The first experimental PCR was carried out in 
1985 by Kary Mullis and the technique was advanced significantly with the introduction of a 
thermostable polymerase isolated from Thermus aquaticus (Saiki et al., 1988). This prevented 
the laborious addition of fresh polymerase following each cycle and improved the quality of the 
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final PCR product. Subsequent adaptations of this technology also led to the advancement of 
DNA sequencing methods. 
  
The reaction comprises Taq DNA polymerase, free deoxynucleotide triphosphates (dNTP’s), 
bivalent cations, buffer solution, oligonucleotide primers and a source of DNA template. Forward 
and reverse primers are designed complementary to a known DNA sequence and so provide 
the specificity of the reaction. The first step of PCR (Figure 3-1) is denaturation during which the 
double stranded DNA is melted into two single strands at a high temperature. The temperature 
is then reduced to promote primer annealing to the DNA template. The final step of the reaction 
is the extension of the newly synthesised DNA strand by incorporation of free dNTPs by Taq 
polymerase, at an optimum temperature required for polymerase activity (~72°C). The reaction 
repeats for 30-40 cycles until the reaction enters a plateau phase whereby DNA synthesis 
efficiency is reduced. Possible reasons for the plateau include limiting of primers or dNTP’s and 
accumulation of PCR products shielding polymerase activity. 
 
The goal of PCR optimisation is to determine PCR conditions that maximise specificity and yield 
of the PCR product. Success of the PCR is usually measured by visualisation of PCR products 
using DNA gel electrophoresis (yield) and/or DNA sequencing (specificity). 
 
Figure 3-1 Polymerase Chain Reaction 
Stages of the Polymerase Chain Reaction (PCR) cycle and subsequent doubling of DNA. Each 







Primer Annealing Extension Exponential Doubling of DNA
~95 C ~55-65 C ~72 C 30-40 cycles
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3.2 Method 
Methods specific to the development of a PCR assay are listed in the section. All other general 
methods including PCR, DNA extraction and DNA agarose gel electrophoresis are described in 
Chapter 2. 
 
3.2.1 DNA sequence retrieval and PCR primer design 
Careful design of forward and reverse oligonucleotide primers is imperative for PCR specificity. 
The complementarity of the 3’ end of the primer to the target DNA is particularly important as 
DNA polymerase requires the binding of primers at the 3’ end to begin elongation.  
 
DNA sequence alignments using the MUSCLE algorithm were constructed using Molecular 
evolutionary genetic analysis (MEGA) software, version 7.00 (Kumar et al., 2016). Primers to 
target bacterial taxa were designed against the 16S rRNA gene. Relevant 16S rRNA sequences 
were retrieved from the Ribosomal Database Project (RDP). To ensure the accurate sequences 
for primer design were obtained, only type strain and cultured isolates over 1200 bp were 
retrieved from the RDP.  Primers to target virulence genes were designed using DNA 
sequences obtained from the genetic sequence databases Genbank at NCBI 
(https://www.ncbi.nlm.nih.gov/genbank) or the European Nucleotide Archive at the European 
Bioinformatics Institute (https://www.ebi.ac.uk/ena).  
 
Metagenomic DNA sequences from clinical samples were retrieved using the Kyoto 
Encyclopedia of Genes and Genomes (KEGG) (Kanehisa et al., 2012) basic local alignment 
search tool (BLAST). Sequences were subsequently added to MEGA DNA sequence 
alignments for primer design. 
 
Some of the primers used in this study were designed by visual inspection of the constructed 
DNA sequence alignments. Primer properties required for an efficient PCR are recommended to 
have certain characteristics (Table 3-1) and so primers were designed accordingly. Multiple 
primer pairs for each target were designed and tested. 
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Primer length of 18-30 nucleotides 
Melting temperature (Tm) of the two primers should between 65°C and 75°C, and within 5°C of 
each other. 
GC content between 40 and 60%, with the 3' of a primer ending in C or G to promote binding. 
A balanced distribution of GC-rich and AT-rich domains 
Avoid runs of 4 or more of one base, or dinucleotide repeats (for example, ACCCC or 
ATATATAT) 
Limit self-complementarity between forward and reverse primers to avoid the creation of primer-
dimers which may reduce efficiency of the reaction 





An online multiple primer designer calculator 
(https://www.thermofisher.com/uk/en/home/brands/thermo-scientific/molecular-
biology/molecular-biology-learning-center/molecular-biology-resource-library/thermo-scientific-
web-tools/multiple-primer-analyzer.html) was used to determine the characteristics of the 
designed primers.  
 
3.2.2 Primer specificity testing 
To select suitable bacterial species for primer specificity testing, phylogenetic trees were 
constructed. Phylogenetic trees were constructed in MEGA using the distance-based 
Neighbour-Joining method with maximum composite likelihood substitutions to include: 
transitions + transversions and gaps/missing data treatment: partial deletion. 
 
3.2.3 Annealing Temperature Optimisation 
PCRs were carried using a range of annealing temperatures including a central Ta chosen by 
calculating 5°C lower than the primer with the lowest melting temperature (Tm) (Table 3-2). A 
non-specific but closely related DNA template and a no template control were also included for 
each annealing temperature tested. 
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27F AGAGTTTGATCMTGGCTCAG 47.5 56.3 20 
1492R TACGGYTACCTTGTTACGACTT 43.2 57.5 22 
Species  
B. fragilis 
BfF1 GGTGGACTGGTAAGTCAGTTGTG 52.2 62.4 23 
BfF2 ACTGTCAGTCTTGAGTACAGTAGAG 44.0 61.3 25 
BfR1 GCAGACTTCGATCCGAACTG 55.0 59.4 20 
BfR2 GTTTCCACATCATTCCACTGC 47.6 57.9 21 





 (Avila-Campos et al., 2007) 




(Avila-Campos et al., 2007) 




(Avila-Campos et al., 2007) 




(Avila-Campos et al., 2007) 
58.8 55.2 17 
BFTF2 
GAACCTAAAACGGTATATGT  
(Kato et al., 2000) 
35.0 52.9 20 
BFTR1 CAGCTGGGTTGTAGACATCC 62.6 62.6 20 
BFTR3 
GTTGTAGACGACATCCCACTGGC 
 (Kato et al., 2000) 
56.5 64.2 23 
B. fragilis 
ubiquitin (ubb) 
UbbF1 GCTGGACCATAACATTAGAGGT 45.5 58.4 22 
UbbR1 GCTAAAGTTCGTCCATCTTCCA 45.5 58.4 22 
Genus 
Fusobacterium 
FusF1 ACTGGACAGATACTGACGC 52.6 56.7 19 
FusF2 GAAAGCGTGGGTAGCAAACAGG 54.5 62.1 22 




FNucF1 CGCGTAAAGAAYTTGCCTCACAG 50.0 61.5 23 
FNucF2 CGGTACCAACAGAAGAAGTGACG 52.2 62.4 23 
FNucF3 GTACTGGAGAGGTAAGCGG 57.9 58.8 19 





SubspNF1a ATTATGATTATAGGGCATCCTAG 34.8 55.3 23 
SubspNF1b GATTATAGGGCATCCTAG 44.4 51.4 18 
SubspNR1 CCTCCTACTCATCGTAGGC 57.9 58.8 19 
SubspNR2 CCTCACGGCTTTGCAACT 55.6 56.0 18 
F. nucleatum 
FadA 
FadAF1 GAAGAAAGAGCACAAGCTGA 45.0 55.2 20 
FadAF2 GATGCAGCAAGTTTAGTAGGTG 45.5 58.4 22 
FadAR1 CWGCTTGAAGTCTTTGAGCTCT 45.5 58.4 22 
FadAR2 GCTTGAAGTCTTTGAGCTCTTTG 43.5 58.9 23 
 
3.2.4 Limit of Detection 
A single colony of the relevant bacterium was grown for 24 hours in 20 mL pre-reduced BHI. A 
sample (100 μL) of the culture was used to make serial dilutions and plated onto FAA + 5% 
horse blood agar plates to determine the number of colony forming units (CFU/mL). The 
remainder of the sample dilution was centrifuged at 12 000 g for 10 mins and the supernatant 
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removed. The bacterial pellet was washed by resuspending in an equal volume of sterile water. 
The bacterial pellet was centrifuged again at 12 000 g for 10 mins and resuspended in an equal 
volume of sterile water. Dilutions were made from this bacterial suspension and used as DNA 
templates (1 μL) for PCR.  
 
3.3 Results 
3.3.1 DNA Extraction and Quality 
Good quality DNA template and optimal template concentration are required for a successful 
and efficient PCR.  Quality of DNA extracted from patient samples was assessed by a 
combination of gel electrophoresis and NanodropTM spectroscopy. Concentration and quality 
was initially assessed using Nanodrop spectroscopy using a selection of pilot colonic biopsy 
samples. The 260/280 nm ratio (considered an indicator of purity) was between 1.84 and 2.00, 
indicative of the presence of pure DNA without protein and phenol contamination. Subsequent 
experiments (section 3.3.4) were carried out to test the suitability of the DNA for its downstream 
application in PCR. 
 
Visualization of the genomic DNA using DNA gel electrophoresis was used to gauge quality via 
the assessment of DNA smearing as an indicator of sheared genomic DNA. A consistent 
volume (1 µL) of extracted biopsy DNA was loaded for each sample to also give an 
approximation of DNA quantity. Figure 3-2 shows an example of DNA extracted from biopsy 
tissue with each lane representing a different sample extract. The gel shows good quality DNA 
as shown by a discrete band at a large size with limited amounts of shearing. 
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Figure 3-2 Assessment of DNA Quality from DNA Extracts 
L= DNA ladder (λ DNA-Hind III digest). Marker sizes (bp) are as follows: 23130, 9416, 6557, 
4361, 2322 and 2027. Lanes are numbered 1-12 representative of DNA extracts from different 
colonic biopsy samples. 
 
There was some variability in DNA yield, as determined by fluorometric quantitation, but was 
typically ~2-10 µg (mean = 4.0 µg). The DNA extraction procedure was not successful for some 
samples and so they were excluded from any downstream analysis. 
 
An initial PCR, without further optimisation of conditions, was performed using primers designed 
to ‘universally’ amplify all bacterial 16S rRNA DNA templates (Figure 3-3). The resultant PCR 
products show that the sample DNA extracts did contain PCR-facilitated amplifiable bacterial 
DNA. The results are unlikely to be from contaminating DNA, as a no template control was 
negative. Additional experimental testing for the presence of PCR inhibitors was carried out later 





M 1 2 3 4 5 6 7 8 9 10 11 12 M
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Figure 3-3 Amplification of bacterial 16S rRNA DNA from patient biopsy samples using 
universal bacterial primers (27F, 1292R) 
(L) = GeneRuler 100bp Plus DNA ladder. Ladder marker sizes (bp) are given to the right of the 
gel with brighter reference bands labelled in bold. (1)=U193, (2)=U199, (3)=U198, (4)=U205, 
(5)=U159, (6)=U195, (7)=No DNA template, (B)=Blank lane. Expected size of PCR amplicon = 
1500bp. 
 
3.3.2 Primer Design and Specificity Testing 
The universal primers (27F and 1492R) confirmed that bacterial colony DNA (1 μL of a bacterial 
colony in 50 μL sterile water) was amplifiable using the PCR protocol (data not shown). PCR 
amplicons were submitted for DNA sequencing and an NCBI BLAST search using the 
sequences confirmed identity of the cultivated isolates to be used for primer specificity testing. 
 
3.3.2.1 Bacteroides fragilis 
Primer design 
Multiple forward and reverse primers were designed with the aim of being specific for the B. 
fragilis species. Primers for the detection of the bacterial taxa B. fragilis, Fusobacterium and F. 
nucleatum were designed against the 16S rRNA gene. DNA sequence alignments were created 
to identify relevant conserved or variable regions of sequence and to determine feasibility of 
primer design for these targets (Figure 3-4). Sequences were aligned, and primers designed by 
eye aiming to include as many nucleotide differences as possible in comparison to closely 
related sequences. 
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Primer specificity:  
A phylogenetic tree (Figure 3-6) was constructed from the DNA sequence alignment used to 
design primers (Figure 3-5). In vitro specificity testing of B. fragilis primer pairs was carried out 
using a panel of species selected to span a range of Bacteroides 16S rRNA sequences and 
species closely related to B. fragilis, as inferred from the phylogenetic tree (Figure 3-6). In 
addition, a distantly related species was also tested (F. nucleatum subsp. nucleatum). 
Specificity testing showed primer pair BfF2 BfR2 to be specific for B. fragilis, generating a single 
amplicon of the correct size (Figure 3-4). 
 
 
Figure 3-4 Primer Specificity Testing:  
B. fragilis Specificity of B. fragilis species-specific primers using genomic DNA from different 
bacteria. The red arrow highlights the desired amplicon and indicates the band size. Each lane 
represents a PCR using a different bacterial DNA template as detailed in the adjacent table. 
  
M 1 2 3 4 5 6 7 M Lane no. Bacterial DNA
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Figure 3-5: Primer Design: B. fragilis 
 DNA sequence alignment of 16S rRNA gene sequences from B. fragilis and Bacteroides 
species. The alignment was produced using MEGA 6 software and MUSCLE alignment 
algorithm. Primers are highlighted in yellow with the primer name above while bases with a 
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Figure 3-6 Evolutionary relationships of Bacteroides 16S rRNA gene and closely related 
Bacteroidales taxa 
The sequence of interest, Bacteroides fragilis, is highlighted in blue while other species used for 
in vitro specificity testing are highlighted in yellow. The evolutionary history was inferred using 
the Neighbour-Joining method (Saitou and Nei, 1987). The percentage of replicate trees in 
which the associated taxa clustered together in the bootstrap test (1000 replicates) are shown 
next to the branches (Felsenstein, 1985). The tree is drawn to scale, with branch lengths in the 
same units as those of the evolutionary distances used to infer the phylogenetic tree. The 
evolutionary distances were computed using the Maximum Composite Likelihood method 
(Tamura et al., 2004) and are in the units of the number of base substitutions per site. The 
analysis involved 44 nucleotide sequences. Codon positions included were 
1st+2nd+3rd+Noncoding. All positions containing gaps and missing data were eliminated. There 
were a total of 1237 positions in the final dataset. Evolutionary analyses were conducted in 
MEGA7 (Kumar et al., 2016). 
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3.3.2.2 Fusobacterium 
Primer Design: The Fusobacterium DNA alignment (Figure 3-7A) showed three regions of the 
16S rRNA gene sequence conserved amongst Fusobacterium species. The designed primers 
are also specific for Clostridium rectum and may select for some Cetobacterium species. This 
issue is discussed further in the discussion (section 3.4.2). 
 
Primer specificity: Species selected for primer specificity testing are highlighted in yellow in 
Figure 3-8. All subspecies of F. nucleatum and the most distantly related Fusobacterium, F. 
mortiferum generated a discrete PCR amplicon of the expected size (Figure 3-7B).  
 
3.3.2.3 Fusobacterium nucleatum 
Primer Design: The generated DNA alignment showed few regions of the 16S rRNA gene that 
were specific for the F. nucleatum group and excluded other Fusobacterium species (Figure 3-
9A).  
 
Primer Specificity: Specificity testing showed that all primer pair combinations generated a 
PCR product of the correct size for the most distantly related Fusobacterium species (Figure 3-
8), F. mortiferum (Figure 3-9B). A non-specific amplicon was also generated against the B. 
fragilis DNA template, which would potential reduce the PCR efficiency if B. fragilis is also 
present in the extracted patient DNA. The F. nucleatum group were excluded from use in the 
study due to the lack of specificity of the PCR to the intended target. 
 
3.3.2.4 Fusobacterium nucleatum subsp. nucleatum 
Primer Design: The DNA sequence alignment revealed limited regions of sequence specific to 
the different F. nucleatum subspecies (Figure 3-10A). A number of primers were designed with 
the aim of being specific for subspecies nucleatum, chosen due to its use in previous studies of 
the oncogenic potential of F. nucleatum (Kostic et al., 2013). 
 
Primer Specificity: Amplicons were generated against F. nucleatum subsp. polymorphum as 
well as, or instead of nucleatum (Figure 3-10B). F. nucleatum subsp. nucleatum was excluded 
from use in the study due to the lack of specificity of the PCR to the intended target. 
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Figure 3-7 Primer Design and Specificity: Fusobacterium genus  
(A) 16S rRNA gene sequences from species in the genus Fusobacterium and other species taxonomically related. Letters with a white background indicate a 
conserved base across all sequences in the alignment. Primers are represented by yellow highlighted bases and are named above. DNA sequence alignment 
produced using MEGA 6 software and MUSCLE alignment algorithm. 
(B) Specificity of Fusobacterium genus specific primers using genomic DNA from different bacteria. The red arrow highlights the desired amplicon and indicates the 
band size. Each lane represents a PCR using a different bacterial DNA template as detailed in the adjacent table. 
FusF1 FusF2 FusR1A PRIMER DESIGN
M 1 2 3 4 5 6 7 M 8 1 2 3 4 5 6 7
Lane no. Bacterial DNA
M GeneRuler 100 bp DNA ladder
1 F. nucleatum ss. nucleatum
2 P. melaninogenica
3 F. nucleatum ss. polymorphum
4 B. fragilis
5 F. nucleatum ss. fusiforme
6 F. periodonticum
7 F. mortiferum
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Figure 3-8 Evolutionary relationships of Fusobacterium 16S rRNA gene and closely 
related taxa 
The evolutionary history was inferred using the Neighbour-Joining method (Saitou and Nei, 
1987). The percentage of replicate trees in which the associated taxa clustered together in the 
bootstrap test (1000 replicates) are shown next to the branches (Felsenstein, 1985). The tree is 
drawn to scale, with branch lengths in the same units as those of the evolutionary distances 
used to infer the phylogenetic tree. The evolutionary distances were computed using the 
Maximum Composite Likelihood method (Tamura et al., 2004) and are in the units of the 
number of base substitutions per site. The analysis involved 44 nucleotide sequences. Codon 
positions included were 1st+2nd+3rd+Noncoding. All positions containing gaps and missing 
data were eliminated. There were a total of 1237 positions in the final dataset. Evolutionary 
analyses were conducted in MEGA7 (Kumar et al., 2016). 
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Figure 3-9 Primer Design and Specificity Testing: F. nucleatum group 
(A) DNA sequence alignment produced using MEGA 6 software and the MUSCLE alignment algorithm.16S rRNA gene sequences were from species in the genus 
Fusobacterium. Letters with a white background indicate a conserved base across all sequences in the alignment while primers are represented by yellow 
highlighted bases and are named above.  
(B) Specificity of F. nucleatum group primers using genomic DNA from different bacteria. The red arrow highlights the desired amplicon and indicates the band 
size. Each lane represents a PCR using a different bacterial DNA template as detailed in the adjacent table. 
FNucF1 FNucF2 FNucF3 FNucR1A PRIMER DESIGN
B PRIMER SPECIFICITY
M 1 2 3 4 5 6 7 8 M 1 2 3 4 5 6 7 8
FNucF1 FNucR1 FNucF2 FNucR1










M GeneRuler 100 bp DNA ladder
1 B. fragilis
2 P. melaninogenica
3 F. nucleatum ss. polymorphum
4 F. nucleatum ss. nucleatum
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Figure 3-10 Primer Design and Specificity Testing: F. nucleatum subspecies nucleatum 
(A) 16S rRNA gene sequences from species in the genus Fusobacterium species and other species taxonomically related. Letters with a white background indicate 
a conserved base across all sequences in the alignment. Primers are represented by yellow highlighted bases and are named above. DNA sequence alignment 
produced using MEGA 6 software and MUSCLE alignment algorithm. 
(B) Specificity of F. nucleatum subspecies nucleatum primers using genomic DNA from different bacteria. The red arrow highlights the desired amplicon and 
indicates the band size. Each lane represents a PCR using a different bacterial DNA template as detailed in the adjacent table.
SubspNF1a SubspNF1b SubspNR1 SubspNR2 
Lane no. Bacterial DNA
M GeneRuler 100 bp DNA ladder
1 F. nucleatum ss. nucleatum
2 B. fragilis
3 F. nucleatum ss. polymorphum





M 1 2 3 4 5 6 7 8 M 1 2 3 4 5 6 7 8 M
SubspNF1a SubspNR1 SubspNF1a SubspNR2
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3.3.2.5 BFT 
Primer specificity: BFT primers were tested against a panel of B. fragilis strains including all 
three toxin subtypes and the non-toxigenic type strain (Figure 3-11A). A combination of 
previously published, newly designed, and adapted versions of previous primers were used in 
specificity testing. PCR amplicons sent for sequencing confirmed the three BFT positive strains 




Primer design: A DNA sequence alignment for ubb primer design was composed of relevant 
sequences obtained from GenBank (Benson et al., 2013). Additional sequences representative 
of those found in the gastrointestinal tract were obtained from MetaHIT (Qin et al., 2010) stool 
metagenomic sequences. As all ubb sequences were homologous, primers were designed 
using the online primer design tool Primer3 web v.4 (http://primer3.ut.ee). As this gene product 
was originally of interest due to its homology to human ubiquitin DNA, sequence alignments 
were modified to include additional similar sequences. The primers designed using the online 
design tool were compared against these analogous, non-specific sequences (Figure 3-12A) 
 
Primer specificity: Primers designed to amplify ubb were tested against a positive control (B. 
fragilis NCTC 9343) that is known to contain the gene (Patrick et al., 2011). There are no other 
bacterial species that are known to contain ubiquitin-like genes therefore the specificity of the 
primers was tested against the previously used panel of bacteria. One discrete amplicon of 
expected size was generated using the positive control DNA template (Figure 3-12B) and no 
PCR products were detected for other DNA templates. 
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Figure 3-11 Primer Design and Specificity Testing: B. fragilis toxin gene (bft) 
(A) DNA gene sequences for the B. fragilis toxin gene were obtained from Genbank and MetaHit metagenomic sequences. Letters with a white background indicate 
a conserved base across all sequences in the alignment, while primers are represented by yellow highlighted bases and are named above. DNA sequence 
alignment produced using MEGA 6 software and MUSCLE alignment algorithm. 
(B) Determination of the specificity of B. fragilis toxin primers using genomic DNA from different bacteria. The red arrow highlights the desired amplicon and indicates 









GeneRuler 100 bp DNA 
ladder
1 JCM 17585 (Bft-1)
2 JCM 17586 (Bft-2)
3 JCM 17587 (Bft-3)
4 NCTC 9343 (Bft negative)
5 No template
M 1 2 3 4 5 1 2 3 4 5 M 1 2 3 4 5 M 1 2 3 4 5
BFET-F1 BFTR1 BFTF2 BFTR1 BFTF3 BFTR4 BFTF4 BFTR4
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Figure 3-12 Primer Design and Specificity Testing: B. fragilis ubiquitin gene (ubb) 
(A) DNA gene sequences for the B. fragilis ubiquitin gene were obtained from Genbank and 
MetaHit metagenomic sequences. Letters with a white background indicate a conserved base 
across all sequences in the alignment, while primers are represented by yellow highlighted 
bases and are named above. DNA sequence alignment produced using MEGA 6 software and 
MUSCLE alignment algorithm. 
(B) Specificity of B. fragilis ubiquitin-like protein primers using genomic DNA from different 
bacteria. The red arrow highlights the desired amplicon and indicates the band size. Each lane 






Lane no. Bacterial DNA









M 1 2 3 4 5 6 7 M
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3.3.2.7 fadA 
Primers targeting fadA were adapted from previously designed primers (Avila-Campos et al., 
2007, Rubinstein et al., 2013) so DNA alignments were not constructed. Primer pairs FadA 
F1R1 and FadA F1R2 both produced non-specific amplicons to non-specific bacterial templates. 
Both FadA F2R1 and FadA F2R2 primer pairs were shown to be suitable for the PCR assay 
following primer specificity testing (Figure 3-13). 
 
 
Figure 3-13 Primer Specificity Testing: Fusobacterium fadA 
Specificity of Fusobacterium fadA primers using genomic DNA from different bacteria. The red 
arrow highlights the desired amplicon and indicates the band size. Each lane represents a PCR 
using a different bacterial DNA template as detailed in the adjacent table. 
 
3.3.3 Annealing Temperature Optimisation 
A summary of the optimal annealing temperature for each primer pair are listed in the table of 
optimised PCR conditions (Table 3-3). Figure 3-14 represents an example experiment to 
determine an optimal annealing temperature. At lower annealing temperatures the fidelity of 
primer binding is decreased therefore an increased PCR product is generated but with a 
reduced specificity. Primer pairs were tested over a range of annealing temperatures to find the 
optimum temperature whereby the maximum desired product was generated with minimal non-
specific amplification products (McPherson and Moller, 2006). 
Non-specific 
band


















FadAF1 FadAR1 FadAF1 FadAR2
FadAF2 FadAR1 FadAF2 FadAR2
96 bp
84 bp
M 1 2 3 4 5 6 7 8 M 1 2 3 4 5 6 7 8 M
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Figure 3-14 Annealing temperature optimisation: B. fragilis 
Graph showing the amplicon band intensity using B. fragilis species-specific primers (BfF2 
BfR2) across different annealing temperatures (47°C, 50°C, 53°C, 56°C, 59°C). The insert 
contains a representative DNA agarose gel with amplicons generated across different annealing 
temperatures.  
 
3.3.4 PCR Inhibitors and Limit of Detection 
PCR using dilutions of B. fragilis DNA only and B. fragilis DNA spiked into extracted biopsy DNA 
were performed in parallel to assess differences in sensitivity of the reaction. Figure 3-15 shows 
comparable amplicon intensities across DNA template dilutions, using both bacterial DNA only 
and bacterial DNA spiked into extracted biopsy DNA (40 ng) thought to be negative for B. 
fragilis. These results indicate that the extracted biopsy DNA was not inhibiting the PCR 
reaction. 
 
Due to the absence of PCR inhibitors the limit of detection was subsequently approximated for 
each gene target using serial dilutions of the relevant bacterial DNA. Figure 3-15 shows that 
lane 5 is the lowest concentration of DNA producing an amplicon, as highlighted by the red 
arrow, and in this case represents 1000 colony forming units (CFUs). As for ubb all other gene 







































ANNEALING TEMPERATURE ( C)
47 C 59 C
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Figure 3-15 Determination of PCR inhibition using spiked biopsy DNA: ubb 
Dilutions of B. fragilis DNA, listed in the adjacent table, were used in PCR reactions for ubb. The 
equivalent dilutions of B. fragilis DNA were added to 40ng extracted biopsy DNA thought to be 
negative for B. fragilis. The red arrows indicate the limit of detection. 
 
3.3.5 Results Summary  
A summary of the optimized PCR conditions that were used to investigate patient samples are 
detailed in Table 3-3. The results of these PCRs used to compare patient cohorts are described 
in chapter 4. 
 










Universal 27F 1492R 30 cycles; Ta = 52 °C; Ext = 90s 1465 bp 
Genus 
Fusobacterium 
FusF1 FusR1 30 cycles; Ta = 55°C; Ext = 45s 490 bp 
fadA FadAF2 FadAR1 30 cycles; Ta = 59°C; Ext = 25s 180 bp 
B. fragilis species BfF2 BfR2 30 cycles; Ta = 59°C; Ext = 45s 374 bp 
bft BFTF2 BFTR1 30 cycles; Ta = 48°C; Ext = 25s 311 bp 
ubb UbbF1 UbbR2 30 cycles; Ta = 56°C; Ext = 25s 142 bp 
Ta = Annealing temperature, Ext = Extension time 
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3.4 Discussion 
The results presented in this chapter determined the primers and PCR conditions to be used for 
the analysis of patient samples. Based on these results it was concluded that the optimised 
PCRs to probe patient samples would target B. fragilis, bft, ubb, the genus Fusobacterium and 
fadA.  
 
3.4.1 DNA template 
A successful DNA extraction requires complete cell lysis, removal of contaminants and minimal 
shearing of the DNA. Microbial communities have a diverse range of cells walls and 
consequently it is essential that DNA extraction procedures allow complete cell lysis, particularly 
for bacteria with thick peptidoglycan layers. Equally a DNA extraction procedure cannot be too 
harsh that it comprises DNA quality.  
 
Biopsy tissue contains many possible inhibitors of the PCR reaction, including blood 
components, bile and complex polysaccharides (Schrader et al., 2012). Common contaminants 
remaining from the DNA extraction procedure that may also inhibit PCR are guanidine HCl and 
chaotropic salts. In the presence of PCR inhibitors lower amounts of DNA template will result in 
more PCR product as the inhibitors are diluted out (Wiedbrauk et al., 1995).  
 
In this study DNA quality, as assessed by NanodropTM spectroscopy and DNA gel 
electrophoresis showed limited shearing and degradation by DNases (Figure 3-13) and limited 
presence of contaminants (Figure 3-15). Further analysis of the extracted DNA for its 
downstream application of PCR demonstrated a negligible effect of any PCR inhibitors (Figure 
3-15) in the sample and amplifiable bacterial DNA (Figure 3-14). Blank controls added to DNA 
extractions (data not shown) had below detectable limits of DNA, as determined by QubitTM 
fluorometer and universal 16S rRNA PCR, suggesting the method of DNA extraction did not add 
any (or below detection) exogenous DNA either from the DNA kit or the surrounding 
environment. 
 
In conclusion the DNA extracted from patient biopsy tissue samples was of a satisfactory 
quantity and quality to investigate the prevalence of the determined gene targets using PCR. 
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3.4.2 Detection methods 
Methods of investigating the CRC microbiome by sequencing 16S rRNA do not give sufficient 
resolution to investigate the role of B. fragilis in colonic tumour development. Only select B. 
fragilis strains contain the bft gene and therefore either metagenomic sequencing or a method 
specifically targeting bft is required.  
 
A study comparing standard, quantitative and digital PCR methods as ways of detecting bft 
found standard end-point PCR to be the least sensitive (Purcell et al., 2016). The development 
of an end-point PCR assay described in this thesis used different bft primers and a series of 
optimisation steps aimed at maximising sensitivity. Another difference is that Purcell et al., 2016 
used faecal samples compared with colonic biopsy samples used in this study. 
 
Other studies investigating bft prevalence in patient samples used culture-based methods to 
determine bft-positivity (Toprak et al., 2006, Boleij et al., 2015). An advantage of using DNA 
extracted from biopsies frozen on collection is that the samples provide a snapshot in time of 
the microbiome. The results described in this chapter show the design of primers that capture all 
in vivo bft sequences, including all three known subtypes. To ensure the specificity of the 
primers, sequences were retrieved from previously published metagenomic studies; this was 
particularly important given that it has been acknowledged (Aitchison et al., 2016) that a 
previously published sequence (Moncrief et al., 1998) was incorrect. Aitchison et al., 2016 
compared bft primers that have been used in previous literature investigating bft prevalence and 
found that these primer sets do not detect all bft subtypes. 
 
An advantage of using a culture-independent method of bft-detection is that bacteria have 
mechanisms to outcompete other species or even strains from the same species during 
culturing. B. fragilis uses type VI secretion systems (T6SS) to target Bacteroidales strains 
(Chatzidaki-Livanis et al., 2016) and a non-toxigenic strain has been shown to outcompete 
ETBF using a T6SS (Hecht et al., 2016). These competition mechanisms may result in an 
altered outcome when using culturing-dependent methods for bacterial identification.  
 
The results presented in this chapter showed that using the 16S rRNA gene to specifically target 
either F. nucleatum as a group or individual subspecies was not possible (section 3.3.2). In 
Chapter 3.4.2 Detection methods 
Chapter 3   100 
order to specifically target F. nucleatum/individual subspecies alternatives to the 16S rRNA 
gene for bacterial identification could be investigated, such as the beta subunit of DNA 
polymerase rpoB. fadA was considered a better target for the F. nucleatum group than using the 
16S rRNA gene, especially due to the association of fadA with virulence (Rubinstein et al., 
2013). Primer pairs targeting the genus Fusobacterium were also designed, as species aside 
from F. nucleatum have been associated with CRC and IBD (Ohkusa et al., 2003, Drewes et al., 
2017). The primers described in this thesis are likely to also detect Clostridium rectum, however 
C. rectum is phylogenetically closely related to F. mortiferum (Figure 3-8), and despite 
phenotypic differences should arguably be reclassified within the Fusobacterium genus (Lee et 
al., 2016a). Future work would further analyse the specificity of the Fusobacterium primers, 
particular against Cetobacterium species, in order to make conclusions based on the 
prevalence results described in section 4.2.4. 
 
Future work would ideally use RT-PCR to quantify and compare expression of bft and mpII 
(section 1.7.5). MPII can bind to, and subsequently prevent cleavage, of the adherens junction 
protein E-cadherin (Remacle et al., 2014) suggesting BFT and MPII have distinct functions. The 
literature suggests these two metalloproteinases are counter transcribed (Remacle et al., 2014)  
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Chapter 4 : PREVALENCE OF BACTERIA AND GENES OF 
INTEREST IN PATIENT SAMPLES  
4.1 Introduction 
Several metagenomic sequencing studies have revealed a different microbiome in patients with 
CRC compared to healthy individuals and an altered microbiome on the tumour tissue 
compared with adjacent healthy tissue (Marchesi et al., 2011). 
 
4.2 Results 
4.2.1 Clinical results 
A total of 78 individuals were recruited for the study (Table 4-1) however some IBD patients 
were also included in other categories (either polyp/cancer or previous polyps/cancer) therefore 
giving a total of 85. Biopsy samples were collected from all individuals while caecal effluent was 
collected from 59 patients and blood from 60. Individuals were included in the previous 
polyps/cancer group if the current colonoscopy was all clear, if new polyps were found they 
were included in the newly diagnosed polyp/cancer cohort. A separate analysis of individuals 
with a history of polyps/cancer and returning or newly diagnosed polyps is seen in section 4.2.6. 
 







Number of individuals 
with caecal effluent 
samples collected 
Number of individuals 




33 18 21 
Inflammatory Bowel 
Disease (IBD) 
15 10 11 
Previous 
polyps/cancer 
14 10 10 
Healthy (anaemia or 
rectal bleeding) 
23 21 18 
Total 85 59 60 
 
Figure 4-1 shows that there was a significant difference in age between some of the patient 
cohorts. The newly diagnosed polyp/cancer cohort had a mean age of 64, the IBD group 51, the 
previous polyps/cancer group 66, and the healthy group 51.  The IBD and healthy group had a 
significantly lower mean age than the polyps/cancer (p values = 0.021 and 0.007 respectively) 
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and previous polyps/cancer (p values = 0.011 and 0.004 respectively) and so interpretation of 
subsequent sample analysis should take this into account. 
 
 
Figure 4-1 Age of individuals recruited to each patient group 
A box plot showing the age distribution amongst patient groups. The box represents the 
interquartile range of the data with the horizontal line signifying the median. The range of the 
data is represented by the ‘whiskers’ of the box. * = p <0.05; ** = p<0.01 
 
A Chi-square statistical analysis showed no significant difference (p = 0.727) between the 
numbers of male or females individuals recruited into the different patient cohorts. 
 
4.2.2 Extracted DNA 
A one-way ANOVA test showed no significant difference in total DNA extracted from biopsy 
samples between patient groups (p = 0.151). There was some variability in the amount of DNA 
extracted from biopsy samples, but in general approximately 4-7 μg of total DNA was extracted 
per biopsy sample. DNA extraction was not successful for some samples or the DNA obtained 
could not be amplified in a universal bacterial PCR using primers 27F and 1492R (6 samples 
from 4 individuals), and so were excluded from the study. Control DNA extractions using no 
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4.2.3 Prevalence of B. fragilis, bft and ubb 
All PCR results for each sample and individual can be found in Appendix D. B. fragilis was 
found in approximately two thirds of individuals, with no significant difference amongst patient 
cohorts (Table 4-2). B. fragilis strains positive for either the bft or ubb gene were a lot less 
prevalent with a detection rate of 11%. There was no significant difference in the presence of 
ubb amongst patient groups however there was a significantly higher detection rate of bft in 
patients with newly diagnosed polyps/cancer compared with healthy individuals (p = 0.045) 
(Figure 4-2). Tables 4-3 and 4-4 list the individuals positive for bft and ubb respectively, 
including relevant clinical data. 
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Figure 4-2 Percentage of individuals (prevalence) PCR-positive for B. fragilis, bft and ubb 
in biopsy samples 
PCR positivity was defined as one or more biopsy samples with a PCR amplicon for the 
specified gene target. Statistical significance was determined by Fisher’s exact test with a * 















Polyps or cancer (n=32) Inflammatory bowel disease
(n=15)
















Patient Cohorts Cases 















32 17 53 5 16 4 13 
Inflammatory Bowel 
Disease 
15 9 60 2 13 3 20 
Healthy (anaemia or 
rectal bleeding) 
22 15 68 0 0 1 5 
Previous 
polyps/cancer 
14 9 64 1 7 1 7 
Total 83 50 60 8 11 9 11 
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Table 4-3 Clinical characteristics of ubb positive individuals 









Sex Disease status Medical History 
BF003 AC IBD (Colonic Crohn’s) 42 F 
Mild patchy inflammation with focal active 
inflammation 
Angina, hypertension 
BF013 AC New polyps N/A M Polyp histology unknown 
Previous polyps in AC and 
caecum 
BF018 AC, DC Healthy 49 M Rectal bleeding  
BF019 NT IBD and new polyps 61 M 
2 x tubulovillous polyps with low grade dyplasia. 1 in 
hepatic flexure, 1 in sigmoid colon (~2 cm). Biopsies 
taken from sigmoid polyp. 
 
BF033 AC, DC IBD (Unclassified UC) 34 M No inflammation  
BF059 AC, DC Previous polyps 51 F Previous pedunculated distal, sigmoid polyp  
BF061 OT, NT, AT New cancer 71 M 
Presented with rectal bleeding and constipation. 
Rectosigmoid cancer 
Osteoarthiritis, thyroid disease 
BF090 AC, DC New polyp 73 F 1cm rectal tubular adenoma 
Diverticular disease, 
hypertension 
Chapter 4.2.3 Prevalence of B. fragilis, bft and ubb 
Chapter 4   106 











Disease status and biopsy 
histopathology 
Other relevant medical 
history 
BF003 AC, DC IBD (CD) N/A 42 F 
Diagnostic biopsies showed mild patchy 








Proximal AC 71 F 
Transverse serrated sessile polyp and 
2cm sessile lesion (biopsies taken from 
this tumour) is adenocarcinoma T3(b) No 
nodes Dukes B 
Recent breast cancer 
diagnosis. Previous skin 
cancer 
BF027 OT, NT, AT Polyp DC 36 M Pedunculated inflammatory pseudopolyp 
 
BF028 OT, NT, AT Polyp Sigmoid 70 F 
Multiple small sessile polyps. Previous 
tubular adenoma and hyperplastic polyps  
BF033 AC, DC IBD N/A 34 M 
Unclassified IBD. Azathiopurine 
treatment for IBD. Diagnostic biopsies 
showed no inflammation. 
 
BF034 OT, NT, AT Polyp Sigmoid 54 F 
Pedunculated tubular adenoma, low-
grade dysplasia. 
Portal vein thrombosis and 
varices. HIV Positive 
BF043 AC, DC Polyp Sigmoid 74 M Inflammatory polyp Anaemia. HIV positive. 
BF080 AC, DC 
Previous 
polyp 
Unknown 75 M 
Family history of CRC (mother and 
father). 
Diverticular disease, COPD, 
gout and hypertension. 
PSC = Primary Sclerosing Cholangitis; HIV = Human Immunodeficiency Virus; COPD = Chronic Obstructive Pulmonary Disease; CD = Crohn’s Disease; UC = 
Ulcerative colitis; AC = Ascending colon; DC = Descending colon; OT = On tumour; NT = Next to tumour; AT = Away from tumou
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4.2.4 Prevalence of Fusobacterium and fadA 
A higher prevalence, although not significant (p = 0.152), of the Fusobacterium genus was 
found in the healthy cohort as compared with individuals with newly diagnosed polyps or cancer 
(Figure 4-3). There was no significant difference amongst patent groups for the fadA gene, 
although across all cohorts fadA had a low detection rate (9%) (Table 4-5).  
 
Fusobacterium was more likely to be found in a single biopsy location as compared with the 
other gene targets (Appendix 7.1). Ascending colon biopsies appeared to be more likely to be 
positive for Fusobacterium than descending colon biopsies with a 28% versus 17% detection 
rate although this was not a significant difference (p = 0.186), as determined by a Fisher’s exact 
test. 
 
Table 4-5 Numbers of individuals positive for Fusobacterium and fadA 












32 9 28 3 9 
Inflammatory Bowel 
Disease 
15 3 20 1 7 
Healthy (anaemia or 
rectal bleeding) 
22 11 50 3 14 
Previous polyps/cancer 14 3 21 1 7 
Total 83 25 30 8 9 
 
4.2.5 Age and PCR positivity 
Due to the significant difference in mean age of individuals from different patient cohorts (Figure 
4-1) and the significantly higher prevalence of bft in the newly diagnosed polyps/cancer groups 
compared with the healthy cohort (Figure 4-2) a comparison of the age of individuals positive 
and negative for PCR targets was carried out (Figure 4-4).  Significant differences in age were 
not found between individuals positive or negative for bft (Figure 4-4 (A)) or the Fusobacterium 
genus (Figure 4-4 (B)). 




Figure 4-3 Percentage of individuals positive for Fusobacterium/FadA 
PCR positivity was defined as one or more biopsy samples with a PCR amplicon for the 
specified gene target. Statistical significance was determined by Fisher’s exact test. 
 
 
Figure 4-4 Comparison of age of individuals separated by bft (A) and Fusobacterium (B) 
positivity  
The box represents the interquartile range of the data with the horizontal line signifying the 
median. The range of the data is represented by the ‘whiskers’ of the box 
(A) A box plot showing the age distribution in individuals PCR-positive or negative for bft patient 
groups. 
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4.2.6 Previous polyps/cancer 
The earlier defined cohort (section 2.1.1) referred to as having previous polyps/cancer had clear 
colonoscopies on their latest surveillance colonoscopy. Some individuals categorised in the 
newly diagnosed polyps/cancer group had previously had tumours removed. From all 
individuals with previous tumours a comparison was made between individuals with newly 
diagnosed polyps/cancer and individuals with an all clear colonoscopy (Figure 4-5A). Bft (p = 
0.556), Fusobacterium (p = 0.389) and fadA (p = 0.566) had a higher detection rate in the new 
polyps/cancer group but no significant differences were found. 
 
4.2.7 Individuals with multiple tumours 
Of potential interest when looking at a possible infectious link with cancer are individuals with 
more than one tumour. A comparison amongst individuals with a single tumour (n = 25), multiple 
tumours (n = 8) and the previously defined healthy group is shown in Figure 4-5B. The highest 
difference in detection rate between the single tumour and multiple tumour groups can be seen 
with B. fragilis, although this is not significant (p = 0.242).  
 




Figure 4-5 Percentage of individuals positive for gene targets: Comparison of alternative 
patient groups 
(A) All individuals had previously had polyps/cancer. Prevalence is compared amongst 
individuals with a clear diagnostic colonoscopy, those with newly discovered tumours and the 
healthy cohort 
(B) All individuals had newly diagnosed polyps. Prevalence is compared amongst individuals 
found to have a single tumour, multiple tumours and the healthy cohort. 
 
4.2.8 Cancer patients 
In this study only three of the patients were diagnosed with a cancerous tumour as determined 
by histological analysis (Table 4-6). This study group is too small to make any statistical 
conclusion, but it should be noted that one individual was positive for bft and one positive for 
ubb, while two of the individuals were positive for fadA. Bft and fadA+ Fusobacterium was 































































Table 4-6 PCR results of individuals with histologically defined cancer  




+ + - + + 
BF035 
Long-term IBD. High 
grade dysplasia 
adenocarcinoma 




+ - + + + 
Detection Rate (%) 100.0 33.3 33.3 66.7 66.7 
 
4.2.9 Culture-based identification utilizing selective media 
A plate wash PCR method using caecal effluent samples (section 2.6.3) was established to 
detect culturable bacterial isolates of interest. The two aims of this experiment were to 
investigate gene target prevalence with this different, luminal sample type and to generate 
stocks of isolates of interest for future analysis. To test for consistency of the method and batch 
to batch variation of the caecal effluent sample, repeat culturing and plate washing was carried 
out using five of the tested patient samples. All repeat samples gave the same PCR results as 
summarised in Table 4-6. A bft positive B. fragilis isolate was recovered from individual BF027 
and from sequence analysis subtyped as bft-1.  
 
Some differences in PCR results were seen between culturing from caecal effluent and DNA 
extracted from colonic biopsies (Table 4-7). The most discrepancies were seen with 
Fusobacterium, but was not detected in a preferred sample type. 
 
 




Table 4-7 Summary of plate wash PCR results from caecal effluent samples compared with biopsy PCR  
Patient ID 
CE Biopsy CE Biopsy CE Biopsy CE Biopsy 
Patient group 
B. fragilis bft Fusobacterium fadA 
BF027 + + (OT, NT, AT) + + (OT, NT, AT) + - N/A - Inflammatory polyp 
BF028 + + (OT, NT, AT) - + (OT, NT, AT) + - + - Polyp 
BF029 faint + (OT, NT, AT) - - - - N/A - Polyp 
BF030 - - - - + - N/A - Polyp 
BF031 - - - - + - - - Healthy control 
BF032 + - - - - - N/A - Polyp 
BF033 + + (AC, DC) - + (AC, DC) - - N/A - IBD (UC) 
BF035 - - - - - - N/A - IBD (UC) 
BF036 - - N/A - - + (AC) N/A - Healthy control 
BF041 + + (AC, DC) - - - + (AC) N/A - IBD (Crohn's) 
BF043 + + (AC) + + (AC) + - + - Polyp 
BF046 faint + - - + + (AC, DC) + - Healthy control 
BF051 + + - - - - - - Healthy 
BF056 + - - - - - N/A - IBD 
BF057 + + (AC, DC) - - - - N/A - Healthy 
BF063 - + (AC, DC) - - + + (AC) + + (AC) Healthy control 
BF070 - - - - - - - - IBD 
BF074 + + (AC, DC) - - - + (AC, DC) N/A - Healthy control 
BF076 + + (AC, DC) - - - - N/A - Previous polyp 
BF086 + + (DC) - - - + N/A - (DC) Healthy control 
BF090 + + (AC, DC) - - - + (AC, DC) N/A + (AC, DC) Polyp 
Orange cells designate a difference between biopsy and CE PCR Result 
 CE = Caecal effluent, AC = Ascending colon, DC = Descending colon, OT = On tumour, NT = Next to tumour, AT = Away from tumour




4.2.10 Bioinformatic data mining 
Data mining of two metagenomic studies, MetaHIT and the Human Microbiome Project (HMP), 
was carried out using KEGG BLAST (section 3.2.1) to compare prevalence results of bft and 
ubb from this study with other published results (Figure 4-6). The results demonstrate a similar 




Figure 4-6 Prevalence of bft and ubb in metagenomic studies 
Sequences retrieved using a KEGG BLAST search. HMP = Human microbiome project 
 
4.3 Discussion 
4.3.1 B. fragilis 
B. fragilis prevalence, even in healthy subjects, can vary widely between studies. Zitomersky et 
al., 2013 found 73% of healthy individuals harboured B. fragilis, similarly to the results 
presented here, where 68% of the healthy cohort were PCR-positive for B. fragilis. While a 
study of the gut metagenomes, taken from stool samples, found 29% of subjects were B. fragilis 
positive in a metagenomic analysis (Chatzidaki-Livanis et al., 2017) 
 
4.3.2 Bft  
In summary, bft was not detected in the healthy group, but bft prevalence was 7% in the 
currently healthy but previously had polyps/cancer group and 13% in both the IBD and newly 
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diagnosed polyps/cancer cohorts (Table 4-2). Previous research on bft epidemiology has varied 
in terms of detection method, sample type, sample location and patient cohorts (Table 4-8). Two 
previous studies found a significantly higher bft prevalence in CRC patients compared with 
healthy controls (38% vs 12% (Toprak et al., 2006)  and 27% vs 10% (Keenan et al., 2016). In 
the same study Keenen et al., 2016 found that culturing colonies on selective media versus 
DNA extraction gave differing results due to some samples having a low abundance of bft DNA. 
The limit of detection of the method may therefore be important when determining significant 
differences amongst cohorts but it is feasible that higher quantities of ETBF colonization is more 
clinically relevant. A higher bft prevalence of 40% than seen in other healthy cohorts was 
described by Zitomersky et al., 2011. 
 
The uppermost bft prevalence detected in a control group was 67% (Boleij et al., 2015) although 
the control group contained many individuals with polyps found during colonoscopy. The same 
study also found cases (adenomatous polyps or CRC requiring surgical resection) to have a 
higher bft detection rate compared with controls. The prevalence of bft was also significantly 
associated with stage of CRC, a feature also seen in a study (Viljoen et al., 2015) with a bft 
detection rate of 26% in CRC individuals. This may explain the lower prevalence seen in the 
results described here as the majority of tumours were adenomatous polyps, while out of the 
three individuals with cancer one was positive for bft (Table 4-6). The results described in this 
thesis found a significant different in bft prevalence between the healthy/control and newly 
diagnosed colonic tumour group, in line with significant differences also found in the 
aforementioned studies. 
  




Table 4-8 Summary of the literature on bft epidemiology 
Study Sample type Method 
Control group bft 
prevalence (%) 
Polyps/CRC group 
bft prevalence (%) 
(Toprak et 
al., 2006) 
Stool Culture 12 38* 
(Keenan et 
al., 2016) 



















* statistically significant  
 
4.3.3 Ubb 
This study found no significant differences in detection rate amongst patient groups, but the 
newly diagnosed polyps and IBD group had higher detection rates, perhaps meriting a larger 
study. The only comparative study for ubb prevalence mined the integrated gene catalogue of 
gut (stool) metagenomes and found ubb to be present in 3.47% of metagenomes, a number 
close to the 5% prevalence in the healthy cohort described here. The two IBD individuals 
positive for ubb were also positive for bft. Whole genome sequencing of the BOB25 (Nikitina et 
al., 2015) clinical isolate showed that this strain contains both ubb and bft, it is therefore 
possible that the individuals with IBD harbour a similar strain. A recently published study 
(Chatzidaki-Livanis et al., 2017) has identified BfUbb as inhibiting the growth of other B. fragilis, 
which may promote chronic colonisation of the strain.  
 
4.3.4 Fusobacterium, fadA and CRC 
A consistent finding in studies of the CRC microbiome is the enrichment of Fusobacterium 
species on tumour tissue in comparison to adjacent healthy mucosa (Marchesi et al., 2011, 
Kostic et al., 2012, Castellarin et al., 2012, Tahara et al., 2015). Whilst no significant differences 
in regard to Fusobacterium and fadA were observed in this study, the results here were 
measuring prevalence in individuals newly diagnosed with tumours compared with a healthy 
cohort, as opposed to abundance within an individual. The majority of tumours collected in this 
study were adenomatous polyps as opposed to cancerous tissue. In fact, of the three 
individuals with CRC two were positive for Fusobacterium and fadA. 
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Unexpectedly, the healthy cohort had a high prevalence of Fusobacterium. One theory to 
explain this finding is that the Fusobacterium primers have not been tested against 
Cetobacterium somerae, which has a closely related 16S rRNA gene sequence and has been 
shown to be present in healthy biopsy tissue (Drewes et al., 2017). Another explanation is that 
there are gastrointestinal commensal Fusobacterium species and distinctive species that are 
associated with CRC. 
 
Leptotrichia is a genus closely related to the genus Fusobacterium and together are in the class 
Fusobacteria. Leptotrichia species can also make the adhesin FadA, considered a virulence 
factor in Fusobacterium-associated carcinogenesis (Rubinstein et al., 2013). The FadA primers 
used here are specific for F. nucleatum and F. periodonticum, possibly primers designed to 
capture F. nucleatum and Leptotrichia FadA would give a different outcome, particularly as 
Leptotrichia species have been found associated with CRC tumour tissue (Warren et al., 2013). 
 
4.3.5 Fusobacterium and IBD 
No significant difference in the detection rate of either Fusobacterium or FadA was found 
between the healthy cohort and individuals with IBD. This is in contrast to some of the published 
literature. Increased levels of the genus Fusobacterium have been found in new onset 
paediatric Crohn’s (Gevers et al., 2014), Crohn’s (Pascal et al., 2017) and IBD patients with 
PSC (Sabino et al., 2016). IBD is a heterogenous disease, differing in the extent of radial 
inflammation, location and age of onset. The aforementioned studies focused on a specific type 
of IBD whereas the IBD cohort in this thesis comprises individuals with UC and Crohn’s, and 
with different levels of severity. 
 
Fusobacterium positive individuals from the IBD group had either previous polyps or new 
polyps. Long-term inflammation in IBD patients is linked to an elevated risk of developing CRC 
(Kim and Chang, 2014). The degree of inflammation correlates to colorectal neoplasia in UC 
(Rutter et al., 2004) but it is possible that a bacterial pathogen could be driving this 
inflammation. Colitis associated cancer has been shown to have a different microbiome to 
sporadic CRC but interestingly Fusobacterium is one of these differentiating microbiomes 
associated with sporadic but not colitis associated cancer (Richard et al., 2017). F. varium had 
been identified as a putative UC pathogen (Ohkusa et al., 2003) capable of invading cells and 
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initiating an inflammatory response.  F. nucleatum is also intracellular with strains isolated from 
inflamed mucosa shown to be more invasive than those isolated from non-affected tissue 
(Strauss et al., 2011). Fusobacterium association with IBD may also be connected with 
geographical location as a different study found F. mortiferum to be the most common 
Fusobacterium species isolated from an IBD cohort (Lee et al., 2016b). 
 
Literature on the microbiome in colitis associated polyps and cancer is limited. Microbes could 
be key drivers of tumorigenesis in IBD patients. In addition, there is scope for using the 
microbiome as a biomarker to identify IBD patients at risk of developing CRC. 
 
4.3.6 B. fragilis, bft and IBD  
Literature on the association of bft and IBD has produced mixed results. The results presented 
in this thesis found a higher prevalence of bft in the IBD cohort although these results were not 
significant. A statistically significant difference in bft prevalence was found using a culture-based 
method from UC biopsy samples (Zamani et al., 2017) by one study but another study found no 
significant difference (Basset et al., 2004). Similar prevalence values to my study were found by 
Prindiville et al., 13.5% in the IBD group versus 2.89% in the control group (Prindiville et al., 
2000). However, they studied stool samples in comparison to the more biologically relevant 
mucosal biopsy samples used in this thesis. Another difference is that the IBD cohort included in 
this thesis were recruited if there were no signs of macroscopic inflammation during 
colonoscopy, whereas Prindiville et al., and Basset et al., found associations between bft and 
active disease. A possible key factor is that Zamani et al., specifically looked at UC, whereas 
Basset and this thesis investigated a variety of IBD types, with and without active disease. 
 
Looking at the species level there is an agreement between Zitomersky et al., Zamani et al., and 
the results presented here in that there is no significant different in B. fragilis prevalence 
between control and IBD groups. This finding and the mixed bft results make an argument 
against using 16S rRNA sequencing to investigate microbial dysbiosis in IBD. 
 
Two individuals positive for bft (section 4.2.3) had inflammatory pseudopolyps but did not have 
IBD. Inflammatory polyps are a rare finding for individuals without colitis, but provides an 
anecdotal link between inflammation, tumorigenesis and bft.  
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Chapter 5 : ANALYSIS OF BACTEROIDES FRAGILIS 
POLYSACCHARIDE A IN VIVO 
5.1 Introduction 
5.1.1 Antigenic and phase variation 
Phenotypic variation within a bacterial population can be manifested by phase variation, a 
method used by bacteria to switch expression of an antigen on and off. Often one antigen will 
be switched off by phase variation and an alternative version is switched on to create antigenic 
variation. This phenomenon of phase variation was first described in 1922 in Salmonella 
typhimurium flagellar antigens by Andrewes (Andrewes, 1922). The classic theory for antigenic 
variation is as a strategy to avoid specific immune responses. Various genetic and epigenetic 
regulatory mechanisms exist to create antigenic variation, described in detail in Van der Woode 
et al., 2004 with common mechanisms summarised in Table 5-1.  
 
5-1 Common mechanisms of antigenic variation 
Mechanism Description Example 
Homologous 
recombination 
Multiple copies of incomplete antigen gene 
variants except the expressed variant, for 
example no transcriptional promoters. DNA 
recombination results in functional, 
chimeric gene formation. 
Neisseria gonorrhoeae 




Misalignment of repeat DNA sequence 
during replication. Can be found in 
promoter regions with the consequence of 
altered efficiency of transcription or if in 
coding sequence causing an altered 
reading frame. 
TA repeats in 
Haemophilus influenzae 
fibriae promoters 
encoded by hif genes 
(van Ham et al., 1993)  
DNA inversion 
Inversion of a DNA element, flanked by 
inverted repeat sequences, by site-specific 
recombination. 





Borrelia burgdorferi is the causative agent of Lyme disease in humans, spread by a tick vector. 
These spirochetes can infect humans for a long period of time and as result have a complex 
mechanism of antigenic variation as a method of immune evasion. The bacterium has a highly 
immunogenic surface antigen (Lawrenz et al., 2004), Vmp-like sequence (VlsE) which is 
hypothesised to stimulate a strong antibody response in order to detract from other surface 
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antigens. Throughout infection novel variants of VlsE are generated via segmental 
recombination between the VlsE expression site and many vls silent gene cassettes (Zhang et 
al., 1997).  
 
5.1.2 Capsular Polysaccharide (PS) biosynthesis and transcription 
Bacterial capsules are a layer, frequently comprised of polysaccharide, outside the cell 
envelope. Capsules are used by bacteria as a strategy to evade the host immune system, for 
example by preventing the formation of a complement attack complex, and to prevent 
bacteriophage attack. Capsules are also used for adhesion and colonisation and for these 
reasons are considered virulence factors 
 
B. fragilis has three distinct capsule layers. Each strain has either a small or large antigenically 
different fibrous outer layer and a narrow, electron dense layer also known as the microcapsule 
(Kasper et al., 1977). This variable surface microcapsule (MC) is located outside the cell 
envelope, is co-expressed with the large capsule and is comprised of different capsular 
polysaccharides (PS). DNA sequencing of the B. fragilis type strain revealed eight different 
capsular polysaccharide biosynthetic loci designated PSA-H (Krinos et al., 2001, Cerdeno-
Tarraga et al., 2005). Genomic comparison of further B. fragilis strains showed an unpredicted 
diversity in PS biosynthetic loci (Patrick et al., 2010) with a total of 28 types discovered to date. 
Each type of capsular PS has its own locus of PS biosynthesis genes for an individual PS type 
(Comstock et al., 1999). Upstream of each of the polysaccharide biosynthetic loci is a single 
promoter region. With the exception of PSC the promoters can undergo inversion of their DNA 
(Krinos et al., 2001). In fact a characteristic of the B. fragilis genome observed as a result of 
whole genome sequencing is the large number and variety of DNA inversions (fragilis invertible 
regions, fin) present in the genome (Kuwahara et al., 2004, Cerdeno-Tarraga et al., 2005). The 
bacterium is capable of switching on and off PS synthesis to alter capsular PS expression in a 
phenotypic switching process known as phase variation. The mechanism of B. fragilis surface 
PS phase variation is by DNA inversion of the PS biosynthesis promoter (Krinos et al., 2001). In 
seven of the eight PS biosynthetic loci the region of invertible DNA is flanked by repeat 
sequences known as fragilis inversion crossover sites (fix) (Patrick et al., 2003). Promoter DNA 
inversion is mediated by a serine site-specific recombinase designated as multiple promoter 
invertase, Mpi (Coyne et al., 2003). 




The first gene of all eight PS biosynthetic loci is the upxY gene where x is replaced by a to h 
depending on the specific PS locus (Figure 5-1). The UpxY family of proteins share homology 
amongst individual proteins, but contain two regions of location specific (a-h) amino acid 
sequence (Chatzidaki-Livanis et al., 2009). The UpxY proteins are able to associate with RNA 
polymerase in the 5’ untranslated region (UTR) to prevent premature termination of 
transcription. The adjacent upxZ genes code for a family of proteins able to prevent the 
transcriptional antitermination function of other PS loci UpxY proteins. Altogether the UpxZ 
proteins prevent simultaneous synthesis of PS types in a single bacterial cell by a hierarchical 
system of regulation with PSC the default locked ‘ON’ promoter (Chatzidaki-Livanis et al., 2010).  
 
 
Figure 5-1 Schematic of the PS promoter and biosynthetic locus 
IR = Inverted repeat, UTR = Untranslated region, PS = Polysaccharide Based on (Coyne et al., 
2001) 
 
5.1.3 Polysaccharide A (PSA) 
The most studied of the capsular polysaccharides is PSA, which is arguably the most 
immunogenic and important. The structure of PSA comprises a tetrasaccharide repeating unit, 
which unusually for a capsular polysaccharide is zwitterionic, comprising a positive amino group 
and a negative carboxyl group (Baumann et al., 1992). The repeating unit makes up a right-
handed helix with the charged groups externally facing allowing for interaction with other 
molecules (Wang et al., 2000). PSA has been studied extensively due to its immunomodulatory 
properties, in part due to the zwitterionic nature and structure of this molecule.  
 
Figure 5-2 illustrates the mechanism of PSA immune stimulation which originates with the 
interaction of PSA with TLR2 on dendritic cells (DCs) (Round et al., 2011, Dasgupta et al., 
2014). DCs process PSA where it is presented on Major Histocompatibility Complex Class II 
(MHC II) (Duan et al., 2008) molecules that interact with T-cell receptors (TCRs). The 
consequence of this interaction is an expansion of interleukin 10 (IL-10) producing CD4+ cells 
(Mazmanian et al., 2005). IL-10 is an anti-inflammatory cytokine and an increase in its 
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production by PSA can mediate the prevention of H. hepaticus-induced colitis in mice 
(Mazmanian et al., 2008). PSA signalling via TLR2 also suppresses Th17 and interleukin-17 (IL-
17) production to promote mucosal colonisation of B. fragilis (Round et al., 2011). 
 
 
Figure 5-2 Mechanism of immune cell activation 
Zwitterionic B. fragilis PSA can activate toll-like receptor 2 (TLR2) signalling in dendritic cells. 
PSA is presented on MHC class II molecules where is can interact with T-cell receptors (TCR) 




5.1.4 Restriction-modification systems 
These systems act as bacterial innate immune systems to guard against invading 
bacteriophage. They comprise a restriction endonuclease (REase) that recognises and cleaves 
specific foreign DNA sequences and a methyltransferase (MTase) to discriminate between self 
and non-self DNA (Vasu and Nagaraja, 2013). The property of restriction enzymes to recognise 
specific DNA sequences has been utilised in many molecular biology techniques such as 
molecular cloning and restriction fragment length polymorphism (RFLP), used in DNA 
fingerprinting and profiling. This chapter uses a previously described method (Krinos et al., 
2001, Troy et al., 2010) using a restriction enzyme to asymmetrically digest DNA within the 
invertible PSA promoter thereby generating different sized DNA fragments depending on the 
orientation of the promoter.  
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The work in this chapter describes the first analysis of PSA promoter orientation in vivo and 
analyses PSA promoter orientation in B. fragilis populations from different patient cohorts. 
Possible downstream implications of PSA production/absence were subsequently investigated. 
 
5.2 Results 
5.3 Polysaccharide A (PSA) promoter orientation 
5.3.1 Restriction Digest optimization 
A method to determine PSA promoter orientation has previously been published (Krinos et al., 
2001, Troy et al., 2010). This method was replicated in the laboratory using a ‘colony’ PCR 
method on a B. fragilis type strain NCTC 9343 colony. However, it was found that the 
manufacturer’s recommended incubation time for the SspI restriction enzyme (10 min) led to 
incomplete digestion of the PCR product. 
 
A series of restriction enzyme incubation times were tested and the extent of PCR product 
digestion determined by resolving on an agarose gel and measuring band intensity (Figure 5-3). 
An incubation time longer than 10 minutes increased the total amplicon digestion to a plateau of 
~86-88%, so an incubation time of 20 min was chosen for subsequent experiments. 
 




Figure 5-3 Optimisation of Restriction Digest Time for the PSA promoter orientation assay 
 
(A) Agarose gel depicting PCR products digested with SspI at different incubation times. Each 
lane represents a different incubation time. The bold arrow indicates the undigested PCR 
product. GeneRuler Express ladder marker sizes are given to the left of the gel with brighter 
reference bands labelled in bold. 
(B) Comparison of the total PCR product digestion with restriction enzyme incubation time 
(C) Table to compare the percentage of PCR product digested with the calculated value for PSA 
promoter ‘ON’ 
 
5.3.2 Identification of a Single Nucleotide Polymorphism (SNP) in UpaY 
Following optimisation of the method, extracted colonic biopsy DNA (Section 2.2.1) was used to 
determine the orientation percentage of the B. fragilis PSA promoter in patient samples. Whilst 
carrying out the PSA restriction digest protocol on clinical samples, it was observed that some 
samples had a different SspI digest pattern. Lanes 12 and 13 in Figure 5-4A show samples with 
two additional bands at approximately 200 and 250 bp. Published results using this method 
have previously used DNA isolated from the B. fragilis type strain (Krinos et al., 2001, Troy et 




























































Figure 5-4 Example Restriction Digest DNA Gel Electrophoresis 
 
(A) PSA PCR products from extracted biopsy DNA digested with SspI restriction enzyme. 
Individual samples (Figure 1-2B) were loaded per lane. GeneRuler Express ladder marker sizes 
are given to the left of the gel with brighter reference bands labelled in bold. 
(B) Characteristics of the sample and calculated PSA promoter % orientated ‘ON’. Colon 
location of the biopsy sample are listed as AC = ascending colon and DC = descending colon. 
(C) Table outlining the band characteristics in lane 12 of the unusual digest pattern. Calculations 
were used to determine the promoter orientation of the individual bands. 
 
 
The undigested PCR products from select samples with and without the alternative digest 
pattern were purified and sent for DNA sequencing. DNA sequences (5’ to 3’) were aligned 
against published sequences from other B. fragilis isolates and sequences from the MetaHIT (Li 
et al., 2014) metagenomic project (Figure 5-5). The alternative digest pattern was found to be 
due to an additional SspI recognition sequence in some of the isolates due to a single 
nucleotide polymorphism (SNP). The codon changes from GAG to GAA, although this will still 
code for a glutamic acid amino acid residue. The SNP is located close to the start of the first 
gene (upaY) of the PSA biosynthetic loci as highlighted in Figure 5-5. 
 
Lane Patient Group Location % ‘ON’
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14 B. fragilis NCTC 9343 Positive Control Uncut
15 B. fragilis NCTC 9343 Positive Control Cut
L 1 2 3 4 5 6 7 8 9 101112131415 L
A B
Band 1 (bp) 
Band 1 
(intensity)
Band 2 (bp) Band 2 (intensity)
Ratio of band size 
(Band 1: 2)
Ratio of band 
intensity (Band 1:2)
340 1845522 160 853818 2.13 2.16













Figure 5-5 Polysaccharide A (PSA) Promoter Region DNA Sequences from Different B. fragilis 
strains 
 
DNA sequences aligned in MEGA of PSA Promoter PCR products from patient samples, 
published sequences and sequences found from the MetaHIT metagenome project. The 
additional SspI restriction enzyme cut sequence in some isolates is highlighted in yellow. UTR = 
Untranslated region 
 
Using a combination of DNA gel electrophoresis digest pattern (Figure 5-4A) and DNA 
sequences (Figure 5-5) the size and orientation of restriction digest fragments in isolates with 
the extra SspI restriction site was determined and is illustrated in Figure 5-6. Following 
separation of restriction digest fragments on an agarose gel the DNA intercalating dye will 
decrease in intensity as the fragment size decreases. This concept was used to determine the 
promoter orientation of the alternatively cut bands (Figure 5-4C), using lane 12 in Figure 5-4A 
as an example. The percentage of the B. fragilis population promoter orientation could then be 
calculated. The method was applied to biopsy DNA isolated from clinical samples that had 
previously be found to harbour B. fragilis (Figure 5-2A). The SNP was found in individuals from 
all patient groups (1 x healthy control, 2 x IBD, 1 x newly diagnosed polyp, 1 x newly diagnosed 
cancer, 1 x previous polyps and 1 x previous cancer). 
UpaYUTR





Figure 5-6 Schematic of Restriction digest fragments of the Polysaccharide A (PSA) promoter 
regions with extra SspI restriction site 
 
The invertible promoter region of the PCR product is coloured in red. SspI cut sites are marked 
by a dashed line with the additional cut site outside the invertible region. 
 
5.3.3 PSA promoter orientation separated by biopsy location 
 
Figure 5-7 Percentage of B. fragilis cells with the Polysaccharide A (PSA) promoter in the ‘On’ 
orientation: comparison between colonic biopsy samples 
 
(A) Comparison of percentage PSA promoter orientated on in biopsy sample B. fragilis 
populations obtained from different colon locations within the same individual. AC = ascending 
colon. DC = descending colon. Samples from the same individual are paired with a straight line. 
A Wilcoxon matched-pairs signed rank test was used to statistically compare biopsy locations. 
(B) Comparison of percentage PSA promoter orientated on in biopsy sample B. fragilis 
populations obtained from different colon locations relative to the tumour within the same 
individual. OP = On the polyp colon. NP = Next to the polyp (2 cm away) and AP = Away from 
the polyp (10 cm away). Samples from the same individual are paired with a straight line. A 
Wilcoxon matched-pairs signed rank test was used to statistically compare biopsy locations. 
 
The percentage of the B. fragilis population with the PSA promoter orientated on was not 











































































































































OP = On polyp
NP = Next to polyp
AP = Away from polyp
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descending colon (Figure 5-7A) as determined by a paired, two-tailed t test (p = 0.976). An 
average percentage of all samples obtained from the same individual were used in subsequent 
analyses.  
 
5.3.4 PSA promoter orientation separated by patient groups 
Individuals were divided into groups according to the results of the diagnostic colonoscopy. 
Figure 5-8 shows that individuals with IBD had a significantly lower proportion of B. fragilis with 
PSA orientated on compared with healthy individuals, those previously with colonic 
polyps/cancer and those with newly diagnosed polyps/cancer. F-tests between patient groups 
determined that there was no significant difference between the variances of the different 
patient group populations. 
 
Figure 5-8 Percentage of B. fragilis cells with the Polysaccharide A (PSA) promoter in the ‘On’ 
orientation: comparison amongst patient groups 
 
Significant differences amongst patient groups was determined using the non-parametric 
Kruskal-Wallis test and pairwise difference between patient groups established using Dunn’s 
post-test multiple comparisons correction (Table 5-3). Error bars indicate the median and 95% 
confidence level. A * designates a p value of less than 0.05 and ** represents a p value of less 
than 0.01. 
 
Figure 5-9(A) shows that that bft positivity was significantly associated (p <0.000) with a low 
percentage of the B. fragilis population with the PSA orientated on. To determine whether this 
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the promoter orientated on was determined for a selection of B. fragilis isolates grown in vitro on 
agar (Figure 5-9B). The PSA promoter orientation on the other hand had no significant 
difference (p = 0.826) with the presence of ubb. 
 
 
Figure 5-9 Individuals with bft positive strains have a significantly lower percentage of B. fragilis 
with the PSA promoter in the 'ON' position 
 
(A) Percentage of B. fragilis cells with the PSA promoter in the ‘ON’ orientation as separated by 
individuals with biopsy samples positive for the B. fragilis toxin gene (bft). Mann-Whitney U test 
was used determined significant differences between bft positive and negative samples. Error 
bars indicate the median and 95% confidence level . 
(B) Each lane represents a different B. fragilis isolate (1) = BF001.DC, (2) = NCTC 9343, (3) = 
JCM 17585 bft-1, (4) = JCM 17586 bft-2, (5) = JCM 17587 bft-3, (NT) = No template control, (L) 
= GeneRuler Express DNA ladder. DC = Descending colon. The calculated percentage of B. 
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5.4 Interleukin 10 (IL-10) 
Following the significant PSA promoter orientation differences amongst patient groups, it was 
decided to investigate the relationship with IL-10 levels as the most probable downstream 
consequence of immunomodulatory PSA (Figure 5-2). Non-parametric statistical tests were 
employed, as the results were not normally distributed as shown in Figure 5-10. 
 
5.4.1 Serum 
The frequency distribution of IL-10 concentration in serum samples from different individuals 
showed a subset of samples having higher IL-10 concentrations, while many of the samples had 
values that were undetectable (Figure 5-10A).  
 
 
Figure 5-10 Frequency distributions of serum and tissue IL-10 concentration do not follow a normal 
distribution 
 
(A) Histogram to show the distribution of serum IL-10 concentrations (pg/mL) 
(B) Histogram to show the distribution of tissue IL-10 concentrations (pg/mg protein) 
 
 
No significant difference in serum IL-10 concentration (p = 0.932) was observed between 
individuals with positive or negative PCR results for B. fragilis (Figure 5-11A). In addition, no 
significant difference in serum IL-10 concentration was detected amongst patient groups (Figure 
5-11B). The highest serum IL-10 concentrations were obtained from individuals (BF001, BF005, 
BF090) with positive B. fragilis results and polyps/IBD. These individuals had long-term, but 
currently quiescent UC; polyp (unknown type); and a tubular adenoma with diverticular disease. 
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Figure 5-11 Serum IL-10 concentration separated by patient groups or between B. fragilis-positivity  
 
(A) Levels of serum IL-10 concentration separated by individuals with biopsy samples PCR-
positive or negative for B. fragilis. Statistical significance was calculated using a Mann-Whitney 
U test. 
(B) Levels of serum IL-10 concentration separated by patient group. Significant differences 
amongst patient groups were determined using the non-parametric Kruskal-Wallis test and 
pairwise differences between patient groups calculated using Dunn’s post-tests multiple 
comparisons correction (Table 5-3). The colour red indicates individuals with B. fragilis positive 
samples. Error bars for figures A and B indicate the median IL-10 concentration (pg/mL) and 
95% confidence level (C.I.).  
 
5.4.2 Tissue lysate 
As with PSA promoter orientation (Figure 5-12), there was no significant difference in IL-10 
concentration amongst colonic biopsies collected from different locations within the same 
individual.  IL-10 concentrations in locations relative to the polyp show slight variation within an 































































































Red = BF Positive
Black = BF Negative





Figure 5-12 Tissue IL-10 concentration amongst biopsy sites 
Dotted lines link samples from the same individual 
(A) Levels of tissue IL-10 concentration in the ascending colon (AC) and descending colon (DC) 
from the same individual. A Wilcoxon matched-pairs signed rank test was used to statistically 
compare IL-10 levels from different biopsy locations. 
(B) Levels of tissue IL-10 concentration at sites relative to a polyp/cancer. Statistical analysis 
amongst biopsy sites was determined using the Wilcoxon matched-pairs signed rank test. 
 
 
Figure 5-13 Tissue IL-10 concentration amongst patient groups  
 
Differences in IL-10 levels in the different patient groups were determined using the non-
parametric Kruskal-Wallis test and pairwise difference between patient groups established using 
Dunn’s post-test multiple comparisons correction (Table 5-3). The colour red indicates 
individuals with B. fragilis positive samples. Error bars indicate the median and 95% confidence 
level. 
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When individuals were separated according to patient group there was no significant differences 
in mean pg IL-10 per mg protein (Kruskal-Wallis p = 0.123) amongst patient groups (Figure 5-
13). Similarly, the Dunn’s multiple comparisons test did not identify (Table 5-2) any significant 
differences in IL-10 quantities between pairs of patient groups. The three individuals with the 
highest tissue IL-10 concentrations were obtained from individuals, BF006, BF008 and BF001, 
with sigmoid polyp, ascending colon adenocarcinoma and quiescent UC respectively (Figure 5-
11).  
 
The median and 95% C.I. of tissue IL-10 concentration (Figure 5-14A) was higher in B. fragilis 
positive samples (0.164) compared to negative samples (0.137) although this difference was not 
significant (p = 0.069). However, BFT positive biopsy samples (Figure 5-14B) had a very similar 
median (0.143) compared with BFT negative samples (0.140), a difference with a larger p value 
as determined by the Mann-Whitney U test (p = 0.3548) 
 
 
Figure 5-14 Tissue IL-10 concentration as separated by the presence of BF or BFT 
 
Error bars for figures A and B indicate the median IL-10 concentration (pg/mL) and 95% 
confidence level (C.I.). A Mann-Whitney U test was used to determine any significant 
differences between positive and negative samples (Table 5-2) 
(A) Serum IL-10 levels separated by individuals with biopsy samples positive for B. fragilis.  
(B) Tissue IL-10 levels separated by individuals with biopsy samples positive for the B. fragilis 
toxin gene (bft). A Mann-Whitney U test was used to determine any significant differences 
between positive and negative samples. 
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5.4.3 Correlation analyses 
 
Figure 5-15 Correlation analysis of serum IL-10 or tissue IL-10 and B. fragilis PSA promoter 
orientation 
 
Correlation was tested statistically using Spearman’s rank correlation  
(A) Scatter graph to identify any correlation between serum IL-10 concentration (pg/mL) and B. 
fragilis PSA promoter orientation 
(B) Scatter graph to identify any correlation between tissue IL-10 concentration (pg/mg protein) 
and B. fragilis PSA promoter orientation 
 
 
The reasoning behind measuring IL-10 concentrations was to establish if they correlated with 
the percentage of B. fragilis cells with PSA promoter orientation. No linear relationship (Figure 
5-15) was found with either serum IL-10 concentration (Spearman r = -0.225, p = 0.417) or 
biopsy tissue IL-10 (Spearman r = 0.134, p = 0.564). The product moment correlation coefficient 
(r) for serum IL-10 is a negative value; therefore if any correlation exists between the two 
variables it is negative. The r-value is close to zero for biopsy tissue IL-10 suggesting there is 
very little or no correlation between the two variables. No correlation was also observed 
between tissue lysate IL-10 and serum IL-10 (p = 0.894) and the Spearman r value was 
negative (r = -0.049).  
 
Age did not correlate with either serum (Figure 5-16B) or tissue IL-10 (Figure 1-16C) 
concentrations. A weak positive correlation (r = 0.283) between age and the percentage of the 
B. fragilis population with the PSA promoter orientated was identified although this was not 
significant (p = 0.093).  
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Figure 5-16 Scatter graphs to identify possible correlation of variables with age of the individual 
 
(A) Scatter graph to identify any correlation between age and B. fragilis PSA orientation 
(B) Scatter graph to identify any correlation between age and serum IL-10 concentration 
(pg/mL) 
Error bars for figures A and B indicate the median IL-10 concentration (pg/mL) and 95% 
confidence level (C.I.).  
(C) Error bars for figures A and B indicate the median IL-10 concentration (pg/mL) and 95% 
confidence level (C.I.).  
Scatter graph to identify any correlation between age and tissue IL-10 concentration (pg/mg 
protein) 
(D) Summary of Spearman’s rank correlation used to statistically identify any correlation 
between age and all variables tested. Spearman’s r values and p values are summarised in the 
table. 
 
5.4.4 Summary of Results  
Presented in this section is a summary of the above results combining PSA promoter orientation 
and IL-10 levels. Table 5-2 shows that the only PCR gene target with a significant association 
with one of the aforementioned variables is bft and PSA promoter orientation, as described 




























































































































































Serum IL-10 0.103 0.639
Tissue IL-10 0.134 0.564
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previously (section 5.3.4). B. fragilis was close to being significantly associated with tissue IL-10 
concentration and so may have some biological significance. 
 
Table 5-2 Summary of p values for significant differences between the variables tested (PSA 
promoter orientation, serum IL-10 concentration and tissue IL-10 concentration) and presence of 
bacterial taxa or virulence genes as detected by PCR 
PCR Gene Target 
p (Mann-Whitney test) 
PSA serum IL-10 tissue IL-10 
B. fragilis 16S rRNA N/A 0.932 0.069 
bft 0.000 *** N/A 0.355 
Fusobacterium 16S rRNA 0.520 0.839 0.710 
FadA >0.999 0.257 0.860 
*** = p value of less than 0.001 
Pairwise comparison of patient groups with PSA promoter orientation, serum IL-10 or tissue IL-
10 (Table 5-3) highlights the significant associations between, IBD and the healthy group and 
the previous polyps/cancer cohort in respect to PSA promoter orientation (section 5.3.4).  
 
Table 5-3 Summary of p values for pairwise significant differences between patient groups for all of 
the variables tested (PSA promoter orientation, serum IL-10 concentration and tissue IL-10 
concentration) 
Patient Groups 
p (Kruskal-Wallis test) 
PSA serum IL-10 tissue IL-10 
Healthy vs previous polyps/cancer >0.999 >0.999 >0.999 
Healthy vs new polyps/cancer >0.999 >0.999 0.506 
Healthy vs IBD 0.018* >0.999 0.396 
Previous polyps/cancer vs new 
polyp/cancer 
0.969 >0.999 0.769 
Previous polyps/cancer vs IBD 0.004** >0.999 0.595 
New polyps/cancer vs IBD 0.058 >0.999 >0.999 
* = p value of less than 0.05; ** = p value of less than 0.01 
 
5.5 Discussion 
5.5.1 PSA promoter orientation in vivo 
The PSA promoter orientation in healthy individuals had a 95% C.I. around the median of 
between 40% and 60% of the B. fragilis population (Figure 5-8). PSA promoter orientation has 
not previously been studied in human tissue samples, with the nearest comparable research 
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carried out in faecal samples from various mouse models (Troy et al., 2010). They found that in 
monocolonised mice after 9 weeks approximately 80% of B. fragilis has the PSA promoter 
orientated ‘ON’, but, after 11 weeks, this value decreased towards ~50%. The results presented 
in this chapter suggest that in intestinal homeostasis and with B. fragilis in a commensal form 
there is a heterogenous population in terms of capsular polysaccharide.  
 
When a complex microbiota from two different litters was used one litter had close to 80% of the 
population oriented on, while the other litter had close to 0%. This demonstrates how the 
microbiota composition may be an environmental factor for influencing PSA promoter 
orientation. Troy et al., 2001 also found that broth cultures in exponential phase had a high 
percentage orientated on as did the first time point for monocolonised mice, so perhaps this a 
feature of an actively growing B. fragilis population. The results presented here are unlikely to 
be directly comparable to the study by Troy et al., 2001 as the digestive system of mice and 
humans differ (Nguyen et al., 2015). Mice have a comparatively larger caecum and colon than 
humans and are coprophagic, denoting that they consume each other’s faeces, therefore within 
a litter the inter-mouse microbiota is likely to be consistent. 
 
The results presented here show that in IBD patients B. fragilis populations have a significantly 
lower percentage of bacteria with the PSA promoter orientated in the ‘on’ position, although 
there is no significant difference based on sample location within an individual. This is an 
interesting result given that PSA can prevent H. hepaticus-induced colitis in mice (Mazmanian et 
al., 2008). Previous research (Troy et al., 2010) implicates microbiota composition as important 
for determining PSA promoter orientation and given that IBD individuals are known to have a 
dysbiotic microbiota this may be one explanation for my findings. Prevention of H. hepaticus-
induced colitis is IL-10 mediated, but the results presented in this thesis show no significant 
difference in tissue IL-10 concentration between healthy individuals and those with IBD. 
Insufficient samples were tested to compare any potential correlation between PSA orientation 
and IL-10 concentration within the IBD patient group, although no correlation was observed 
when comparing all samples (Figure 5-15). A feature of IBD is a lack of immunotolerance 
towards commensal bacteria. The results reported in the current study may reflect the bacterium 
requiring phenotypic variation of capsular polysaccharides to evade the dysregulated immune 
response. 




The only PCR target found to have a significant link with PSA promoter orientation was bft. 
Perhaps this association is observed because BFT is more likely to be found in individuals with 
GI disease, while PSA is more likely to be switched ‘OFF’ when intestinal homeostasis is 
disrupted i.e. in IBD. An alternative view is that BFT is a virulence factor associated with B. 
fragilis the pathogen and so will use capsular switching to avoid host adaptive immune 
responses or requires a new capsule for colonisation outside of the usual environmental niche.   
 
5.5.2 Identification of a SNP 
Whilst determining the B. fragilis PSA promoter orientation in patient biopsies an alternative cut 
pattern was observed leading to the identification of a SNP in the upaY gene. Due to the 
degeneracy of the genetic code, the DNA sequence change observed does not result in a 
difference in amino acid sequence. Serum and tissue IL-10 results were not available for all 
individuals with this SNP as it was not feasible to collect serum from every individual and so 
there were insufficient data to observe any downstream, functional consequences in IL-10 
response of these individuals. Conversely, it has been found the upaY is conserved across 
many Bacteroides capsular polysaccharides (Krinos et al., 2001) and in the above DNA 
sequence alignment (Figure 5-5) the SNP is surrounded by a conserved DNA sequence. This 
study found the SNP-containing strain in multiple individuals so perhaps there is an, as yet, 
unidentified reason for its positive selection. A possible result of the SNP, despite an unchanged 
protein sequence, could be an altered secondary structure at the 5’ end of mRNA which is 
capable of influencing translational efficiency (de Smit and van Duin, 1990). As the UpxY family 
of proteins are involved in prevention of premature transcription termination within the 5’ 
untranslated region between the promoter and the UpxY gene (Chatzidaki-Livanis et al., 2009), 
and assuming the SNP results in reduced translational efficiency of upaY this would result in 
reduced expression of PSA. 
 
5.5.3 Serum IL-10  
The anti-inflammatory cytokine IL-10 is considered to have an important role in maintaining 
gastrointestinal homeostasis. Polymorphisms in the IL-10 gene have been linked to IBD 
susceptibility (Tagore et al., 1999) and a meta-analysis has shown that a high level of serum IL-
10 is significantly associated with a worse survival outcome in cancer patients (Zhao et al., 
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2015). This study found no significant difference in serum IL-10 concentrations amongst the 
different patient groups tested. Table 5-4 summarises literature measuring serum IL-10 
concentrations in CRC and IBD groups. Mean serum concentrations in the healthy group varied 
across the studies, but a consistent finding across most of the literature is that healthy IL-10 
levels are lower than in IBD or CRC cohorts. Furthermore, Stanilov et al., 2010 show that 
increased IL-10 levels are associated with later stages of CRC. The results presented here are 
in agreement in that median serum IL-10 was higher in the tumour and IBD groups compared 
with healthy individuals, although not statistically significant. 
 
Table 5-4 Summary of literature measuring serum IL-10 Levels in IBD and CRC 
Authors Method 
Mean serum IL-10 levels (pg/mL) 
CD UC CRC Healthy 
(Kucharzik et al., 
1995) 
Sandwich ELISA 




Inactive: 52  
N/A  44  













2.16   4.40  1.99  1.35  




 N/A  N/A 16.09  5.1  
(Wang et al., 2011) ELISA (BD)  4.77  N/A N/A  2.58  
(Miteva et al., 2014) 
ELISA (R&D 
systems) 
 N/A  N/A 12.6  6.42 
(Abtahi et al., 2017) 
ELISA 
(eBioscience) 
 N/A N/A  0.452  0.812 
CD = Crohn’s Disease; UC = Ulcerative colitis 
 
5.5.4 Tissue IL-10 
Tissue IL-10 levels, similarly to serum IL-10 concentrations, showed no significant difference 
amongst patient groups. The lowest p value was observed comparing the healthy and IBD 
groups so perhaps a larger IBD cohort separating CD and UC patients would see significant 
differences. Tissue IL-10 levels are also going to depend on the vascularisation of the mucosal 
biopsy tissue, which may be more pronounced in tumour tissue. 
 
No correlation was observed between tissue IL-10 concentration and serum IL-10 levels for 
individuals where both samples were measured. A possible explanation for this is that immune 
cell responses can be very tissue-specific (Hu and Pasare, 2013). 
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5.5.5 PSA promoter orientation is not correlated with IL-10 concentration 
No correlation was identified between PSA promoter orientation and either serum or tissue IL-10 
levels (Figure 5-15). Our hypothesis that a positive correlation would be observed between the 
PSA promoter orientation and either serum or tissue IL-10 levels was not fulfilled. Possible 
reasons for why this may be the case are discussed below. 
 
5.5.5.1 Other zwitterionic capsular polysaccharides 
B. fragilis have been shown to synthesis chemically different versions of PSA, for example B. 
fragilis strain 638R expresses PSA2 (Wang et al., 2000). The restriction digest method used in 
this thesis employed primers directed at inverted repeats surrounding the PSA operon and 
would not differentiate between these chemically different, and possibly dissimilar immune-
stimulatory versions of PSA.  B. fragilis is able to synthesise many different types of 
polysaccharide, including PSB that is also zwitterionic (Baumann et al., 1992). Altogether this 
adds to the complexity of the relationship between PSA promoter orientation and IL-10 levels. 
 
Other bacterial species have been shown to synthesise ZPSs. Streptococcus pneumoniae can 
synthesise the zwitterionic type 1 polysaccharide (Sp1) (Lindberg et al., 1980) while another 
well studied zwitterionic capsule is Staphyloccoccus aureus CP8 (Wu and Park, 1971). 
Taxonomically diverse species, including other Bacteroides species, are predicted to produce 
the amino sugar acetamino-2, 4, 6-trideoxygalactose (AATGal). AATGal contains a positive 
charge key for the immunomodulatory properties of zwitterionic capsular polysaccharides (Neff 
et al., 2016); therefore, it is proposed that taxonomically diverse gastrointestinal bacteria can 
produce immunomodulatory zwitterionic capsular polysaccharides. This would also explain the 
lack of correlation seen between PSA orientation and IL-10 concentrations, as the complexity of 
this potential correlation is beyond the scope of this study.  
 
5.5.6 The biological significance of capsular phase variation 
In the healthy cohort the PSA promoter is orientated on in approximately 50% of the B. fragilis 
population. This concurs with a theory of the biological significance of phase variation that it 
creates heterogeneity within a clonal population allowing for diversity to protect against sudden 
environmental stresses (Van Der Woude and Bäumler, 2004). Other possible reasons for 
capsular polysaccharide phase variation include temporal heterogeneity that allows for 
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avoidance of specific immune responses or colonisation of multiple niches within the host 
(Weiser et al., 1994).  
 
Evidence from B. fragilis research has shown that PSA can activate TLR2 on Fox3p+ regulatory 
T cells reducing Th17 responses (Round et al., 2011). Suppression of Th17 by PSA allows for a 
small population of mucosal-associated B. fragilis to survive within colonic crypts. This may 
represent a small quantity of B. fragilis, but they are possibly more potent in their 
immunomodulatory capacity due to their expression of PSA. A stable acapsular mutant B. 
fragilis has been shown to be outcompeted by B. fragilis with the ability to synthesise one 
capsular polysaccharide (Coyne et al., 2008), further suggesting the importance of the capsule 
for colonisation of the bacterium. 
 
5.5.7 Future research 
To begin to answer the biological significance of phase variable capsules in B. fragilis, future 
work should elucidate whether the difference observed in the IBD cohort is due to B. fragilis 
cells actively employing phase variation or PSA expressing populations being selected against 
based on host selection pressures. 
 
Assuming promoter orientation relates to expression, the output of the restriction digest method 
used in this study describes the proportion of the B. fragilis population expressing PSA, but did 
not quantify the amount of B. fragilis and/or PSA. This could be significant as a threshold level 
may be required to stimulate immune cell populations. Future research in this area should also 
use immunohistochemistry or fluorescent in-situ hybridisation (FISH) to obtain localisation 
information about the bacterium, as this could be important for PSA-induced stimulation of 
different immune cell populations. This study found no significant difference in PSA promoter 
orientation within B. fragilis populations between different longitudinal colonic locations, but it is 
feasible that transverse localisation is more relevant, for example is B. fragilis luminally located 
versus deep within colonic crypts. Perhaps a more appropriate method is required to look at the 
downstream consequence of an altered PSA promoter orientation in the IBD group. A more 
relevant output of PSA immunomodulation could be measurement of specific IL-10 responses in 
peripheral blood mononuclear cells (PBMCs), lamina propria mononuclear cells (LPMCs) or IL-
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10 activation of signalling pathways, possibly by using RT-qPCR to measure gene expression of 
IL-10 regulated genes. 
 
A more direct method of measuring PSA expression such as an antibody to B. fragilis PSA or 
AATGal-ZPS would bypass any mechanisms of transcriptional regulation. The field requires 
more knowledge on expression conditions and mechanisms of the various B. fragilis capsules 
and following the findings presented here particularly how this relates to IBD. Future work could 
investigate PSA promoter orientation in a larger cohort of individuals with IBD with the aim of 
investigating differences between active and inactive disease and between CD and UC. Finally, 
a more speculative approach could be the use of PSA promoter orientation as a putative 
biomarker for gastrointestinal health; however more research is required first to see whether 
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Chapter 6 : GENERAL DISCUSSION 
Presented in this thesis is a PCR-based method for the detection of bacterial taxa and genes 
hypothesised to be important in gastrointestinal health. The gene coding for a putative 
oncogenic B. fragilis virulence factor, bft, was found at a significantly higher prevalence in 
individuals newly diagnosed with polyps/cancer compared with a healthy cohort. Prevalences of 
Fusobacterium and fadA were not significantly different in the cohorts investigated in this study. 
Detection rates of bft and B. fragilis ubb were higher in IBD patients compared with healthy 
individuals. These last results were not significant but merit further study. 
 
Colonic location and histological type of Fusobacterium-positive tumours did not exhibit any 
significant associations, but the trends observed support previous suggestions of an association 
between Fusobacterium species and right-sided colon cancer (Mima, 2016). Similarly, no 
statistical significance between bft and tumour location was observed but the results support the 
association of bft with left-sided tumours (Purcell et al., 2017). In addition, a potential feature of 
bft tumorigenesis is the development of multiple polyps and the growth of new tumours following 
polypectomy. This observation was not significant in this study and therefore requires further 
research involving a larger sample size. 
 
This thesis also contains the first reported determination of B. fragilis capsular PSA promoter 
orientation in vivo. In a healthy population the PSA promoter was on in 40-60% of individuals, 
whereas a significantly lower percentage of the B. fragilis population had PSA orientated on in 
individuals with IBD and positive for bft. PSA promoter orientation may therefore signify a novel 
biomarker of gastrointestinal health. One possible consequence of decreased PSA expression 
is reduced IL-10 production, but this was not observed in this study when looking at serum or 
tissue levels.  
 
CRC has been classified into different numbers of subtypes using a variety of methods, 
including whole genome sequencing (Muzny et al., 2012), gene expression (Guinney et al., 
2015) and proteomics (Zhang et al., 2014). The results from this thesis did not find 
Fusobacterium and bft in all polyps and cancer samples supporting the idea that a subgroup of 
CRC could be microbial-induced, or that CRC categories with different properties are a result of 
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diverse oncogenic microbes. It should not be forgotten that colon cancer develops over many 
years and therefore the tumour environmental niche, and the tumour microbiome, could change 
temporally. The results presented in this thesis do not disprove or support the driver-passenger 
model (section 1.7.1) but have shown that FadA positive Fusobacterium species can coexist in 
cancer tissue with bft and so do not have to be mutually exclusive (Tjalsma et al., 2012). 
 
6.1.1 Polyposis 
A higher prevalence of bft was found in individuals with more than one polyp/cancer compared 
with patients with a single colonic tumour. This finding was not significant, which may reflect the 
small sample size. This is believed to be the first study to compare single and synchronous 
polyps in terms of the microbiome. The microbiome of patients with the inherited polyposis 
syndrome FAP (section 1.4.4) has been investigated, although this was in respect to dysbiosis 
in pouchitis (Tannock et al., 2012) (Zella et al., 2011). A study found that 23.5% of patients with 
CRC have synchronous polyps (Demetriades et al., 2004), raising the question of whether there 
is a different etiology in patients with synchronous tumours compared with a single tumour? A 
meta-analysis (Jayasekara et al., 2017) showed that a proximal location of CRC is a risk factor 
for metachronous CRC, likewise Fusobacterium is associated with the right colon (Mima et al., 
2016, Yu et al., 2016). 
 
Similarly, when comparing individuals with a history of polyps/cancer the detection rate of bft 
was higher in individuals with new tumours compared with a clear colonoscopy outcome. As 
with multiple polyps, it appears that these groups have not previously been compared in respect 
to the microbiome. 
 
6.1.2 Biogeography 
Differences in prevalence results between caecal effluent (CE) and biopsy samples from the 
same individual could be for a number of reasons. The CE sample was analysed by a culture-
dependent method in comparison to the culture-independent DNA extract from biopsy tissue. 
Future work would use the DNA extraction method on CE to compare with the culturing results. 
In addition, the culturing study would be extended to all individuals from which caecal effluent 
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was collected. This would give a clearer picture as to whether the results are dependent on the 
type of methodology or the type of sample and its location within the colon.   
 
Just one study has associated bft with tumour location and histological type (Purcell et al., 
2017). ETBF positivity was found to be associated with left-sided tumours; similarly, out 5 bft-
positive individuals with tumours presented in this thesis 3 were sigmoidal and 1 was in the 
descending colon. Purcell et al., 2017 also found an association between bft and serrated 
polyps and tubular adenomas. My results support this finding as 3 out of 5 individuals positive 
for bft had either sessile, serrated polyps or tubular adenomas. The other bft-positive tumours 
were rare inflammatory polyps not present in the Purcell et al., 2017 study. 
 
Future research in this field requires more information on localization and biogeography of the 
different taxonomic groups. The literature has consistently found Fusobacterium to be more 
abundant on tumour tissue compared with adjacent healthy mucosa (Tahara et al., 2015) but a 
study of the oral microbiome using FISH (Mark Welch et al., 2016) showed a distinct spatial 
arrangement of the microbiome with less abundant species in potentially important geographical 
patterns. Blind sampling of the oral microbiome without this biogeographical knowledge could 
result in abundance-based results misinterpreting biological relevance. In respect to the 
colorectal tumour microbiome it is therefore important to first establish what is present, then to 
answer where is it, and finally what is being expressed. 
 
6.1.3 Fusobacterium and F. nucleatum taxonomy 
Comparative genomics of whole bacterial genomes revealed Fusobacterum species fall into 
three main lineages (McGuire et al., 2014). Research into F. nucleatum as a pathogen often 
overlooks the heterogeneity between the different subspecies. Multiple studies have suggested 
F. nucleatum subspecies are diverse enough to be considered separate species (Manson 
McGuire et al., 2014, Kook et al., 2017). The expanded HMP dataset (HMP1-II) revealed that F. 
nucleatum is niche-associated for body site (Lloyd-Price et al., 2017) suggesting that oral and 
gastrointestinal strains may represent different subspecies.  Phylogenetic analysis using the 
RNA polymerase β subunit (rpoB) gene and the 16S rRNA gene revealed a distinction between 
oral and gastrointestinal isolates (Strauss et al., 2008). Strauss et al., 2008 found subspecies 
animalis to be the most common type isolated from gut biopsies, while this subspecies has 
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rarely been found in the oral cavity (Gmur et al., 2006). F. nucleatum subsp. animalis has also 
been found to be the most prevalent subspecies in CRC (Ye et al., 2017). F. nucleatum strains 
can differ in their invasiveness, a feature particularly associated with IBD (Strauss et al., 2011), 
with an especially invasive isolate shown to have bacteriophage within its genome (Cochrane et 
al., 2016). Strain importance was also highlighted in the Apc(Min/+) mouse model of intestinal 
tumourigenesis, where one strain initiated tumorigenesis (Kostic et al., 2013) and another did 
not replicate this finding (Tomkovich et al., 2017). Altogether the literature on F. nucleatum 
points towards specific strains, and perhaps even particular virulence genes, being associated 
with IBD/CRC.   
 
Whole genome sequencing of Ruminoccocus gnavus strains isolated from healthy and IBD 
patients revealed another example of the importance of strain-level information (Hall et al., 
2017).  Two clades of R. gnavus were identified with one of the strains enriched in individuals 
with IBD; consequently some of these bacterial genes were almost exclusively present in IBD 
patients.  
 
In conclusion, overall the results presented indicate that the common gastrointestinal species, 
B. fragilis, can have wide ranging effects on gastrointestinal health. Between-strain differences 
and within-strain antigenic variation were shown to have significant associations with patient 
populations and argue for a gene-centric, and not taxonomic-centric, approach to microbiome 
research.  
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2016 (version 1) for the above study.  I have had the opportunity to consider the 
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2. I understand that my participation is voluntary and that I am free to withdraw at 
any time without giving any reason, without my medical care or legal rights being 
affected. 
 
3. I understand that relevant sections of my medical notes and data collected during 
the study may be looked at by individuals from the Department of 
Gastroenterology where it is relevant to my taking part in this research.  I give 
permission for these individuals to have access to my records. 
 
4. I understand that samples of blood and colonic tissue and fluid donated by me will 
either be analysed immediately or stored until no later than September 2024 in 
case we need to undertake further analysis as a result of our research. 
 
5. I agree to my donated samples being used to analyse my 
DNA.   
 
 
6. I understand that samples donated by me may be analysed anonymously in 
laboratories in France, Sweden, Denmark and Italy as well in the UK and stored 
for this research and destroyed no later than September 2024. 
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1st Floor, College House, South Wing 
St Thomas' Hospital 
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We would like to invite you to take part in our research study.  Before you decide, we would like 
you to understand why the research is being done and what it would involve for you.  We will be 
happy to answer any questions you may have before you decide to take part.  You may also 
wish to discuss the study with friends and family.  Participation is entirely voluntary and you may 
withdraw from the study at any time without giving a reason 
 
Am I eligible to take part? 
We are looking for adults, aged 18 to 80 years, who are undergoing routine colonoscopy to 
investigate symptoms of altered bowel habit, abdominal pain or rectal bleeding or as a follow up 
examination for colonic polyps, bowel cancer or inflammatory bowel disease and therefore are 
recruiting a range of patients with a range of conditions. We are asking about 300 people to 
take part in the study. Participating in the study will not alter your routine care. Your eligibility to 
take part in the study will be confirmed on the day of your procedure by the endoscopist 
(doctor). 
 
What is the study for? 
We want to find out whether certain toxin-producing bacteria are involved in the development of 
colorectal (bowel) cancer 
 
The main objective of the study is to: 
Investigate whether certain types of bacteria that produce toxins (for example, Bacteroides and 
E. coli) are present in the intestine in individuals found to have bowel cancer or pre-cancerous 
polyps or in people with longstanding inflammation of the bowel (inflammatory bowel disease). 
 
The secondary objectives of the study are to: 
• Determine the presence of toxin producing bacteria in samples of the bowel lining taken 
during routine colonoscopy 
• Determine if the presence of toxin producing bacteria is linked to the presence of polyps, 
bowel cancer or bowel inflammation 
• Determine the presence of toxin producing bacteria in faecal contents taken from the right 
colon during colonoscopy 
• Assess the relationship between bacterial toxins and the cells of the immune system in the 
gut and blood     
 
Do I have to take part? 
It is up to you if you decide to take part in the study. We will describe the study and go through 
this information sheet. If you agree to take part, we will then ask you to sign a consent form. You 
are free to withdraw at any time, without giving a reason. This will not affect the standard of care 
you receive. 




What will happen if I take part? 
The study involves taking some additional samples from the lining of the bowel (called biopsies) 
during your colonoscopy. It is routine to take numerous small biopsy samples from the lining 
during a colonoscopy and you do not feel this. As many as 30 of these may be taken routinely 
during a colonoscopy. In our study, we are asking your permission to take up to 14 biopsies 
additional to those for routine diagnosis from different sites in the bowel. The site will be chosen 
depending on the findings at your colonoscopy but will be either just from normal lining or from 
normal and abnormal areas such a polyp or bowel cancer. Taking samples from abnormal areas 
will only be done if it has no impact on the accuracy of your medical diagnosis and treatment.  
 
In addition, we will take a small sample of faecal liquid from the inside of the colon (aspirated up 
the colonoscope) which you will not feel.  
 
We are also asking you to provide a 26 mL sample of blood (about 4 and half teaspoons) which 
will be taken from the cannula already placed in your arm or hand and will therefore not involve 
any additional needles or cause discomfort.  
 
What will happen to my samples? 
Your samples will be marked with your participant number, the date, sample type and sample 
code only, so you will not be identifiable to the researchers studying your samples.  The 
samples of bowel lining and faecal fluid will be analysed for the presence of bacteria and 
bacterial toxins using molecular (DNA) and antibody-based detection methods. Bacteria will be 
grown from the biopsy and faecal fluid samples. The blood sample will be used to analyse the 
cells of the immune system and how these interact with bacteria found in the biopsy and faecal 
liquid samples. Molecular (genetic) analysis will be done on your own DNA (genes) to determine 
whether certain genes react with bacteria or bacterial toxins to make colonic polyps or cancers 
occur. 
 
The samples will either be analysed immediately or be stored in a freezer in a locked laboratory 
on a corridor not accessible to the public. Once processed, your samples will be analysed at 
Kings College London (Microbiology). They may also be sent anonymously to participating 
research centres in Europe (Karolinska Institute, Stockholm, Sweden; University of 
Copenhagen, Denmark; National Institute of Health, Rome, Italy; University of Bologna, Italy; 
Pasteur Institute, France; Centre Hospitalier Universitaire de Toulouse, France). They will be 
stored until September 2024 in case we need to undertake further analysis as a result of our 
research into bacteria and colon cancer. Your samples will either be completely used for 
analysis or destroyed according to the Human Tissue Act (HTA) guidelines. 
 
What are the advantages/disadvantages in taking part? 
The study involves taking the type of samples done as a routine part of undergoing a 
colonoscopy. By taking up to 14 samples, additional to any taken for routine diagnosis, the 
procedure will take up to 8 minutes longer but will not be more uncomfortable. Each biopsy is 
painless and leads to a tiny amount of bleeding from the lining of the bowel which quickly stops.  
Aspirating the faecal liquid takes about half a minute. The blood sample will be taken during 
your recovery period so will not prolong the procedure in any way. We don’t anticipate any direct 
benefits to participants from taking part, but it will help us understand the factors which promote 
the development of bowel cancer. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible harm 
you might suffer will be addressed. The detailed information about this is given in part 2. 
 
Will my taking part in this study be kept confidential? 
Yes. We will follow ethical and legal practice and all information will be handled in confidence. 
The details are included in part 2. 
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What will happen if I wish to withdraw from the study? 
You are free to withdraw from the study at any time without giving a reason.  If 
you decide to do so after the samples have been taken, we will destroy your 
samples and any information relating to you. If you decide to withdraw, it will not 
affect your normal care in any way.  
 
Who is organising and funding the study?  
The project is organised by researchers from Guy’s & St. Thomas’ Hospitals 
NHS Foundation Trust. Some funding has been awarded by the Food and Gut 
Research Fund, Guy’s & St’ Thomas’ Charity and the Danish Council for 
Independent Research. The study has also been reviewed and given a 
favourable opinion by Wales REC7 (14/WA/1221) Research Ethics Committee, 
an independent group of people who protect the interests of research 
participants. 
 
What if there is a problem? 
If you have any questions/concerns about any aspect of this study, you should 
ask to speak to the researchers (020 7188 2497, jeremy.sanderson@kcl.ac.uk), 
who will do their best to answer your questions. 
Address for correspondence:  
Dept of Gastroenterology, Guy’s & St. Thomas’ Hospitals 
1st Floor, College House, St. Thomas’ Hospital 
Westminster Bridge Road, London, SE1 7EH 
 
If you have a complaint, you should talk to your research doctor who will do 
their best to answer your questions. If you remain unhappy and wish to 
complain formally, you can do this through the NHS complaints procedure. 
Details can be obtained through the Patient Liaison and Advisory Service 
(PALS) at Guy’s & St. Thomas’ Hospitals on 02071887188, address: PALS, 
KIC, Ground Floor, North Wing, St. Thomas’ Hospital, Westminster Bridge 
Chapter 6.1.3 Fusobacterium and F. nucleatum taxonomy 
163 
 
Road, London, SE1 7EH. This study is insured by Guy’s & St. Thomas’ NHS 
Foundation Trust under the clinical negligence scheme for trials. 
All professional staff involved in the study hold professional indemnity to work 
within Guy’s & St. Thomas’ NHS Trust. In the event that you are harmed during 
the research and this is due to negligence then you may have grounds for legal 
action for compensation against Guy’s & St. Thomas NHS Trust but you may 
have to pay your legal costs. The normal NHS complaints mechanisms are still 
available to you. 
 
Will my taking part in this study be kept confidential? 
All samples collected about you will be anonymised after collection by assigning 
a study number. We will keep details of your colonoscopy report and the 
histopathology report, containing your name, age and hospital number. This 
information will be stored in a locked filing cabinet and will only be accessible by 
the named investigators in the study. A secure database of samples collected in 
the study will contain your initials and study number only. After the study is 
completed, any records where you are personally identifiable will be destroyed. 
Any paper will be shredded and disposed of via a secure contractor.  Computer 
records will be destroyed using appropriate data destruction software. 
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APPENDIX D: PCR Results Summary  
Healthy Cohort PCR Results 
Sample ID B. fragilis bft ubb Fusobacterium fadA 
BF012.AC - - - + - 
BF012.DC - - - - - 
BF018.AC + - + - - 
BF018.DC + - + - - 
BF022.AC + - - - - 
BF022.DC + - - - - 
BF031.AC - - - - - 
BF031.DC - - - - - 
BF036.AC - - - + - 
BF036.DC - - - - - 
BF046.AC + - - + - 
BF046.DC + - - + - 
BF051.AC + - - - - 
BF051.DC + - - - - 
BF052.AC - - - - - 
BF052.DC - - - - - 
BF057.AC + - - - - 
BF057.DC + - - - - 
BF063.AC + - - + + 
BF063.DC + - - - - 
BF064.AC + - - - - 
BF064.DC + - - - - 
BF065.AC + - - + + 
BF065.DC + - - + + 
BF074.AC + - - + - 
BF074.DC + - - + - 
BF077.AC - - - - - 
BF077.DC - - - + - 
BF086.AC - - - - - 
BF086.DC + - - + - 
BF088.AC + - - - - 
BF088.DC + - - - - 
BF095.AC + - - - - 
BF095.DC + - - + - 
BF106.AC + - - - - 
BF106.DC + - - - - 
BF111.AC + - - + + 
BF111.DC + - - + + 
BF121.AC + - - + - 
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BF121.DC + - - + - 
BF123.AC - - - - - 
BF123.DC - - - - - 
BF124.AC - - - - - 
BF124.DC - - - - - 
Sample ID is Patient ID. Biopsy location 
AC = ascending colon; DC = descending colon, OT = on tumour, NT = next to tumour, AT = 
away from tumour 
- = PCR negative + = PCR positive 
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IBD Cohort PCR Results 
 
Sample ID B. fragilis bft ubb Fusobacterium fadA 
BF001.DC + - - - - 
BF003.AC + + + - - 
BF003.DC + + - - - 
BF014.AC + - - + + 
BF014.DC + - - - - 
BF015.AC + - - - - 
BF015.DC + - - - - 
BF019.OT + - - - - 
BF019.NT + - + - - 
BF020.AC - - - - - 
BF020.DC - - - - - 
BF033.AC + + + - - 
BF033.DC + + + - - 
BF035.AC + - - - - 
BF041.AC + - - + - 
BF041.DC + - - - - 
BF049.OT - - - - - 
BF049.NT - - - - - 
BF049.AT - - - - - 
BF056.AC - - - - - 
BF056.DC - - - - - 
BF070.AC - - - - - 
BF070.DC - - - - - 
BF084.AC - - - + - 
BF084.DC - - - - - 
BF099.AC + - - - - 
BF099.DC + - - - - 
BF117.AC + - - - - 
BF117.DC - - - - - 
Sample ID is Patient ID. Biopsy location 
AC = ascending colon; DC = descending colon, OT = on tumour, NT = next to tumour, AT = 
away from tumour 
- = PCR negative + = PCR positive 
 
  




Previous polyps/cancer cohort PCR results 
Sample ID B. fragilis bft ubb Fusobacterium fadA 
BF014.AC + - - + + 
BF014.DC + - - - - 
BF016.AC - - - + - 
BF016.DC - - - - - 
BF017.AC - - - - - 
BF017.DC - - - - - 
BF024.AC - - - - - 
BF042.AC + - - - - 
BF042.DC + - - - - 
BF045.AC - - - - - 
BF045.DC + - - + - 
BF059.AC + - + - - 
BF059.DC + - + - - 
BF060.AC - - - - - 
BF060.DC - - - - - 
BF071.AC + - - - - 
BF071.DC + - - - - 
BF076.AC + - - - - 
BF076.DC + - - - - 
BF080.AC + + - - - 
BF080.DC + + - - - 
BF091.AC - - - - - 
BF091.DC - - - - - 
BF097.AC + - - - - 
BF097.DC + - - - - 
BF098.AC - - - - - 
BF098.DC - - - - - 
Sample ID is Patient ID. Biopsy location 
AC = ascending colon; DC = descending colon, OT = on tumour, NT = next to tumour, AT = 
away from tumour 
- = PCR negative + = PCR positive 
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New polyps/cancer cohort PCR results 
Sample ID B. fragilis bft ubb Fusobacterium fadA 
BF002.OT - - - - - 
BF002.NT - - - - - 
BF002.AT - - - + - 
BF005.OT - - - - - 
BF005.NT - - - - - 
BF006.OT + - - + + 
BF006.NT + - - + + 
BF006.AT + - - + + 
BF007.OT - - - - - 
BF007.NT - - - - - 
BF007.AT - - - - - 
BF008.OT + + - + + 
BF008.NT + + - + + 
BF008.AT + + - + + 
BF009.AC + - - - - 
BF009.DC + - - - - 
BF011.AC + - - + - 
BF011.DC + - - - - 
BF013.OT + - - - - 
BF013.AC + - + + - 
BF019.OT + - - - - 
BF019.NT + - + - - 
BF027.OT + + - - - 
BF027.NT + + - - - 
BF027.AT + + - - - 
BF028.OT + + - - - 
BF028.NT + + - - - 
BF028.AT + + - - - 
BF029.OT + - - - - 
BF029.NT + - - - - 
BF029.AT + - - - - 
BF030.AC - - - - - 
BF030.DC - - - - - 
BF032.DC - - - - - 
BF034.OT + - - - - 
BF034.NT - - - - - 
BF034.AT - - - - - 
BF035.AC + - - - - 
BF041.AC + - - + - 
BF041.DC + - - - - 
BF043.AC + + - - - 
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BF044.AC - - - - - 
BF047.AC - - - + - 
BF047.DC - - - + - 
BF048.OT - - - - - 
BF048.NT - - - - - 
BF048.AT - - - - - 
BF049.OT - - - - - 
BF049.NT - - - - - 
BF049.AT - - - - - 
BF054.AC - - - - - 
BF054.DC - - - - - 
BF056.AC - - - - - 
BF056.DC - - - - - 
BF058.OT - - - - - 
BF058.AC - - - - - 
BF061.OT + - + + - 
BF061.NT + - + + - 
BF061.AT + - + - - 
BF071.AC + - - - - 
BF071.DC + - - - - 
BF072.OT - - - - - 
BF072.NT - - - - - 
BF072.AT - - - - - 
BF079.NT + - - - - 
BF079.AT + - - - - 
BF090.AC + - + + + 
BF090.DC + - + + + 
BF100.AC - - - - - 
BF100.DC - - - - - 
BF115.OT - - - - - 
BF115.NT - - - - - 
BF115.AT - - - - - 
Sample ID is Patient ID. Biopsy location 
AC = ascending colon; DC = descending colon, OT = on tumour, NT = next to tumour, AT = 
away from tumour 
- = PCR negative + = PCR positive 
  


















T30082 MH0068 bft-1 scaffold939_15:3969..5186 F 54 Healthy Danish 
T30068 MH0054 bft-2 
scaffold81981_3:complem
ent(4090..5307) 
M 49 Healthy Danish 
T30112 O2. UC-22 partial bft-1 C4157881_1:380..772 M 44 IBD Spanish 
T30099 MH0085 ubb 
scaffold58215_1:complem
ent(450..761) 
F 59 Healthy Danish 
T30094 MH0080 ubb scaffold64380_5:82..393 F 59 Healthy Danish 
 
